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ENVELOPE DETERMINANTS OF EIAV VACCINE PROTECTION AND THE EFFECTS 
OF SEQUENCE VARIATION ON IMMUNE RECOGNITION 
 
Tara Lynn Tagmyer, PhD 
University of Pittsburgh, 2007 
 
Developing an effective lentiviral vaccine has been an elusive goal, largely due to immune 
evasion mechanisms of lentiviruses.  Lentiviral envelope (Env) proteins pose a major obstacle to 
vaccine development due to extreme antigenic variation, but research with equine infectious 
anemia virus (EIAV) has indicated Env to be a primary determinant of vaccine efficacy. We 
have developed an attenuated EIAV vaccine capable of protecting horses from disease after 
homologous challenge.  However, when variant challenge strains with divergent Env proteins are 
utilized, vaccine protection is incrementally decreased with increasing divergence from the 
homologous Env.  I hypothesize there may be Env-specific immune responses associated with 
vaccine protection and believe antigenic variation may have profound effects on immune 
recognition.  Utilizing thymidine incorporation and chromium release assays on PBMC from 
vaccinated horses challenged with the homologous strain, I identified broadly reactive regions of 
Env recognized by T-helper and CTL cells.  With PBMC from vaccinated ponies challenged 
with divergent EIAV strains I identified Env-specific immune responses associated with vaccine 
protection from disease.  Although I was unable to correlate antibody neutralization with 
protection, I found one T-helper and eight CTL peptide responses associated with vaccine 
protection.  Three of the CTL peptides were located in variable domains of Env.  To understand 
the effects of variation on immune recognition, I utilized sera and PBMC from vaccinated and 
 iii
variant infected ponies to analyze the cross-reactivity of humoral and cellular immune responses.  
Due to limited proliferative activity, I was unable to fully analyze the effects of Env variation on 
lymphoproliferation; however, CTL analysis indicated Env variation had profound effects on 
immune recognition in EIAV vaccinated and infected ponies.  The most remarkable effects of 
Env variation were observed in in vitro neutralization assays, where there was no detectable 
cross-reactivity of neutralizing antibodies.  Collectively, these results indicate that eliciting key 
immune responses to more conserved regions of the EIAV Env may be crucial in developing an 
effective EIAV vaccine.  The peptide-specific responses identified in this dissertation could 
serve as important targets for future EIAV vaccines and this analysis may be a valuable 
complement to ongoing work in SIV and HIV.     
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1.0 INTRODUCTION TO EQUINE INFECTIOUS ANEMIA VIRUS, IMMUNOLOGY 
AND VACCINE DEVELOPMENT 
 
 
 
 
1.1 STRUCTURE OF EIAV 
 
 
Equine infectious anemia virus (EIAV) is a member of the lentivirus genus in the Retroviridae 
family of viruses and shares genetic and structural similarity with human (HIV), simian (SIV) 
and feline (FIV) immunodeficiency viruses.  With an RNA genome of 8.2kb, EIAV is the 
smallest of the known lentiviruses (75).  All lentiviruses contain gag, pol and env genes which 
encode for the structural and enzymatic proteins of the virus.  EIAV gag encodes the matrix 
(p15), capsid (p26), nucleocapsid (p11) and p9 proteins (Fig 1.1).  While p9 is critical for virion 
release from the plasma membrane of the infected macrophage, the other Gag proteins provide 
the structure of EIAV (20).    The hallmark of every lentivirus is the bullet shaped capsid, which 
encloses the nucleocapsid encased RNA genome.  Surrounding the capsid, are matrix proteins 
which underlie the lipid bilayer and interact with the Env proteins.  The lipid bilayer, obtained 
during budding from infected macrophage, is studded with the env encoded proteins, gp90 and 
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gp45.  Gp90 is the surface protein responsible for binding the ELR1 receptor on equine 
macrophage (142) and is non-covalently linked to gp45, the membrane spanning protein.  
 
Surface 
protein
Transmembrane 
protein
Matrix
Nucleocapsid
Reverse 
Transcriptase
Integrase
Protease
Capsid
RNA
Lipid 
Bilayer
LTR tat tat
S2 Rev Rev
LTRMA CA p9NC SU TM
PR RT DU IN
Gag
Pol
Env  
Figure 1.1 EIAV virion and genomic organization. 
  
 EIAV pol encodes the enzymatic proteins needed for productive viral infection.  Reverse 
transcriptase-RNaseH (p66) is essential for the conversion of viral RNA into DNA.  RT lacks a 
proofreading enzyme; hence, numerous mutations are introduced in the viral genome every time 
the RNA is reverse transcribed.  These mutations allow the virus to rapidly evolve and evade the 
host immune responses.  Because EIAV infects non-dividing macrophages, there is a limited 
supply of dTTP, an essential nucleotide for DNA synthesis.  Macrophage must synthesize RNA 
for protein production; therefore there is an abundant supply of dUTP.  EIAV pol encodes for a 
dUTPase (p15) that is capable of converting dUTP to dUMP and PPi, which is an essential step 
in the de novo synthesis of dTTP (71).  Once the viral genome is converted to DNA, viral 
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integrase (p30) incorporates the DNA into the genome of the macrophage.  EIAV, like all 
lentiviruses, relies on host cell machinery to transcribe the DNA to messenger RNA for protein 
translation.  Many of the viral proteins are translated as polyproteins and need to be cleaved 
before a mature virion may assemble.  EIAV encodes a protease (p12) capable of cleaving the 
viral polyproteins into the functional proteins required for virus assembly.     
 In addition to the proteins coded by gag, pol and env, EIAV has three accessory proteins: 
Tat, Rev and S2, making EIAV the least complex lentivirus.  Tat and Rev are common to all 
lentiviruses; Tat functions as a transcription activator, while Rev regulates RNA splicing and 
RNA transport from the nucleus (135).  The function of S2 is currently not defined (75), but 
studies have shown that knocking out S2 down-regulates in vivo replication without altering in 
vitro viral kinetics (79, 81). 
 
 
 
 
1.2 CLINICAL COURSE OF EIAV INFECTION 
 
 
While genetically similar to other lentiviruses, the clinical course of EIAV is dramatically 
different from its lentiviral relatives.  While HIV, SIV and FIV are all primarily lymphotropic 
viruses transmitted through direct contact with infected individuals, EIAV is a macrophage 
tropic virus that infects equids through horse fly bites or contaminated needles.  Infection with 
HIV, SIV or FIV cause similar clinical progressions that entail a slow, progressive degenerative 
disease that culminates in the collapse of the immune system and eventual death of the host to 
opportunistic infection (3).  Conversely, EIAV produces a rapid and dynamic infection that 
ultimately leads to a life-long asymptomatic phase (97). 
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 Two months post exposure to EIAV, infected horses develop an acute episode of disease 
characterized by fever, thrombocytopenia, anemia and viremia (Fig 1.2).  Sequencing of plasma 
RNA from experimentally infected ponies during the acute episode reveals the original EIAV 
inoculum (77).  The equine immune system gains control of the acute episode causing a drop in 
viral load without eradicating the virus.  Eventual EIAV evasion of the immune responses allows 
for rapid viral replication which triggers another febrile episode, marking the beginning of the 
chronic phase of disease.  The hallmark of EIAV infection is the chronic phase where infected 
horses cycle through recurrent disease episodes, characterized by fever, thrombocytopenia, and 
peak plasma viremia (97).  Each disease episode can be attributed to a new viral quasispecies 
that was capable of escaping host immune control and that is distinct from the preceding episode 
(77).  Infected horses continue cycling with chronic disease for approximately one year, after 
which an inapparent carrier phase is achieved.  
 
Immune 
Suppression
Inapparent 
Carrier 
Chronic 
Phase
Acute 
Episode
 
Figure 1.2 Clinical course of EIAV infection.  Figure adapted from Leroux et al. 2004. Vet. 
Res. 35:485-512 (75). 
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 Inapparent carriers of EIAV strictly control virus replication and are free from further 
disease episodes for the remaining live span of the horse.  The inapparent stage of disease cannot 
be attributed to attenuation of the virus, as whole blood transfers from inapparent carriers to 
naïve horses induce disease in recipient animals.  Additionally, stressing or immune suppressing 
inapparent carrier horses can cause a recrudescing disease with a distinct quasispecies from the 
last febrile episode, indicating that viral evolution is maintained during the inapparent stage, and 
suggesting that there is strict immunological control of EIAV (64, 89, 97).  Greater than 90% of 
horses infected with EIAV advance to inapparent carriers, which is in stark contrast to SIV, 
where less than 5% of experimentally infected monkeys are nonprogressors (48).  In addition to 
gaining immunologic control of EIAV, inapparent carrier horses are resistant to further EIAV 
challenge, demonstrating natural, prophylactic immunity (97) that is desirable for a lentiviral 
vaccine.   
 
 
 
 
1.3 HOST IMMUNE RESPONSE TO VIRAL INFECTIONS 
 
 
The host immune response to viral infections is complex, involving multiple cellular reactions 
between distinct cell types.  For the purpose of this dissertation, only the adaptive immune 
responses of T-helper cells, cytotoxic T-lymphocytes and neutralizing antibodies will be 
discussed.  The immunology described here is adapted from the text of Retroviruses and also 
Immuno Biology 5 (3, 66).  
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  Upon infection of a naïve host, viruses are transferred to the nearest lymphatic organ.  In 
the case of blood borne viruses, such as EIAV, the virions are transported to the spleen where 
they are engulfed by professional antigen presenting cells (APC), such as dendritic cells (DC) 
and macrophages.  The APC process the pathogen and present antigenic peptides bound to major 
histocompatibility complex (MHC) molecules on the cell surface.  Cells of the adaptive immune 
system capable of recognizing the MHC:peptide complexes bind the APC and become activated 
effector cells (Fig 1.3). 
  There are two major classes of MHC molecules able to present antigenic peptides.  Class 
I MHC molecules bind both ends of a short antigenic peptide (~9-10 amino acids) for 
presentation to CD8+ T-lymphocytes.  These peptides are derived from intracellular pathogens, 
such as viruses.  For MHC II molecules, the peptides are derived from extracellular pathogens 
taken up by cells through various forms of endocytosis.  MHC II molecules present antigenic 
peptides in a binding cleft.  The binding cleft is capable of recognizing peptides of variable 
length, with typical lengths exceeding 13 amino acids.  Naïve CD4+ T-lymphocytes bind 
peptides complexed with MHC II.  
  MHC:peptide recognition is not sufficient to drive T-cell activation, co-stimulatory 
signals from the APC must be received by the binding T-lymphocyte for full activation to occur.  
The first co-stimulatory interaction, which initiates T-cell activation, involves B7 proteins on 
APC interacting with CD28 on T-cells.  The activation signal is completed by the T-cell CD40 
ligand binding to the APC CD40 receptor.  Once activated, T-cells begin producing IL2, a 
necessary cytokine for T-cell expansion.  The interaction between CD40 and CD40 ligand also 
causes the APC to produce more B7, thereby prolonging T-cell activation.  These co-stimulatory 
signals are sufficient for activating CD4+ T-cells into effector T-helper cells (Th).   Effector Th 
 6
cells “help” other cells of the adaptive immune system through cytokine release and APC 
activation (Fig 1.3).   
       APC presenting viral peptides in the context of MHC I molecules interact with CD8 T-cells.  
The same co-stimulatory events occur as for CD4 T-cell activation, but due to the destructive 
nature of effector CD8 T-cells, further co-stimulation is required for the differentiation of CD8 
T-cells to cytotoxic T-lymphocytes (CTL).  The additional co-stimulation can be achieved by 
two separate means.  If the CD8 cells are bound to DC, which have natural intrinsic co-
stimulatory activity, the DC can stimulate the CD8 to synthesize IL-2, and drive their own 
proliferation and differentiation.  If the CD8 cells recognize antigen on weakly co-stimulating 
cells, effector Th must activate the same APC to trigger an increased expression of co-
stimulatory molecules on the APC.  The APC are then capable of activating CD8 T-cells to make 
their own IL-2.   
 Once activated, effector CTLs circulate and identify virally infected cells through 
peptide:MHC I complexes.  Binding of the CTL T-cell receptor to the peptide:MHC I complex 
on virally infected cells permit other co-receptors to crosslink and form an immune synapse, 
which allows for the targeted release of lytic granules from the CTLs to the infected cell (Fig 
1.3).  The lytic granules contain cytolytic proteins capable of destroying virally infected cells.  
After the deadly delivery, the CTLs disengage and move to the next virally infected target cell.  
By destroying virally infected cells, CTLs help the immune system control viral replication. 
 7
MHC I
MHC II
Th CTL
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Figure 1.3 Host immune response to viral infection.  After activation by antigen presenting 
cells (APC), T-helper cells (Th) cells provide the necessary cytokines and signals to activate 
cytotoxic T-lymphocytes (CTL) and B lymphocytes.  CTL recognize and destroy virally infected 
cells; B lymphocytes produce antibodies to bind whole virus and viral antigens.  Adapted from 
www.influenzareport.com/ir/images/image27.jpg 
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  In addition to the cellular immune response, adaptive immunity also includes a humoral 
response which involves the production of antigen specific antibodies by B-lymphocytes.  B-
cells are uniquely adapted to bind soluble molecules through their cell-surface immunoglobulin, 
IgM.  B-cells internalize soluble antigens and display peptides on MHC II molecules, allowing 
effector Th cells to bind and drive B-cell activation and differentiation.  Th activated B-cells 
undergo immunoglobulin class switching and produce vast amounts of antigen specific 
antibodies.  Some antibodies are capable of coating the virus to allow for better uptake by 
phagocytic cells.  Phagocytic cells express receptors for the Fc portion of the antibody.  The Fc 
receptors bind and engulf the antibody coded antigen in a process termed opsonization.  Other 
antibodies trigger the complement system, which may directly destroy the pathogen or enhance 
opsonization.  For viral infections, the most desirable antibody response is the development of 
neutralizing antibodies, which bind the virus and prevent it from entering new target cells (Fig 
1.3).      
 With the aid of Th cells, neutralizing antibodies and CTLs are capable of halting viral 
infection and removing the pathogen from circulation.  After clearing the infection, memory T 
and B cells continue to circulate in the host for extended periods, sometimes for the remaining 
life span of the host.  When the same pathogen is encountered again, a faster, more efficient 
immune response is mounted by the host’s memory cells to prevent re-infection and disease.  
These are the immune responses that make vaccination possible.  Instead of causing illness with 
a live pathogen, vaccines use non-pathogenic forms of infectious agents to mount immune 
responses with lasting memory.  Then, if the pathogen is encountered by the vaccinated host, the 
memory B and T cells can produce an appropriate immune response to preclude infection.     
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 1.4 HOST IMMUNE RESPONSE TO EIAV INFECTION 
  
 
CTL are effective at controlling lentiviral acute episodes, while neutralizing antibodies develop 
later in infection to aid the CTL in controlling viral replication and spread.  The CTL and 
neutralization response develop with the aid of Th cells.  Unfortunately, for most lentiviral 
infections, CD4+ Th cells are the primary target for infection (66).  While the CTL and 
neutralizing antibody responses are successful at controlling replication, they are incapable of 
clearing the virus from the host.  In the case of HIV, SIV and FIV, rapid mutations allow the 
lentivirus to escape host immune control and infect new CD4+ Th cells, ultimately leading to the 
collapse of the immune system.  Unlike its lentiviral relatives, EIAV is eventually controlled by 
the horse’s immune system.          
 There has been limited exploration into specific immune responses that control EIAV 
infection in horses.  Like other lentiviral infections, control of the acute episode is associated 
with  the appearance of CTL (90) and non-neutralizing antibodies (109, 122).  CTL cells 
fluctuate throughout the course of infection, where as antibodies plateau after six months post 
infection (52).  Neutralizing antibodies, originally thought to develop two months post infection, 
have recently been detected after the resolution of the acute episode (93).  These antibodies, 
which are directed against a principal neutralization domain (PND) in gp90 (76, 77), continue to 
increase in titer and breadth of specificity throughout the first year of infection (12, 52, 60, 104).  
Each disease episode during the chronic phase of EIAV infection corresponds to viral escape of 
host immune control.  The new quasispecies, which is distinct from the previous febrile episode, 
is brought under control by new type specific neutralizing antibodies.  Immune responses to 
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EIAV eventually prevail, controlling viral replication and disease for the remaining lifespan of 
the infected horse without ever clearing the virus.     
 Attempts to understand EIAV immune control have led to the identification of CTL and 
T-helper (Th) epitopes in the Gag and Pol proteins of the virus (22, 46, 93, 94).  Vaccines aimed 
at inducing these epitope-specific immune responses have not been effective at preventing 
infection or disease (45, 119).  While the humoral response to gp90 has been extensively 
investigated, the cellular immune response to Env has remained virtually unexplored.  To date, 
no immune correlates of protection have been revealed for EIAV or any other lentivirus.  
 
 
 
 
1.5 LENTIVIRAL VACCINE DEVELOPMENT 
 
  
The development of successful vaccines in the past has been based on empiric observations, 
without a firm understanding of appropriate immune responses.  The most cited example is 
Edward Jenner using cowpox to inoculate individuals against smallpox infection (114).  Jenner’s 
success sparked a wave of vaccine development that has brought many deadly diseases such as 
rabies, influenza, plague, typhoid, measles, and diphtheria under control.  With such success, it 
was anticipated that the same techniques could be used to develop an effective HIV vaccine.   
 Most vaccines against viral infections, such as smallpox and flu, elicit neutralizing 
antibodies capable of preventing virus entry into target cells.  Therefore, the first HIV vaccines 
to be tested focused on evoking a neutralizing antibody response using recombinant Env 
proteins.  Most of these trials failed in phase 1 and 2 testing (107).  Extensive research 
demonstrated that HIV is capable of evading neutralizing antibodies through various 
 11
mechanisms, including N-linked glycosylation of the Env proteins (117), conformational 
masking of receptor-binding sites (73), and escape mutations (118, 138).  Failure of the empiric 
approach in developing an effective HIV vaccine led to the exploration of immune mechanisms 
necessary for protective immunity.   
 Natural immunity to an infectious agent is desirable when attempting to identify key 
immune responses required for vaccine protection.  Unfortunately, less than 5% of individuals 
infected with HIV are long-term nonprogressors, meaning their immune response is capable of 
controlling HIV replication and the individual is free of clinical symptoms of AIDS for greater 
that 10 years after infection (39).  In need of a system to identify correlates of protective 
immunity, focused turned to the SIV macaque model system.   
1.5.a SIV vaccine development 
 
 
SIV is the “gold standard” for studying perspective AIDS vaccines in preclinical studies.  
Numerous vaccine strategies have been explored with SIV, including attenuated virus, whole-
inactivated virus, viral vectors, DNA, and subunit vaccines.  Only the use of attenuated SIV 
vaccines has offered complete or near-complete protection from homologous or heterologous 
virulent challenge (5, 37, 38, 70, 95, 102, 103, 127, 139).  A comparison of attenuated vaccine 
strategies against other SIV vaccine strategies reveals that 95% of attenuated SIV vaccines lower 
viral loads by more than 3 logs, where as only 7% of other immunization strategies are capable 
of similar efficacy (70).    
 Attempts to correlate immune responses with SIV vaccine protection have proven less 
than successful.  Neutralizing antibodies are the focus of an ongoing debate.  Several researchers 
have found a protective role for neutralizing antibodies in SIV protection (85, 86, 115), while 
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others have been unable to correlate neutralization with protection (95, 102, 103, 127).  With no 
clear association between protection and neutralizing antibodies, focus has been shifting to the 
CTL response.  Like neutralizing antibodies, the role of CTL cells can not definitively be 
correlated with SIV protection (67, 87, 124, 127).  Frustrated with a lack of correlates of 
protection, there is now a concerted effort by the Live Attenuated Consortium of the 
International AIDS Vaccine Initiative to identify the mechanisms of protection conferred by 
attenuated SIV vaccines in monkeys (70).  
 An additional aspect of SIV that makes it an attractive model for HIV studies is the 
ability to manipulate the SIV genome to express HIV Env instead of SIV Env.  SHIV, as it is 
known, is capable of establishing infection in nonhuman primates without causing disease.  
During the course of infection, HIV specific antibodies develop which are capable of 
neutralizing the parental HIV strain (98).  HIV Env specific immune responses in non-human 
primates can therefore be studied with the SHIV system.  Similar to SIV vaccines, the best 
protection from heterologous challenge was obtained with attenuated SHIV vaccines.  While 
sterilizing immunity was not achieved with any of the vaccines, lower viral set points and slower 
disease progression was observed in some of the vaccinated animals.  Like SIV, studies with 
SHIV have yet to reveal any correlates of vaccine immunity (15).     
1.5.b EIAV vaccine development   
 
To understand immune mechanisms responsible for controlling lentiviral infections, non-primate 
lentivirus, such as EIAV and FIV, may also be utilized.  Experimentation with these lentiviruses 
offers dual benefits in contributing to a better understanding of lentiviral protection while also 
aiding in the development of effective veterinary vaccines.  The extensive research with FIV 
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actually led to the first USDA approved, commercially available lentiviral vaccine against in 
2002 (134).  Reported efficacy in FIV vaccinated kittens is 84%, compared to the 90% infection 
rate in control cats (1).  While Fel-O-Vax FIV demonstrates that protective lentiviral vaccines 
are possible, the greatest benefit of FIV and EIAV vaccine research may be the observation of a 
remarkable spectrum of vaccine efficacy, ranging from apparent sterilizing immunity to severe 
disease enhancement.   
 EIAV is particularly interesting to study because of its unique clinical course of disease.  
EIAV is the only lentiviral system where the natural host develops disease then gains 
immunologic control of the evolving pathogen.  In addition, inapparent carrier horses of EIAV 
are resistant to further virulent challenge.  The natural immunologic control and prophylactic 
immunity of inapparent carrier horses suggests that an effective vaccine against EIAV can be 
developed.  In fact, the Chinese routinely vaccinate all their horses with an attenuated strain of 
EIAV.  Unfortunately, no independent evaluation of the Chinese vaccine has been performed to 
confirm the efficacy against preventing infection and disease (98).    Concerns over reversion to 
virulence of attenuated vaccines, and the lack of a marker to differentiate infected verse 
vaccinated horses led researchers to investigate other strategies for vaccination (Table 1.1).  
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Table 1.1 Summary of EIAV vaccines and their protective efficacies. 
VACCINE DESCRIPTION # OF ANIMALS CHALLENGE TYPE # INFECTED
CLINICAL 
SIGNS REFERENCE
12 homologous 0/12 asymptomatic
secondary heterologous 12/12 typical (3), none (9)
4 homologous 0/4 asymptomatic
4 heterologous 4/4
enhancement (2), 
typical (1), 
asymptomatic (1)
4 homologous 0/4 asymptomatic
17 heterologous 17/17
enhancement (5), 
typical (5), 
asymptomatic (3)
Attenuated
EIAVΔDU - deletion in the 
dUTPase coding region 2 homologous 2/2 typical
Lichtenstien et al. 
1995 (83), 
Hammond et al. 
1999 (54)
Particulate 
gpEIAV covalently coupled to 
glutaraldehyde-activated iron 
oxide beads
4 homologous 4/4 delayed disease Hammond et al. 1999 (51)
Attenuated
EIAVΔS2 - two stop codons 
introduced into S2 9 homologous 0/9 asymptomatic Li et al. 2003 (79)
Pepitde gp90 specific lipopeptide 3 homologous 3/3 less severe disease
Ridgely et al. 
2003 (119)
DNA codon optimized SU 4 homologous 4/4 typical
Cook et al. 2005 
(28)
12 homologous 0/12 asymptomatic Craigo et al. 2007 (32)
24 heterologous/homologous Env 24/24
typical (9), 
asymptomatic (15)
Craigo et al. 2007 
(36)
Attenuated
EIAVD9 - EIAVΔS2 with 9 
base pair deletion in S2
Inactivated Whole 
Virus
Subunit 
Recombinant
Wang et al. 1994 
(136), Raabe et al. 
1998 (116)
Issel et al.  1992 
(65)
Issel et al.  1992 
(65)
LLgp - lectin affinity purified 
envelope glycoproteins
formalin-inactivated
rgp90 - baculovirus-expressed 
recombinant gp90
 
  
 Outside of the attenuated vaccines, one of the first vaccination approaches tested for 
EIAV was a formaldehyde inactivated form of the virion (65).  The inactivated EIAV, produced 
from a cell adapted strain of the virus, was used to immunize 12 ponies.  Upon challenge with 
the homologous EIAV strain, none of the 12 ponies became infected or developed signs of 
disease.  One hundred days after homologous challenge, the ponies were challenged a second 
time with a pony-virulent cell adapted strain of EIAV (EIAVPV).  All 12 ponies became infected 
after this heterologous challenge, and three developed classic signs of equine infectious anemia 
(EIA).  Nine of the 12 vaccinated ponies remained asymptomatic after heterologous challenge, 
suggesting some degree of protection was offered by the formalin inactivated EIAV vaccine.  
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Upon analysis of neutralizing antibodies in the vaccinated ponies, there was no detectable 
correlation between vaccine protection and neutralizing antibody development (65).  
 A subunit vaccine composed of lectin affinity-purified EIAV Env was compared to the 
protection achieved with the formalin inactivated EIAV.  Eight ponies were vaccinated with the 
subunit vaccine; four were protected from homologous challenge, while the other four became 
infected after EIAVPV challenge.  Two of the EIAVPV challenged ponies demonstrated enhanced 
febrile episodes.  PBMC from ponies immunized with the subunit vaccine had diminished EIAV-
specific proliferation responses compared to PBMC from horses vaccinated with inactivated 
EIAV.  These findings indicate that eliciting a cellular immune response may be an important 
component of an effective vaccine (65). 
 A third trial vaccination utilized recombinant EIAV gp90 and yielded surprising results.  
A baculovirus-expressed recombinant gp90 was used to vaccinate 17 ponies (116, 136).  
Following heterologous challenge with virulent EIAVPV, the 17 ponies became infected and 
demonstrated a range of clinical disease presentation.  Three of the vaccinated ponies remained 
asymptomatic, five developed typical EIA signs and nine demonstrated enhanced clinical disease 
characterized by early onset of acute episode with severe thrombocytopenia.  While a correlation 
between the severity of disease and level of viral RNA in the plasma was established, there was 
no definitive association between enhancement and serum antibody reactivity (116).  At first it 
was thought that the macrophage tropism of EIAV led to the enhancement of disease, but this 
was unfounded as a recombinant FIV vaccine also caused enhanced disease after virulent 
challenge (128).  Unlike EIAV, FIV is a predominantly lymphotropic virus.   
 Various other EIAV vaccine strategies were attempted with little success at protecting 
from infection or disease.  A particulate virus aimed at targeting gradient purified EIAV into the 
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phagocytic pathway to elicit a cell mediated response failed to protect ponies from infection, but 
did delay the onset of clinical disease and viremia (51).  A lipopeptide vaccine containing a 
immune dominant Env epitope transiently induced a CTL response, however, each horse became 
infected and developed low grade fevers after virulent challenge (119).  A DNA vaccine 
containing codon optimized gp90 was able to induce EIAV-specific antibodies and 
lymphoproliferation, but was unable to protect ponies from infection or disease when challenged 
with EIAVPV (28).   
 Research aimed at elucidating the mechanisms of EIAV replication, persistence and 
pathogenicity inadvertently assisted in vaccine development.  In an attempt to understand the 
requirement of dUTPase, an EIAV DU knockout was constructed and tested in vitro and in vivo.  
Deleting DU resulted in delayed in vitro replication in bone marrow derived macrophage, the 
natural targets of EIAV, but the knockout had no effect on in vitro replication kinetics in fetal 
equine kidney cells (FEK), which are permissive for EIAV replication (83).  The role of DU in in 
vivo replication kinetics was explored by infecting Shetland ponies with EIAVΔDU.  There was 
a 10-100 fold decrease in viral loads compared to EIAVPV infected ponies.  Despite lower viral 
loads, EIAVΔDU infected ponies mounted similar antibody responses to EIAVPV infected 
ponies.  To determine if the immune responses elicited by EIAVΔDU were protective, two 
EIAVΔDU infected ponies were challenged with EIAVPV.  The two ponies developed signs of 
classical EIA, indicating that the immune responses elicited by EIAVΔDU were not protective 
(54).   
 Investigating the role of S2 in EIAV replication led to another attenuated vaccine 
candidate.  While the role of the accessory proteins Tat and Rev are clearly understood, the 
function of the S2 protein is not.  In an effort to understand the mechanism of action, S2 mutants 
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of EIAV were developed.  In vitro replication kinetics of the EIAVΔS2 mutant in equine 
macrophages was equivalent to the parental EIAV (81).  When used to infect ponies, EIAVΔS2, 
like EIAVΔDU, had reduced in vivo replication kinetics and also produced virus specific 
immune responses (80).  To determine if these ponies were protected from virulent challenge, the 
EIAVΔS2 infected ponies were challenged with EIAVPV.  Apparent sterilizing immunity was 
achieved as each pony was protected from infection and disease (79), which is in stark contrast 
to EIAVΔDU infected ponies, where challenge by EIAVPV produced disease.  Protective 
immunity correlated with the development of a mature Env-specific immune response, as 
measured by antibody titer, avidity index and conformational ratio.  Like previous EIAV 
vaccines, there was no correlation between in vivo immune protection and in vitro serum 
neutralizing titer.  However, this vaccine proved that attenuated EIAV vaccines can elicit 
protective immunity even against a rigorous virulent EIAV challenge.   
 
 
 
 
1.6 IMMUNE MATURATION TO ENVELOPE PROTEINS IN EIAV AND SIV 
INFECTED ANIMALS 
  
In an effort to identify correlates of lentiviral protective immunity, independent studies with 
EIAV and SIV were conducted yielding similar results.  An antigen specific immune maturation 
to EIAV and SIV was revealed during an immunological analysis of longitudinal serum from 
EIAV infected horses (52) and SIV infected monkeys (23, 25).  Quantitative and qualitative 
antibody measurements with serum antibody displayed an increased immune maturation to the 
Env proteins of both viruses (Fig 1.4).  The quantitative measurement endpoint titer revealed that 
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Env specific antibodies titers increase during the first 2-3 months post infection, before 
maintaining an indefinite steady state level in infected hosts. 
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Figure 1.4 Qualitative and quantitative antibody measurements.  Reciprocal endpoint titer is 
measured with a standard ConA ELISA.  The avidity index is measured by comparing the 
binding of primary antibody to gradient purified EIAV after washing with or without 8M Urea.  
Avidity indices >30% are indicators of mature immunity.  The confirmation ration reflects a 
comparison of primary antibody binding to gradient purified EIAV versus denatured EIAV.  A 
ratio >1.0 represents predominant antibody reactivity with conformational epitopes. 
 
 A prolonged evolution of specific antibody parameters was revealed using three different 
qualitative measurements: avidity index, conformational ratio, and neutralization titer.  For both 
EIAV and SIV, initial antibody binding to the virus is weak, but begins to increase in avidity 
over 6-8 months before reaching steady state levels.  Unlike the avidity, the progression of 
antibody conformational dependence is opposite for these two lentiviruses.  EIAV Env specific 
antibodies initially recognize predominantly linear epitopes, but mature to identify 
predominantly conformational epitopes (Fig 1.4); SIV Env specific antibodies maintain high 
conformational ratios, but throughout the course of infection, the ratio begins to decline.  For 
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both EIAV and SIV, the evolution of conformational epitope recognition evolves in parallel with 
increasing antibody avidity.   
 A general broadening of neutralizing antibodies was observed for both EIAV and SIV 
fectio
 
1.7 IMMUNE MATURATION IN VACCINATED ANIMALS 
 
 
or both EIAV and SIV, the best protection from infection was achieved with attenuated 
a 
mpar
in ns.  However, the levels of neutralizing antibodies fluctuate in both infections, making 
them unreliable indicators of mature immune responses.  Therefore, measurements of avidity and 
conformational ratio of serum antibodies serve as reliable indicators of immune maturation to 
EIAV and SIV infection, while levels of Env specific antibodies and neutralizing antibodies do 
not accurately track the maturation process (99).           
 
 
 
F
vaccines.  Interestingly, both systems required six months to develop protective immunity after 
vaccination (99) indicating a close correlation between immune maturation and vaccine 
protection.  Analysis of SIV vaccinated monkeys established that protective vaccine immunity is 
associated with mature antibody responses.  Non-protected vaccinated monkeys or monkeys that 
developed enhanced disease after virulent challenge demonstrated characteristic immature 
immune responses (25).   The wide spectrum of vaccine efficacy observed in EIAV offered 
researchers the same opportunity to explore immune responses elicited by different vaccines.   
 To discern antibody correlates of protective immunity and disease enhancement 
co ative analysis was performed on seven EIAV vaccines that demonstrated a spectrum of 
protective efficacy.  The study included day of challenge serum from horses/ponies vaccinated 
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with either the attenuated viruses (EIAVΔS2 and EIAVΔDU), formalin-inactivated EIAV, or 
gp90 subunit vaccines (lentil-lectin purified Env (LLgp), HPLC purified gp90 (Vgp90), and two 
recombinant baculovirus gp90 (rgp90)) (54).  Antibody titer, neutralization titer, avidity index 
and conformational ratio were all measured in the vaccinated animals.  No single antibody 
parameter absolutely correlated with vaccine protection or enhancement of disease (Fig 1.5). 
 Contrary to the immune maturation model, where protected animals developed high titer 
ntiboda ies with strong avidity to conformational epitopes, the EIAV vaccinated animals 
protected from disease did not exhibit all the necessary qualitative measurements (Fig 1.5).  
While the antibody titer and conformational ratio of symptomatic animals were consistent with 
the maturation model, not all of the protected animals developed high avidity antibody 
responses.  Additionally, no virus neutralizing activity was observed at day of challenge in any 
of the vaccinated animals.  Overall, it was established that all of the in vitro humoral immune 
parameters identified by the maturation model to lentiviral infection were not absolutely required 
for the protective immune response generated by this cohort of vaccines.  Interestingly, the 
EIAVΔS2 vaccine, which provided apparent sterilizing immunity, satisfied the criteria of the 
immune maturation model (54). 
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Figure 1.5 Antibody titer and conformation ratio as indicators of vaccine protection.   A 
mature immune response in infected ponies is characterized by high endpoint titer (A) and high 
avidity (B) to conformational epitopes (C).   The antibody profile of Ponies vaccinated with 
EIAVΔS2 (▲), EIAVΔDU (Δ), inactivated whole virus (□), lentil-lectin purified Env (◊), HPLC 
purified gp90 (♦), or recombinant baculovirus gp90 (○ and ●) were analyzed to determine if 
there were antibody correlates of vaccine efficacy and enhancement. Figure adapted from 
Hammond et al. 1999. Virology 262:416-430 (54).   
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 In addition to illustrating a correlation between vaccine protection and antibody endpoint 
titer and conformation, the comparative analysis exposed an apparent dependence of vaccine 
efficacy on EIAV Env proteins.  The conformational ELISAs revealed marked differences in 
antibody specificities which could be traced to the nature of the Env proteins in the different 
EIAV vaccines.  The attenuated EIAV vaccines, which offered the best protection from infection 
and disease, displayed natural, oligomeric viral glycoproteins.  The Env proteins of the 
attenuated EIAV strains were identical to virulent virus, and were therefore able to elicit 
antibodies to conformational epitopes, much like natural EIAV infection.  Fixing EIAV with 
formaldehyde caused the envelope to be rigid and non-dynamic, potentially masking some 
antibody epitopes, thereby lowering the conformational ratio and perhaps reducing the protective 
efficacy compared to the attenuated vaccines.  For the recombinant vaccines, the lentil-lectin 
purification process used to purify Env was mild and allowed for conformational epitopes to be 
displayed, while the harsh HPLC purification of the Vgp90 vaccine lead to non-native 
glycoprotein structures and resulted in the recognition of only linear antibody epitopes.  Finally, 
recombinant gp90 produced in baculovirus infected insect cells was only able to produce linear 
epitopes, most likely due to the differences of insect protein production compared to mammalian 
protein production.  LLgp offered the best protection from disease out of the recombinant 
vaccines, while the rgp90 caused severe enhancement of disease (54).  Taken together, these 
observations emphasize the importance of using native viral glycoproteins in lentiviral vaccine 
preparations.   
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1.8 EIAV ENVELOPE PROTEINS 
 
 
The EIAV Env, presented as a trimer on the virion surface, is composed of a surface 
glycoprotein (gp90) and a transmembrane glycoprotein (gp45) (Fig 1.6).  The non-covalently 
linked proteins are anchored in the lipid bilayer through the membrane spanning domain of gp45.  
The cytoplasmic tail of gp45 is the most conserved portion of the two Env proteins, while gp90 
is the most variable protein of the entire virus.  The error prone lentiviral RT permits the 
development of mutations in the Env proteins, which rapidly accumulate enabling EIAV to 
escape host immune control.  In addition to escape mutations, Env employs glycosylation to 
mask the virus from the immune system.  The envelope proteins are heavily glycosylated with 18 
predicted N-linked glycosylation sites on gp90 and four on gp45.  With these immune evasion 
techniques, EIAV breaks free of immune control, rapidly replicates and induces new febrile 
episodes.  Longitudinal sequencing analysis of plasma viral RNA from a chronically infected 
pony revealed that Env mutations are not randomly distributed.  Instead, eight variable regions 
(V1 to V8) were identified where amino acid sequences were more than 30% divergent from the 
consensus sequence (77).   
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Figure 1.6 EIAV Env glycoproteins.  EIAV Env is composed of a surface glycoprotein, gp90, 
non-covalently linked to a transmembrane glycoprotein, gp45.  N-linked glycosylation sites are 
indicated with a *.  The predefined variable domains of gp90 are highlighted in blue and labeled 
V1-V8.  The shaded box on gp45 indicates the lipid bilayer. Adapted from Tagmyer et al. 2007. 
JGV 88:1324-1336 (132). 
  
  The gp90 protein serves as the target for neutralizing antibodies.  Longitudinal serum 
neutralization analysis against homologous virus from a chronically infected pony revealed that 
EIAV Env evolution during persistent infection leads to an increasingly neutralization resistant 
phenotype (60).  Three neutralization epitopes were identified in gp90 using monoclonal 
antibodies (12), two of these epitopes span V3 and compose the principal neutralization domain 
(PND) while the third is in the V5 region.  As expected, a pony infected with an EIAVΔPND 
mutant did not develop a measurable neutralization titer.  However, after immune suppression 
with dexamethasone, neutralizing antibodies were detected in the EIAVΔPND infected pony, 
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demonstrating that V3 is not required for the development of a neutralization response (33).  
 With the extensive variability and rapid ability to evade host immune responses, Env 
poses a major obstacle the development of any lentiviral vaccine (18).  The previously described 
work with EIAV and SIV established an immune maturation to the Env proteins during infection 
and vaccination.  Additionally, EIAV vaccine efficacy was shown to be highly dependent on the 
conformation of Env.  For these reasons, I hypothesize that Env is a primary determinant of 
vaccine efficacy, and that effective vaccines must elicit appropriate immune responses to 
conserved regions of the viral envelope.  To test this hypothesis, a new attenuated vaccine, 
EIAVD9, was developed to test the effects of Env variation on vaccine efficacy.   
 
 
 
 
1.9 EIAVD9 VACCINE 
  
 
The EIAVΔS2 was the most effective vaccine at preventing infection and disease after virulent 
challenge, however, as with all other attenuated lentiviral vaccines, reversion to virulence 
remained a major concern (98).  The original EIAVΔS2 vaccine was developed by introducing 
two stop codons into the S2 gene of the infectious molecular clone EIAVUK (81).  The mutations 
did not disrupt the second exon of tat, the initiation codon of env, or the putative rev-response 
element (RRE).  The insertion of the first stop codon introduced a novel Spe I site in S2 that was 
not found in the parental S2, discriminating EIAVΔS2 from the parental EIAVUK (32, 79).  Due 
to rapid evolution of lentiviral genomes and the ability to easily overcome two stop codons, a 
new EIAVΔS2 mutant was developed to minimize the potential reversion to virulence.  
Overlapping PCR mutagenesis techniques were utilized to create EIAVD9 which has a nine base 
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pair deletion in EIAVΔS2 (32).  The deletion conserved the two stop codons of EIAVΔS2, and 
also did not affect tat, env or the rev-response element (Fig 1.7). 
 
EIAVD9 Vaccination (IM)
0         1            2            3            4            5 6            7           8            9
Months
103 HID 103 HID 103 TCID50
EIAV Challenge (IV)
A.
B.
 
Figure 1.7 EIAVD9 vaccine and immunization strategy.  (A)  The EIAVD9 vaccine was 
developed by deleting nine amino acids from the EIAVΔS2 construct.  The shaded box indicates 
one of the two preserved stop codons of EIAVΔS2.  (B)  EIAVD9 is administered in two 
intramuscular doses 30 days apart.  Seven months after the first immunization, the animals are 
intravenously challenged with virulent EIAV.  HID = horse infectious dose, TCID50 = tissue 
culture infectious dose. Adapted from Craigo et al. 2007. Vaccine 25:834-845 (32). 
  
 Twelve horses were immunized with EIAVD9.  None of the twelve immunized hoses 
became infected after homologous challenge with EIAVPV, indicating apparent sterilizing 
immunity (32).  Since EIAVUK is a molecular clone of EIAVPV, the two are considered to be 
homologous (29).  Each vaccinated horse developed antibody responses consistent with the 
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immune maturation model and indicated that a mature immune response was achieved at the 
time of challenge.  To test the apparent “sterilizing” immunity of the 12 vaccinated horses, a 14 
day dexamethasone treatment was used to immune suppress each immunized horse two months 
after EIAVPV challenge.  Before dexamethasone treatment, all 12 horses were free of EIA and 
detectable plasma viremia, as measured by Real-time RT-PCR.  Immune suppression caused six 
of the 12 horses to develop EIA, and post-dexamethasone treatment revealed 50% of the horses 
were infected with EIAVPV.  Despite not achieving “sterilizing” immunity, the EIAVD9 vaccine 
did prevent disease and apparent infection before immune suppression, making EIAVD9 valuable 
in discerning the contribution of Env to vaccine efficacy. 
 Towards this goal, Env variants of EIAV were developed to be used as challenge strains 
for the EIAVD9 vaccine.  The majority of Env variation takes place in gp90, with little variation 
occurring in gp45 (77), therefore the focus of the trial involved variation of the gp90 protein.  
Plasma samples were obtained from a pony chronically infected with EIAVPV to isolate variant 
viruses during sequential disease episodes.  From this study, three variants were isolated that 
diverged from the EIAVPV gp90 by 6, 10 and 13% at the amino acid level (Fig 1.8).   
 The gp90 of each variant was placed into the backbone of EIAVUK3.  In developing 
EIAVUK from EIAVPV, a 68 base pair duplication in the 3’LTR and an arginine at position 103 
instead of a tryptophan in the second exon of rev were introduced (27).  For EIAVUK3 clone, the 
duplication was deleted, and the tryptophan was restored, making EIAVUK3 equivalently 
pathogenic as EIAVPV in horses.  Therefore, EIAVUK3 was used to construct the variant Env 
EIAV challenge strains.  Ponies infected with the three Env challenge strains EV0, EV6, and 
EV13 developed EIA and sustained viral loads (36).  
 
 28
  
                                    V1
EV0    MVSIAFYGGIPGGISTPITQQSEKSKCEENTMFQPYCYNNDSKNSMAESKEARDQEMNLK  
EV6    MVSIAFYGGIPGGISTPITQQSEKSKCEENTMFQPYCYNNDSKNSMAESKEARDQEMNLK  
EV13   MVSIAFYGGIPGGISTPITQQSEKSKCEENTIFQPYCYNNDSKNSMAESKEARDQEMNLK  
                
EV0    EESKEEKRRNDWWKIGMFLLCLAGTTGGILWWYEGLPQQHYIGLVAIGGRLNGSGQSNAI  
EV6    EESKEEKRRNDWWKIGMFLLCLAGTTGGILWWYEGLPQQHYIGLVAIGGRLNGSGQSNAI  
EV13   EESKEEKRRNDWWKIGMFLLCLAGTTGGILWWYEGLPQQHYIGLVAIGGRLNGSGQSNAI  
                              V2 
EV0    ECWGSFPGCRPFQNYFSYETNRSMHMDNNTATLLEAYHREITFIYKSSCTDSDHCQEYQC  
EV6    ECWGSFPGCRPFQNYFSYETNRSMHIDNNTATLLEAYHREITFIYKSSCTDSDHCQEYQC  
EV13   ECWGSFPGCRPFQNYFSYETNRNIHIDNNTATLLEAYHREITFIYKSSCTDSDHCQEYQC  
                  V3 
EV0    KKVNLNSSDSSNP----VRV---EDVMNTTEYWGFKWLECNQTENFKTILVPENEMVNIN  
EV6    NKVNLNLNSFDSS----IHV---EDVKDTTEYWGFKWLECNQTENFKTILVPENEMVNIN  
EV13   KKVNFTVSKANGSSIPSIHVGGVEDAETTIEYWGFKWLECNQTENLKTILVPENEMVKIK  
       V4                                  V5            
EV0    DTDTWIPKGCNETWARVKRCPIDILYGIHPIRLCVQPPFFLVQEKGIANTSRIGNCGPTI  
EV6    DNDTWIAKGCNETWARVKRCPIDILYGIHPIRLCVQPPFFLVQEKEVANTSRIGNCGPTI  
EV13   N-GTWTPKGCNETWARVKRCPIDILYGIHPIRLCVQPPFFLVQENRGDNIARIGNCGPTI  
                       V6 
EV0    FLGVLEDNKGVVRGNYTACNVSRLKINRKDYTGIYQVPIFYTCNFTNITSCNNEPIISVI  
EV6    FLGVLEDNKGVVRENYTACNVSHLRINRKDYTGIYQVPIFYTCNFTNITSCNNESIISVI  
EV13   FLGVLEDNKGVVRGSPTACNVRKLGINRKDYTGIYQGPMFYTCNFTSITSCNDESITSVI  
                     V7                         V8 
EV0    MYETNQVQYLLCNNNNSN-NYNCVVQSFGVIGQAHLELPRPNKRIRNQSFNQYNCSINNK  
EV6    MYETNQVQYLLCNNNNSN-HYNCVVQSFGVIGQAHLELPRPNKRIRNQSFNQYNCSINNK  
EV13   MYETNQVQYLLCKYNTTDSNYTCVVQSFGVIGQAHLELPRPNKRIMNPNFNQYNCSINNK  
                 
EV0    TELETWKLVKTSGITPLPISSEANTGLIRHKR  
EV6    TELETWKLVKTSGITPLPISSEANTGLIRHKR  
EV13   TELETWKLVKTSGITPLPISSEANTGLIRHKR   
Figure 1.8 Alignment of EIAV variant gp90 proteins.  Divergent amino acids between the 
three variant challenge strains are highlighted in yellow.  The predefined variable domains are 
labeled V1-V8, potential N-linked glycosylation sites are in blue. 
  
 To test the contribution of Env to vaccine efficacy, 24 ponies were immunized with 
EIAVD9 and subsequently challenged 7 months post vaccination with EV0 (EIAVUK3), EV6 (6% 
variant Env) or EV13 (13% variant Env).  By 120 days post challenge, one EV0, three EV6 and 
five EV13 ponies developed EIA, demonstrating a clear inverse correlation between Env 
divergence and vaccine protection (36) (Fig 1.9).   
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Figure 1.9 Disease outcome of variant challenged EIAVD9 vaccinated ponies. 
 
 As Env is the only variant protein in the three different challenge strains, there must be 
Env-specific immune responses associated with vaccine protection from disease.  Differentiating 
the responses between the protected and non-protected ponies would provide valuable insight 
into the appropriate humoral and cellular immune responses necessary for vaccine induced 
immunity to EIAV.  Identifying Env-specific immune responses could also help to address the 
effects of Env variation on immune recognition while also aid in the development of more 
effective lentiviral vaccines by developing new vaccine strategies to target the specified immune 
responses.     
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2.0 HYPOTHESIS AND SPECIFIC AIMS 
 
 
 
While many vaccines against infectious diseases have been developed through empiric 
methodologies, it is clear that understanding specific immune responses will be necessary to 
develop an effective lentiviral vaccine.  The best way to dissect protective anti-lentiviral immune 
responses is through animal vaccine model systems.  While SIV has been the “gold standard” for 
identifying key immune responses for HIV vaccine development, researchers have fallen short of 
finding immune correlates of vaccine protection.  However, the EIAVD9 vaccine, in combination 
with the different challenge strains provides a unique opportunity to identify key determinants of 
vaccine induced protective immunity.  Additionally, the three challenge strains allow for the 
investigation of the effects of natural Env sequence variation on immune recognition.  By 
analyzing the immune responses of protected and non-protected vaccinated ponies after 
challenge, I hypothesize there may be Env-specific cellular and humoral immune responses 
associated with vaccine protection from disease.  Additionally, I believe that the natural Env 
sequence variation between the three challenge strains will alter both the cellular and 
humoral immune responses in infected and vaccinated ponies.          
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The specific aims addressed in this dissertation are: 
 
SPECIFIC AIM 1:  Define Env peptide-specific cellular reactivity of the EIAV reference 
strain.  A necessary foundation for defining determinants of vaccine protection is an 
understanding of the humoral and cellular immune responses to the Env proteins of the vaccine 
and the homologous challenge strain.  Previous work identified the V3 and V4 regions as integral 
to neutralizing antibody recognition, but the cellular immune response to Env have remained 
unexplored.  The first objective is to utilize day of challenge PBMC from 12 EIAVD9 vaccinated 
horses and PBMC from two EIAVPV infected horses to identify broadly reactive Env specific Th 
and CTL peptide responses.  Cellular responses will be analyzed using thymidine incorporation 
to measure Th proliferation and chromium release to measure CTL cytolytic activity.  These data 
will provide a basis for identifying cellular immune responses associated with vaccine protection 
and provide a reference for analyzing the effects of amino acid variation on immune recognition. 
 
SPECIFIC AIM 2:  Identify humoral and cellular immune determinants associated with 
vaccine protection from disease.  Challenging 24 EIAVD9 vaccinated ponies with divergent 
Env strains demonstrated that Env is a primary determinant of vaccine efficacy.  The vaccine 
trial provides the unique opportunity to elucidate immune responses associated with vaccine 
protection from disease.  Day of challenge PBMC from the 24 vaccinated ponies will be used to 
analyze Env specific Th proliferation and CTL cytolytic activity to identify Env peptide-specific 
immune responses associated with vaccine protection from disease.  Additionally, day of 
challenge and four week post challenge sera will be used to analyze vaccine-specific and 
challenge strain-specific neutralizing antibodies to determine if a relationship exists between 
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neutralization activity and protective efficacy.  These data will provide valuable insight into 
lentiviral vaccine protection and may aid in the development of more effective EIAV vaccines.       
 
SPECIFIC AIM 3: Analyze the effects of natural Env variation on immune recognition in 
EIAV infected and vaccinated ponies.  Lentiviruses utilize numerous escape mechanisms to 
evade the host immune responses.  Among the escape mechanisms is antigenic variation of 
immune epitopes.  To examine the effects of natural Env variation, we will analyze the humoral 
and cellular immune responses of ponies infected with each of three challenge strains.  Sera from 
infected ponies will be used to measure the level of cross-reactivity between the three variant 
strains, and also to map the neutralization specificity in Env.  PBMC from ponies infected with 
each variant will be used to map Env peptide-specific Th and CTL responses and to analyze the 
effects of amino acid variation on cellular immune recognition.  Additionally, sera and PBMC 
from EIAVD9 vaccinated ponies will  also be used to define the effects of variation on vaccine 
induced immunity.  Collectively, these data will help to provide a better understanding of Env 
variation on immune recognition, which may have profound effects on vaccine efficacy.              
 
 With the EIAVD9 vaccine trials, we are poised to identify critical immune determinants 
necessary for vaccine protection from disease and how natural Env variation may affect immune 
responses elicited by protective vaccines.  These data may provide solid groundwork for further 
investigation of immune responses associated with vaccine protection.  Additionally, this work 
may help to develop more effective EIAV vaccines.  Understanding the immune responses and 
effects of Env variation in the EIAV model system, could possibly aid in the investigation of 
protective immune responses in other lentiviral systems.       
 33
 34
 
 
 
 
 
3.0 ENVELOPE-SPECIFIC T-HELPER AND CTL RESPONSES 
ASSOCIATED WITH PROTECTIVE IMMUNITY TO EQUINE 
INFECTIOUS ANIMEMIA VIRUS 
 
 
 
 
This chapter was modified from: 
Tara L. Tagmyer, Jodi K. Craigo, Sheila J. Cook, Charles J. Issel, Ronald C. Montelaro.  
Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective 
immunity to equine infectious anemia virus. (2007). Journal of General Virology. 88:1324-1336. 
Reprinted with permission from the Journal of General Virology 
 
3.1 INTRODUCTION 
 
 
Equine infectious anemia virus (EIAV) is a lentivirus of equids that shares genetic and structural 
similarities with HIV-1, but causes a unique disease process among the known lentiviruses (97).  
While human and other animal lentiviruses cause progressive degenerative or immune 
suppressive disease, EIAV infection of horses is characterized by dynamic recurring disease 
cycles in the first year of infection.  Following this chronic stage of disease, most infected horses 
progress to a long term inapparent carrier state in which disease and virus replication is strictly 
controlled for the life span of the horse.  This inapparent state is not attributable to attenuation of 
the infecting virus, as whole blood transfers from inapparent carriers can induce disease in naïve 
recipient horses and immune suppression of inapparent horses can induce a recurrence of 
disease, indicating the potential virulence of the infecting EIAV (64, 89, 97).  In addition, 
inapparent carriers of EIAV appear to be highly resistant to additional exposure to diverse and 
highly virulent strains of EIAV, suggesting that the immune response in inapparent carriers not 
only controls the existing infection, but provides a high level of prophylactic immunity (97).  
Thus, the EIAV system is useful in examining the natural immunologic control of a pathogenic 
lentivirus infection, despite the array of persistence mechanisms employed by these viruses.   
During the past 20 years, we have evaluated a number of experimental EIAV vaccines, 
with the results revealing that EIAV-specific immune responses are a double-edged sword that 
can protect or enhance viral disease and infection upon virus challenge of experimentally 
vaccinated horses (34, 54, 65, 79, 83, 116, 136).  As observed in similar studies of experimental 
vaccines in the SIV and FIV systems, attenuated EIAV vaccines have to date produced the 
highest level of vaccine immunity against virulent EIAV challenge (15).  Interestingly, however, 
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these attenuated lentiviral vaccines do not achieve optimum protective immunity until six months 
post inoculation, indicating a progressive maturation of virus-specific immunity.  In addition to 
the protective immunity observed in EIAV inapparent carriers, the mature immunity elicited by 
attenuated EIAV vaccines provides a complementary model for defining critical immune 
correlates of enduring broadly protective vaccine immunity to a lentiviral infection. 
Based on a comparison of the quantitative and qualitative properties of lentiviral Env-
specific antibodies, we have defined an association between immature/non-protective or 
enhancing and mature/protective virus-specific immunity in the EIAV/horse (54), SIV/monkey 
(23, 25), and SHIV/monkey (24) vaccine systems.  Thus, we propose that lentiviral vaccines 
must sufficiently drive this immune maturation to achieve protective efficacy.  Additionally, we 
hypothesize that the EIAV Env is a major determinant of vaccine efficacy and that the 
maturation to protective immunity is associated with a redirection of host immune responses 
from immunodominant variable Env domains to relatively immunorecessive conserved Env 
domains.   
There is to date only limited characterization of cellular and humoral immune responses 
associated with enduring protective EIAV immunity.  Clearance of the acute viremia typically 
correlates with the appearance of CTL (90) and non-neutralizing antibodies (109, 122).  While 
levels of CTL fluctuate throughout the disease course, neutralizing antibodies generally do not 
appear until two months post-infection  and increase in titer and breadth of specificity during the 
first year post-infection (12, 52, 60, 104).  Recently, however, Mealey et al have shown the 
presence of neutralizing antibodies immediately after the resolution of acute disease, perhaps 
suggesting an earlier role for neutralizing antibodies in controlling EIAV replication in 
experimentally infected horses (93).  During the chronic phase of EIAV infection, there is a high 
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propensity for the selection of antigenic variants of EIAV that are able to temporarily escape the 
existing neutralizing antibodies directed to Env proteins or CTL responses directed to Gag 
protein epitopes (22, 60, 63, 94).  The prevalence of antibody and CTL antigenic variants is 
consistent with a role for these specific immune responses in controlling EIAV infection.  
McGuire and colleagues have thoroughly examined the specificity of CTL responses to EIAV 
Gag and Pol proteins to identify broadly reactive Th and CTL epitopes in these proteins (22, 60, 
63, 94).  However, vaccines based on these broadly reactive T-cell epitopes have failed to elicit 
protective immunity against EIAV challenge (45), indicating that immune responses to other 
viral proteins, such as Env, may be an important component to the establishment of protective 
immunity to EIAV.   
To explain the observed requirement of maturation for protective immunity, we have 
proposed that the progression towards protection is associated with recognition of conserved 
immunorecessive epitopes of the Env proteins.  A necessary foundation for testing this 
hypothesis is a detailed characterization of humoral and cellular epitopes in the Env proteins that 
are recognized during protective immunity.  We have previously examined in detail the 
neutralizing epitopes of EIAV Env proteins and the effects of sequence variation on viral 
neutralization properties (12, 33, 60).  In contrast to the detailed studies of Env neutralization 
determinants, there have been limited studies of the Th and CTL epitopes of EIAV Env proteins.  
Thus, in the current study we have used 12 horses immunized with a highly protective attenuated 
EIAV vaccine and two experimentally infected asymptomatic carrier horses, with the infecting 
virus strain in both groups of horses expressing identical Env proteins, to elucidate regions of 
EIAV Env that are broadly recognized by Th and CTL.  The results of these studies for the first 
time provide a comprehensive mapping of Env specific Th and CTL peptides associated with 
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enduring protective immunity to EIAV and provide a foundation for determining the effects of 
Env variation on immune recognition. 
 
 
3.2 MATERIALS AND METHODS 
 
3.2.a Experimental subjects  
 
 
All equine procedures were conducted at the Gluck Equine Research Center of the University of 
Kentucky according to protocols approved by the University of Kentucky IACUC.  Twelve 
horses were vaccinated with the live attenuated EIAVD9 vaccine (31).  Serological typing of the 
MHC I locus was performed by the University of Kentucky Equine Blood Typing Laboratory 
using established techniques for the 11 A-locus antigenic specificities of the equine lymphocyte 
alloantigen (ELA-A) (Table 3.1) (9, 10).  Direct sequencing of the DRA and DQA MHC II loci 
was performed using previously published protocols (4, 44).  C23, C66 and B81 were not MHC 
II typed due to lack of cells.  After allowing the horses seven months to establish a mature 
immune response to the vaccine, blood was drawn from each horse, and Peripheral Blood 
Mononuclear Cells (PBMC) were isolated over a Histopaque gradient.  On the following day, the 
vaccinated horses were subsequently challenged intravenously with a reference virulent EIAVPV 
using a low dose multiple exposure challenge to mimic the predominant natural route of EIAV 
infection by horse fly bites (79).   
Two naive horses were challenged in parallel with three times 101 HID (horse infectious 
dose) as positive infection controls for the EIAVPV low dose multiple exposure challenge.  Blood 
was obtained from these horses at regular intervals, including after each EIAV febrile episode.  
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PBMC used in these experiments were obtained during asymptomatic stages of infection for 
these two horses.  Five naive horses were included in the study as uninfected controls.  All 
purified PBMC were resuspended in autologous serum and 10% DMSO, and cryopreserved in 
liquid nitrogen.   
 
3.2.b Production of synthetic peptides   
 
 
Eighty-five 20-mer peptides overlapping by 10 residues representing the entire EIAVUK 
(GeneBank AF0161316) Env were synthesized in the Biomedical Research Support Facilities 
Peptide Synthesis Core of the University of Pittsburgh using an Advanced Chemtech Model 396 
Omega Synthesizer.  All peptides were HPLC purified and confirmed by mass spectrometry.  
The peptides were dissolved at 2mg/ml in 100% DMSO and stored at -80°C until further use.  
Pools of 9-10 peptides were constructed in a standard matrix such that each peptide was 
represented in two pools.  The pools were used to stimulate PBMC from the vaccinated and 
control horses in lymphoproliferation assays, and to pulse target cells for chromium release 
assays.  The design of the matrix was such that reactive peptides were indicated by a 
proliferative or a cytolytic response to the two distinct pools containing the peptide.  Reactive 
peptides were then assayed individually to determine their reactivity in the separate assays (121).  
3.2.c Lymphoproliferation assays   
 
 
PBMC from the 12 vaccinated, two infected, and five uninfected horses were tested for 
recognition of EIAV envelope peptides in a standard seven-day thymidine incorporation assay, 
as previously described (46) with minor modifications.  Cryopreserved PBMC from the 
vaccinated, challenged and naïve horses were >80% viable upon thawing and maintained 
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viability throughout the assays, as measured by trypan blue exclusion.  PBMC, at 2 X 105 
cells/well, were assayed in six replicates in complete RPMI-1640 (10% fetal equine serum, 1% 
penicillin/streptomycin, 1% L-glutamine, 55uM β-mercaptoethanol).  In initial experiments, we 
observed relatively high lymphoproliferation backgrounds in PBMC in the absence of peptide 
stimulation, apparently resulting from in vitro amplification of vaccine or challenge virus 
infection in the cultured cells.  The addition of AZT (5uM) (Sigma) to the PBMC upon plating, 
and its replenishment every two days, abrogated virus production and eliminated the observed 
background lymphoproliferation (data not shown).  Cell viability assays with trypan blue 
exclusion and MTT (Roche) staining indicated there were no deleterious effects of AZT on 
PBMC viability.  Pokeweed Mitogen (PWM) and acetone-extracted EIAV (AE-EIAV) were 
used as positive proliferative controls throughout the assays at 2.5ug/ml and 10ug/ml 
respectively.  The peptide pools were used at 20ug/ml, and individual peptides were used at 
10ug/ml.  DMSO was added to the media control wells to match the DMSO concentration in the 
peptide wells.  The PBMC were incubated with PWM for 48 hours, acetone-extracted EIAV for 
four days, and the peptides for six days prior to labeling with 0.75uCi [3H]thymidine (Amersham 
Biosciences).  The cells were incubated an additional 16-18 hours with [3H]thymidine before 
being harvested and quantified for 3H incorporation by liquid scintillation counting.  Stimulation 
indices (SI) were calculated by dividing the mean counts per minute (c.p.m.) of stimulated cells 
by the mean c.p.m. of non- stimulated cells.  A positive response to the peptide pools was SI>1.  
A positive response to the individual peptides was set at least 2X the naïve PBMC stimulation, 
SI>2.5.  Reactive peptides were defined as having >2.5 SI in greater than 50% of the horses, and 
a p-value <0.05 in the Wilcoxon Ranked Sums Test.   
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3.2.d MHC Blocking Assay   
 
 
To determine the MHC specificity of the observed peptide-specific lymphoproliferation, a 
blocking assay was performed using anti equine MHC I (H58A) and MHC II (EqT2) antibodies 
(VMRD).  Preliminary blocking assays showed the optimal antibody concentration for MHC I 
and MHC II to be 10ug/ml.  The optimal concentration for the IgG control was 5ug/ml.  The 
antibodies were incubated with PBMC (2 x 106 cells/ml) for one hour at 37°C, 5% CO2 before 
stimulation with peptides at 20ug/ml.  After one hour of peptide stimulation in the presence of 
antibody, the cells were washed three times with 1X PBS 1% horse serum (HS) and resuspended 
in 200ul of RPMI complete.  A standard seven day thymidine incorporation assay was then 
performed as described above.  Proliferation was considered MHC II-restricted when the 
stimulation index of the MHC II antibody treated PBMC was decreased by >50% compared to 
the stimulation index of PBMC treated with IgG or MHC I antibodies.  Since MHC II molecules 
present peptides to CD4 Th cells, it can be inferred that MHC II restricted peptides cause Th 
proliferation.        
3.2.e CTL assays   
 
Standard chromium release assays previously employed for the identification of EIAV CTL 
epitopes in Gag and Pol were used for these studies, with minor modifications (53, 90, 91, 119, 
143).  PBMC from the vaccinated or infected horses were expanded in vivo for 7-10 days with 
either 2.5ug/ml PWM or 10ug/ml gradient purified EIAV in complete RPMI supplemented with 
20U rhIL2 (Hoffmann-La Roche INC.).   After expansion, the PWM stimulated cells were 
labeled with 100uCi 51Cr (Na51CrO) (MP) for one hour at 37°C, 5% CO2.  Cells were washed 
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four times with 1X PBS 1% HS and 30,000 cells/well were plated prior to peptide pulsing.  
Peptide pools were used at a final concentration of 20ug/ml, and individual peptides were used at 
a final concentration of 10ug/ml.  The target cells were pulsed for one hour at 37°C, 5% CO2.  
EIAV-stimulated cells were used as effector cells at a 20:1 E:T ratio.  After the effector cell 
addition, the cells were incubated 12-16 hrs prior to being harvested. Following this incubation, 
25ul of cell supernatant was added to 175ul of OptiPhase SuperMix scintillation fluid (Perkin 
Elmer) and analyzed for 51Cr release with a MicroBeta reader (Perkin Elmer).  Maximum 51Cr 
release was determined by plating 51Cr-labeled target cells with the non-ionic detergent Nonidet 
P-40 to lyse cells.  Background spontaneous lysis was determined by plating 51Cr-labeled target 
cells with 0.1ml of medium alone.  Percent specific lysis was calculated as follow: 
(51Cr release in peptide wells - spontaneous 51Cr release) x 100/ (51Cr release by NP-40- 
spontaneous 51Cr release) = % Specific lysis 
Reactive peptides were defined as causing >10% specific lysis in >50% of the reactive 
horses and have a p-value <0.05 in the Mann-Whitney Test.       
 
 
3.3 RESULTS 
 
3.3.a Experimental subjects   
 
 
The 12 vaccinated horses were subjects of a vaccine trial to test the efficacy of an attenuated 
vaccine strain, EIAVD9, containing an engineered nine-base pair deletion and two termination 
codons in the viral S2 gene.  Each vaccinated horse seroconverted by 35 days post infection, and 
Env-specific serological assays performed on longitudinal serum samples confirmed the 
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establishment of mature immune responses to the vaccine strain of virus by six months post-
infection (31).  Before the horses were challenged with the reference virulent EIAVPV strain, 
whole blood was drawn, and PBMC were isolated for use in cellular immune assays.  All 12 
horses were protected from virulent virus challenge as evidenced by lack of EIA signs and 
detectable challenge virus in plasma.  Two naive horses were experimentally infected with 
EIAVPV to serve as infection and virulence controls for the EIAVPV challenge.  PBMC from 
these EIAVPV-infected horses were isolated after at least six months post infection, when mature 
EIAV Env-specific immune responses were documented.  PBMC from five naïve horses were 
included in the lymphoproliferation assays to establish appropriate background levels. 
3.3.b Proliferation in response to the synthetic peptide pools   
 
 
Preliminary proliferation assays were performed using PWM or AE-EIAV as stimulants in a 
standard thymidine incorporation lymphoproliferation assay.  All the horses responded well to 
PWM, with stimulation indices (SI) above 50 (Table 3.1).  In response to AE-EIAV, all horses 
displayed a positive proliferation with SI values ranging from 3-140, presumably reflecting the 
variation in virus-specific immune responses among this outbred population of horses (Table 
3.1).  Proliferation in response to PWM and AE-EIAV demonstrated that the PBMC maintained 
proliferative capabilities following cryopreservation and thawing.  Based on these preliminary 
observations, the PWM and AE-EIAV were used as positive controls for lymphoproliferation in 
parallel assays to the peptide stimulations.  
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Table 3.1 Preliminary cellular data from vaccinated and infected horses. 
MHC I % Specific Lysis (§)
Horse (*) Age ELA-A (†) DRA DQA PWM AE EIAV Envelope Pool
C13 yearling A2/A3 101 301/401 178 +/- 91 12 +/- 3 9 +/- 7
C15 yearling A2/W11 101/301 301 132 +/- 34 3 +/- 1 5 +/- 7
C55 4 years A4/A7 101/201 201/1301 67 +/- 13 19 +/- 14 18 +/- 3
B81 10 years A1/A11 ND(║) ND 105 +/- 36 10 +/- 4 15 +/- 7
C9 yearling A3/A5 301/501 301/1301 136 +/- 46 3 +/- 2 negative
C16 yearling A1/A3 301/501 301/1301 176 +/- 18 43 +/- 15 11 +/- 8
C66 3-4 years A2/A5 ND ND 53 +/- 23 20 +/- 5 15 +/- 12
C62 19 years A2/W11 101/301 201/1301 161 +/- 25 12 +/- 6 26+/- 15
C22 yearling A2/A8 201/301 201/701 163 +/- 83 24 +/- 11 11 +/- 5
C23 yearling W11/A3 ND ND 294 +/- 81 18 +/- 4 1.3 +/- 1.5
B61 5 years A2/A10 101 301/501 134 +/- 15 6 +/- 2 4 +/- 2
266 10 years A2/A3 101 401 283 /- 9 7 +/- 5 negative
D64 6 years A2/A9 101 501 156 +/- 70 27 +/- 12 2 +/- 0
D58 3 years A2/A5 101/301 101/301 135 +/- 40 133 +/- 80 negative
(║) There were not sufficient PBMC to determine the haplotype
(§) A pool of gp90 peptides was used to pulse target cells in the chromium release assay.  Specific lysis is reported as the mean +/- SD.
(*) Horses were vaccinated with the live attenuated D9 vaccine.  PBMC were obtained from each vaccinated horse at seven months post-
vaccination.  Challenged horses were infected with EIAVPV and PBMC were obtained after 13 months post-challenge.
(†) Horses were ELA-A typed at the University of Kentucky Equine Blood Typing Laboratory to establish the heterogenity of the group.
(‡) PWM and AE EIAV were used to stimulate cells in the thymidine incorporation assay.  Stimulation indices are reported as the mean 
+/- SD. 
Stimulation Indices (‡)
D9 Vaccinated 
Horses
PV 
Challenged 
Horses
MHC II 
 
 
An inclusive scan of all potential T-helper peptides was conducted using a peptide matrix 
strategy.  Eighty-five peptides (20-mers overlapping by 10 amino acids), encompassing the 
EIAVUK Env proteins gp90 (SU) and gp45 (TM), were synthesized and used in pools of 9-10 
peptides (Figure 3.1A) to stimulate PBMC from the vaccinated and infected horses in a standard 
thymidine incorporation assay and also to label target cells for the chromium release assay.  
Figure 3.1B is a representative graph of the matrix results for the lymphoproliferation assay.  An 
SI>1.0 was used as the cutoff for determining positive proliferation.  
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Figure 3.1 Proliferation and CTL lysis with EIAV Env peptide matrix.  A.  A panel of 
sequential overlapping Env 20-mer peptides encompassing gp90 and gp45 were synthesized and 
pooled into a matrix format.  B.   Representative graph of the reactivity of individual matrix 
pools in stimulating PBMC for the lymphoproliferation assay.  A proliferative response to the 
peptide pools is defined as an SI>1, as indicated by the solid line on the graph.  C.  
Representative graph of the cytolytic reactivity of individual matrix pools in labeling target 
PBMC in the chromium release assay.  A positive CTL response to the peptide pools was 
defined as Specific Lysis >10%, as indicated by the solid line. 
 
Two independent assays were conducted on PBMC from each horse for a total of 28 
assays.  If a peptide was identified as positive (SI>1) in eight out of the 28 assays (~30%), the 
peptide was subsequently tested individually to determine peptide-specific proliferative 
properties (Table 3.2).  Based on these criteria, 21 peptides were identified and tested 
individually (Table 3.2).  An additional five peptides were also chosen (#23, #60, #73, #74 and 
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#77) because the corresponding peptide pools produced high stimulation indices in PBMC from 
several horses, but not in the minimum of eight horses. 
Table 3.2 EIAVUK peptides and peptide matrix results. 
GP90 
Peptides Peptide Sequence
(*) Proliferation(‡) CTL(§)
GP45 
Peptides Peptide Sequence
(*) Proliferation(‡) CTL(§)
1 MVSIAFYGGIPGGISTPITQ 9 1 45 RHKRDFGISAIVAAIVAATA 2 4
2 PGGISTPITQQSEKSKCEEN 4 1 46 IVAAIVAATAIAASATMSYV 4 3
3 QSEKSKCEENTMFQPYCYNN 3 4 47 IAASATMSYVALTEVNKIME 3 3
4 TMFQPYCYNNDSKNSMAESK 8 2 48 ALTEVNKIMEVQNHTFEVEN 10 3
5 DSKNSMAESKEARDQEMNLK 6 4 49 VQNHTFEVENSTLNGMDLIE 0 3
6 EARDQEMNLKEESKEEKRRN 5 1 50 STLNGMDLIERQIKILYAMI 10 3
7 EESKEEKRRNDWWKIGMFLL 12 3 51 RQIKILYAMILQTHADVQLL 0 2
8 DWWKIGMFLLCLAGTTGGIL 2 2 52 LQTHADVQLLKERQQVEETF 7 3
9 CLAGTTGGILWWYEGLPQQH 12 4 53 KERQQVEETFNLIGCIERTH 1 4
10 WWYEGLPQQHYIGLVAIGGR 4 2 54 NLIGCIERTHVFCHTGHPWN 4 3
11 YIGLVAIGGRLNGSGQSNAI 10 3 55 VFCHTGHPWNMSWGHLNEST 4 1
12 LNGSGQSNAIECWGSFPGCR 5 2 56 MSWGHLNESTQWDDWVSKME 7 1
13  ECWGSFPGCRPFQNYFSYET 4 3 57 QWDDWVSKMEDLNQEILTIL 1 3
14 PFQNYFSYETNRSMHMDNNT 5 2 58  DLNQEILTILHGARNNLAQS 11 3
15 NRSMHMDNNTATLLEAYHRE 6 2 59 HGARNNLAQSMITFNTPDSI 4 3
16 ATLLEAYHREITFIYKSSCT 5 2 60 MITFNTPDSIAQFGKDLWSH 7 1
17 ITFIYKSSCTDSDHCQEYQC 10 4 61 AQFGKDLWSHIGNWIPGLGA 4 3
18 DSDHCQEYQCKKVNLNSSDS 3 2 62 IGNWIPGLGASIIKYIVMFL 2 4
19 KKVNLNSSDSSNPVRVEDVM 9 1 63 SIIKYIVMFLLIYLLLTSSP 4 3
20 SNPVRVEDVMNTTEYWGFKW 3 1 64 LIYLLLTSSPKILRALWKVT 4 4
21 NTTEYWGFKWLECNQTENFK 4 4 65 KILRALWKVTSGAGSSGSRY 4 3
22 LECNQTENFKTILVPENEMV 4 2 66 SGAGSSGSRYLKKKFHHKHA 11 3
23 TILVPENEMVNINDTDTWIP 6 4 67 LKKKFHHKHASREDTWDQAQ 2 3
24 NINDTDTWIPKGCNETWARV 2 1 68 SREDTWDQAQHNIHLAGVTG 11 4
25 KGCNETWARVKRCPIDILYG 15 3 69 HNIHLAGVTGGSGDKYYKQK 2 1
26 KRCPIDILYGIHPIRLCVQP 1 4 70 GSGDKYYKQKCSRNDWNGES 9 3
27 IHPIRLCVQPPFFLVQEKGI 17 4 71 CSRNDWNGESEEYNRRPKSW 3 3
28 PFFLVQEKGIANTSRIGNCG 2 4 72 EEYNRRPKSWVKSIEAFGES 4 3
29 ANTSRIGNCGPTIFLGVLED 14 3 73 VKSIEAFGESYISEKTKGEI 6 1
30 PTIFLGVLEDNKGVVRGNYT 2 3 74 YISEKTKGEISQPGAAINEH 6 2
31 NKGVVRGNYTACNVSRLKIN 4 3 75 SQPGAAINEHKNGSGGNNPH 2 2
32 ACNVSRLKINRKDYTGIYQV 2 4 76 KNGSGGNNPHQGSLDLEIRS 11 4
33  RKDYTGIYQVPIFYTCNFTN 6 2 77 QGSLDLEIRSEGGNIYDCCI 5 2
34 PIFYTCNFTNITSCNNEPII 3 3 78 EGGNIYDCCIKAQEGTLAIP 3 1
35 ITSCNNEPIISVIMYETNQV 14 4 79 KAQEGTLAIPCCGFPLWLFW 9 2
36 SVIMYETNQVQYLLCNNNNS 2 3 80 CCGFPLWLFWGLVIIVGRIA 1 3
37 QYLLCNNNNSNNYNCVVQSF 2 1 81 GLVIIVGRIAGYGLRGLAVI 8 2
38  NNYNCVVQSFGVIGQAHLEL 2 2 82 GYGLRGLAVIIRICIRGLNL 3 3
39 GVIGQAHLELPRPNKRIRNQ 1 4 83 IRICIRGLNLIFEIIRKMLD 10 2
40 PRPNKRIRNQSFNQYNCSIN 2 4 84 IFEIIRKMLDYIGRALNPGT 5 2
41 SFNQYNCSINNKTELETWKL 2 4 85 YIGRALNPGTSHVSMPQYV 3 2
42 NKTELETWKLVKTSGITPLP 7 1
43  VKTSGITPLPISSEANTGLI 2 3
44 ISSEANTGLIRHKRDFGISA 3 3
(§) For the CTL assay, a peptide had to be indicated four times (shaded) to be considered for individual analysis.
Matrix Hits(†) Matrix Hits(†)
(*) 20-mer peptides overlapping by 10 amino acids were synthesized by the Biomedical Research Support Facilities Peptide Synthesis Core of the University of 
Pittsburgh.    
(†) Matrix Hits sums the number of times that a peptide was indicated in the cellular assays using the matrix pools.
(‡) For the proliferation assay, a peptide had to be indicated eight or more times (shaded) to be considered for individual ananlysis.  
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3.3.c Peptide-specific lymphoproliferation   
 
 
To clearly delineate broadly reactive peptides from non-reactive peptides, the 26 peptides 
identified from the peptide matrix assays were used to stimulate the PBMC from the same panel 
of vaccinated and infected horses.  Background proliferation in response to these peptides was 
established by stimulating PBMC from five naïve horses with the 26 peptides.  The average 
background stimulation index was < 0.9.  We defined a reactive peptide as 1) having a 
stimulation index >2.5 (greater than two times the background) in seven of the 14 horses and 2) 
having a p-value < 0.05 in the Wilcoxon Ranked Sums Test. 
Overall, the PBMC from the vaccinated and infected horses proliferated in response to a 
variety of peptides (Figure 3.2).  Of the 26 tested peptides, 23 peptides were positive for 
proliferation in seven of the 14 horses (Figure 3.3A).  Only peptides #17, #48 and #58 did not 
cause proliferation in 50% of the horses, and were therefore not considered reactive.  For the 23 
peptides that were positive for proliferation in >50% of the horses, the Wilcoxon Ranked Sums 
Test was used to establish the statistical significance of the SI values.  This test takes into 
consideration the number of positive events and also the magnitude of stimulation. The ranks 1, 
2 and 3 were defined as SI of 2.5-5, 5-7.5 and >7.5, respectively (Figure 3.2).  All 23 peptides 
that caused stimulation in seven of the 14 horses also had p-values < 0.05, and were thus 
considered to be reactive (Figure 3.3A).       
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Figure 3.2 Proliferation with individual Env peptides.  Individual peptides indicated by the 
peptide matrix pool analysis (Table 3.2) were assayed in a standard thymidine incorporation 
assay against PBMC isolated from the 14 horses.  A proliferative response to the individual 
peptides is defined as an SI > 2.5.  Graphs are averages of three individual assays.  The ranks 1, 2 
and 3 were defined as a SI 2.5-5, 5-7.5, >7.5, respectively. 
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Figure 3.3 Identification and characterization of reactive T-Helper peptides.   A. A panel of 
five naïve horses was used to establish background proliferation with the 26 peptides.  The 
average background was a stimulation index of 0.9.  (*) Individual horses were positive for the 
peptide if the peptide caused a SI > 2.5. (†) The p-value was determined using the Wilcoxon 
Ranked Sums Test.  (‡) Reactive peptides were defined by two criteria: 1) a peptide causing 
proliferation in seven of the 14 horses tested and 2) the peptide having a p-value < 0.05 in the 
Wilcoxon Ranked Sums Test.  B.  MHC blocking assay.  PBMC were either blocked with MHC 
I, MHC II or IgG antibody prior to stimulation with the broadly reactive peptides.  A decrease in 
stimulation >50% compared to the stimulation index of PBMC treated with IgG or MHC I 
antibody is considered significant.  CD4 restricted peptides are underlined. 
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3.3.d T-Cell specificity of peptide specific lymphoproliferation   
 
 
Since Th cells recognize peptides presented by MHC II receptors, blocking assays were 
performed to determine if the peptides were CD4-dependent.  Horse D64 was chosen for the 
depletion assay because PBMC from this horse responded well in the previous proliferation 
assays.  Monoclonal antibodies specific for MHC I or MHC II antigens or control IgG were 
incubated with the cells prior to stimulation with the peptides.  A standard seven-day 
proliferation assay with 3H-thymidine was then performed to determine the effects of the 
antibodies on peptide stimulation.  A 50% decrease in SI of the cells incubated with the MHC II-
specific antibody compared to the SI of cells incubated with the MHC I-specific or control IgG 
antibody indicated that the peptide was MHC II-restricted, indicating the peptide is CD4-
dependent. Fourteen of the 23 peptides were determined to be CD4-restricted with this assay 
(Figure 3.3B).  Five of the peptides demonstrated a pattern that indicated both CD4 and CD8 
cells were proliferating in response to those peptides.  Peptides #7, #60, #66, #68, and #77 all 
decreased in SI when MHC I or MHC II antibodies were used.  Further studies are needed to 
verify the results.  Peptides #11, #19, #76 and #83 failed to produce significant stimulation in 
this assay; therefore, we were unable to determine the CD4/CD8 restriction of these peptides 
(Figure 3.3B).         
 
3.3.e Cytolytic response to the synthetic peptide pools   
 
 
Preliminary CTL assays were conducted to determine the cytolytic capabilities of the PBMC 
from the panel of vaccinated and infected horses against a pool of sequential Env 20-mer 
peptides representing the entire gp90 protein sequence.  PBMC from the 12 vaccinated horses 
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displayed cytolytic activity to the envelope peptide pool with specific lysis values ranging from 
0-30% (Table 3.1).  The PBMC samples from the two infected horses failed to display 
significant CTL activity against the Env peptide pool at the six month post infection time point.   
To identify reactive CTL peptide peptides, the envelope peptide pool matrix was again 
utilized to screen CTL activity of PBMC from four of the vaccinated horses.  Figure 3.1C is a 
representative graph of the matrix results for the CTL assay.  Four horses were used to identify 
potentially positive peptides.  The cutoff for a positive cytolytic response was set at 10% specific 
lysis, and each peptide had to cause lysis in all four assays to be tested individually.  With these 
criteria, 20 peptides were chosen for further analysis as individual peptides (Table 3.2).  
Additionally, peptides #50, #52 and #54 were chosen because they caused high specific lysis in 
three of the four CTL assays.  
 
3.3.f Peptide specific CTL responses   
 
 
To determine which peptides were recognized by CTL cells, the 23 peptides identified with the 
peptide matrix were tested individually in chromium release assays (Figure 3.4).  Of the 12 
vaccinated horse PBMC samples, eight had clear CTL activity against individual envelope 
peptides.  PBMC from horses C15, 266 and C9 did not have detectable CTL to the individual 
peptides at the day of challenge time point, and were therefore not used to determine which 
peptides were reactive.  Due to insufficient B61 PBMC, this horse was also excluded from 
determining reactive peptides.  Specific lysis of PBMC from untreated and non reactive horses 
was typically < 2.0%, so a 10% specific lysis cutoff was set for determining which peptides were 
positive. 
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Figure 3.4 CTL lysis with individual peptides.  Individual reactive peptides identified in the 
matrix assay (Table 3.2), were used to assay cytolytic activity of PBMC from the 12 vaccinated 
horses in a standard chromium release assay.  A specific lysis >10% was considered positive.  
Graphs are averages of three individual assays.  * indicate horses that were used as non-reactive 
horses for determining broadly reactive peptides. 
 52
 The eight horses that responded to the peptides were used to determine which peptides 
were reactive.  For a peptide to be considered reactive, it had to 1) cause 10% specific lysis in 
four of the eight responder horses, and 2) have a p-value < 0.05 in the Mann-Whitney test.  Of 
the 23 peptides tested, only seven peptides (#5, #9, #17, #23, #27, #50 and #52) caused >10% 
specific lysis in four or more of the reactive horses (Figure 3.5).  The remaining 16 peptides had 
less than 5% specific lysis in this cohort of horses.  The Mann-Whitney test was used to 
determine the significance of the specific lysis in the responder horses compared to non 
responder horses.  Peptides #5, #9, #17, #23, #27, #50 and #52 had p-values < 0.05 (Figure 3.5), 
and were subsequently considered to be reactive.  Although peptide #28 did have a p-value < 
0.05, it was not considered reactive because only three horses responded to that peptide. 
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Figure 3.5 Identification of reactive CTL peptides.  The reactive CTL peptides were identified 
using a panel of eight vaccinated horses that demonstrated detectable levels of CTL activity.  The 
remaining three non responding horses were used to establish the background specific lysis for 
the peptides.  (*) Individual horses were positive for the peptide if the peptide caused specific 
lysis >10%.  (†) The p-value was determined using the Mann-Whitney test.  (‡) Reactive 
peptides were defined by two criteria: 1) a peptide causing significant specific lysis in four of the 
eight reactive horses and 2) a peptide having a p-value < 0.05 in the Mann-Whitney test. 
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3.4 DISCUSSION 
 
 
The goal of the current study was to use synthetic peptide methodologies to characterize in detail 
the specificity of EIAV envelope-specific cellular immune responses associated with the 
protective immunity produced in horses inoculated with an attenuated viral vaccine (12 horses) 
and in asymptomatic carrier horses (two horses).  The results of these comprehensive analyses 
reveal for the first time the overall specificity of Th and CTL responses to EIAV envelope that 
are recognized in horses with protective immunity.  These data provide a necessary foundation to 
examine the evolution of cellular immune responses associated with the progressive maturation 
of host immunity to a protective stage, to evaluate the role of specific cellular epitopes in the 
control of EIAV infection, and to evaluate experimental Env-based vaccines designed to 
optimize the immunogenicity of these reactive cellular immune epitopes. In this regard, these 
studies will provide an important complement to similar studies by McGuire and colleagues that 
have focused on the nature and protective role of cellular immune responses to EIAV Gag 
proteins (22, 45, 46, 93, 94). 
For a peptide to be considered broadly reactive, the peptide must be presented by the 
majority of expressed MHC alleles.  Two MHC II loci, which present peptides to Th cells, were 
typed in this study, and nine of the eleven typed horses had distinct DRA/DQA combinations.  
C9 and C16 both shared DRA*101/DRA*301 and DQA*301/DQA*1301, but still differed in 
their proliferative response to the individual peptides.  Therefore, it can be reasoned that they 
differ at another MHC II locus.  Allelic restriction at the less polymorphic DRA allele is not 
evident with the 23 reactive peptides.  At the more polymorphic DQA allele, seven different 
haplotypes were observed.  The dominant allele of the horses typed was DQA*301, with six of 
the eleven horses expressing that allele.  None of the 23 reactive peptides look to be DQA*301 
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restricted as horses with and without DQA*301 reacted to the same peptides.  Peptides 29, 68 
and 74 appear not to be presented by DQA*301, but seem to be widely presented by the 
remaining alleles.  The next dominant allele was DQA*1301, which was expressed in four of the 
eleven horses typed.  Peptides 76 and 83 are the only two peptides excluded from Th recognition 
in animals expressing DQA*1301.   On closer examination it is found that only horses with 
DQA*301, 401 and 501 can recognize peptide 76; and horses expressing DQA*101, 401 and 701 
can recognize peptide 83.  With less than half the expressed DQA alleles recognizing these two 
peptides, they are not broadly reactive.  While peptides 79 and 81 are not presented by the 
dominant DQA*301 and DQA*1301, they are considered to be broadly reactive because they 
seem to be presented by the remaining five alleles.  Peptides 7, 9, 11, 19, 23, 25, 27, 35, 60, 66, 
70 and 77 appear to be presented by four or more (>50%) of the DQA alleles, and are thereby 
broadly reactive.  Of the 23 identified reactive peptides, it appears that 17 are broadly reactive 
across a majority of DQA haplotypes (Figure 3.6).  
CTL cells recognize peptides presented by MHC I molecules.  Only the ELA-A locus has 
been defined in horses, and it is less polymorphic than the human counterpart.  The lack of 
defined ELA-A types may be due to the serological reagents used in the typing process (21).  
Additionally, there are problems with serological typing such as allele mismatching.  It was 
reported that target cells from one horse with an ELA-A5 haplotype were not lysed by memory 
CTL from another horse with the ELA-A5 haplotype, indicating that the serological reagents 
used for haplotyping can non-specifically recognize more alleles than originally thought (143).  
Until a more discriminating MHC I typing procedure is developed, we cannot definitively assign 
ELA-A allelic restriction to the defined peptides.  It does appear that peptide 50 may not be 
broadly reactive, in that only one horse without the A2 allele recognizes that peptide.  The 
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remaining six peptides are recognized by a range of diverse ELA-A types, and can therefore be 
considered broadly reactive (Figure 3.6). 
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Figure 3.6 Location of broadly reactive peptides in the Env proteins.  A. gp90 protein.  
Schematic model of gp90 adapted from Ball et al (12).  Variable domains in the Env sequence 
are circled and labeled V1-V8.  N-Linked glycosylation sites are marked with a star.  The PND is 
the principal neutralization domain.  The T-helper peptides are highlighted in yellow, and the 
CTL peptides are highlighted in blue.  Overlapping CTL and T-helper peptides are highlighted in 
green.  B. gp45 protein.  Schematic model of gp90 adapted from Montelaro et al (97).  The 
shaded box represents the lipid bilayer of the viral envelope differentiating the ectodomain (top) 
and intracytoplasmic tail (bottom) of gp45. N-linked glycosylation sites are marked with a star.  
The T-helper peptides are highlighted in yellow and the CTL peptides are highlighted in blue.  
Overlapping CTL and T-helper peptides are highlighted in green. 
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Of the 17 broadly reactive T-helper peptides, nine were located in the gp90 protein, and 
eight in the gp45 protein.  Gp90, which is the more variable portion of envelope, has eight 
defined variable domains which are assumed to occupy the outer exposed loops on a 3D 
structure of the protein, like the HIV-1 gp120 protein (77).   Of the nine broadly reactive T-
helper peptides from the gp90 sequence, four are located in these variable domains (Figure 
3.6A).  Peptide 19 is in V3, peptide 23 is in V4, and peptides 27 and 29 are both in V5.  Only 
two of the five CTL peptides in this protein are contained in variable domains.  Peptide 23 is 
located in the V4 domain and peptide 27 in the V5 domain.  The principal neutralization domain 
(PND), along with other major neutralization antibody determinants (V4 and V5), are located in 
the variable loops of gp90.  These antibody determinants have considerable overlap with T-
helper and/or CTL peptides.  The remaining T-helper and CTL peptides are in more conserved 
regions of gp90 that are shielded by the variable loops and are perceived to be immunorecessive.    
There are no predetermined variable domains in the gp45 protein, but it is accepted that 
the cytoplasmic tail is more conserved than the ectodomain.  Only one T-helper peptide (peptide 
60) is found in the ectodomain, along with the only CTL peptide of this protein (peptide 52).  
The remaining seven T-helper peptides are found in the putative intracytoplasmic tail (Figure 
3.6B).   
Lentiviral envelope proteins are some of the most heavily glycosylated proteins 
characterized to date.  The role of N-linked glycosylation in antigen presentation has yet to be 
established.  The EIAV gp90 protein has 18 predicted N-linked glycosylation sites, yet the 
majority of the identified broadly reactive T-helper and CTL peptides lack potential 
glycosylation sites.  Additionally, gp45 contains four potential N-linked glycosylation sites, and 
none of them are included in the identified cellular peptides.  These data are consistent with the 
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concept that lentiviruses sequester glycosylated Env sequences from cellular recognition, as 
observed for the SIV Env protein (123).     
With the current characterization of T-helper and CTL peptides of EIAV gp90 and gp45 
associated with protective immunity, we now have the necessary foundation to examine the 
evolution of these cellular immune responses during maturation to protective immunity, and to 
evaluate these peptides as correlates of protective vaccine immunity.   
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4.0 ENVELOPE-SPECIFIC TH AND CTL DETERMINANTS OF EIAV VACCINE 
PROTCTION FROM DISEASE 
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Montelaro.  Determinants of EIAV vaccine protection and the effects of sequence variation on 
immune recognition.  Submitted to Journal of Virology. 
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4.1 INTRODUCTION 
 
 
Equine infectious anemia virus (EIAV) is a macrophage tropic, equine lentivirus that has been 
used extensively as a model for HIV-1 persistence and pathogenesis and for AIDS vaccine 
development (15, 36, 52, 54, 59, 76, 97-99, 108).  Compared to other progressively degenerative 
lentiviral infections, EIAV is characterized by three distinct phases of infection: acute, chronic 
and inapparent.  By two months post EIAV exposure, most horses experience an acute disease 
episode characterized by high fever, drop in platelets, and high viral load.  The horse then enters 
a chronic stage of infection characterized by recurrent disease episodes, which typically progress 
to the inapparent carrier stage of disease for the lifespan of the animal (97).  During the 
inapparent phase, the horse has gained immunologic control of the virulent and constantly 
evolving lentivirus, as demonstrated by the fact that whole blood transfers from inapparent 
carriers to naïve horses can cause an acute episode within two months (64, 89, 97).  Additionally, 
if the inapparent carrier is immune suppressed or stressed, there can be recrudescing disease 
associated with a new viral quasispecies.  Inapparent carriers of EIAV appear to be resistant to 
additional exposure to EIAV variant strains, indicating the horse has gained a high level of 
prophylactic immunity (97).  This type of immunity is especially desirable for lentiviral 
vaccines, which makes EIAV a valuable model system for studying vaccine protection. 
 Immune control of acute EIAV viremia has typically been associated with the appearance 
of cytotoxic T lymphocytes (CTL) (90) and non-neutralizing antibodies (90, 109, 122).  
Recently, virus-specific neutralizing antibodies have been found to develop after the resolution 
of the acute episode (93), and continue to increase in titer and breadth of specificity throughout 
the first year of infection (12, 52, 60).  We have previously identified V3 and V4 of the surface 
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envelope (Env) glycoprotein (gp90) as major neutralization epitopes, with V3 containing the 
principal neutralization domain (PND) of EIAV (12, 60, 76, 77).  However, there has been only 
limited characterization of cellular immune responses to EIAV Env that are associated with 
protective immunity.  McGuire and colleagues have thoroughly examined Gag and Pol specific 
T-helper (Th) and CTL responses (22, 46, 93, 94), but vaccines based on these broadly reactive 
immune determinants has failed to elicit a protective immune response against EIAV challenge 
(45).   
 Previous work with EIAV, SIV, and SHIV has shown there is a progressive maturation of 
virus-specific immunity in response to these various attenuated lentiviral vaccines (23-25, 54).  
A comparison of quantitative and qualitative lentiviral Env-specific antibodies reveals a 
correlation between an immature immune response with non-protection or enhancement, and a 
mature immune response with protective vaccine immunity.   Based on these earlier studies, we 
have proposed that EIAV Env is a primary determinant of vaccine efficacy and that an effective 
vaccine must be able to elicit broad humoral and cellular immune responses to conserved Env 
determinants. 
 Previously, we described a highly effective attenuated EIAV vaccine (EIAVD9) that 
protects 100% of horses from disease by homologous virulent challenge (32).  In that study, we  
were able to identify regions of EIAV gp90 and gp45 envelope proteins that were broadly 
recognized by CTL and Th cells from protected horses with diverse MHC haplotypes (132).  It 
has always been assumed that Env variation poses a major obstacle to lentiviral vaccine 
protection; therefore, vaccine strategies have focused on the more conserved Gag proteins to 
elicit protective immune responses.  To directly examine the role of Env variation on vaccine 
efficacy, 24 ponies were vaccinated with the highly effective EIAVD9 vaccine (32, 36). Seven 
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months post vaccination, the ponies were challenged with either a homologous Env strain (EV0), 
or variant Env strains with 6% (EV6) or 13% (EV13) divergence from the homologous Env.  
During the 120 day observation period, one EV0, three EV6, and five EV13 ponies developed 
signs of equine infectious anemia (EIA), clearly revealing an inverse correlation between 
protection from disease and divergence from the homologous Env (36).  In light of the marked 
differences in vaccine protection observed against the variant Env challenge viruses, we 
hypothesized that analyses of vaccine immunity to the variant Env proteins could reveal 
important correlates of vaccine protection.  Thus, the goal of the current study was to use this 
panel of experimentally immunized ponies displaying different levels of vaccine protection to 
evaluate potential immune correlates of protective immunity by in depth analyses of vaccine 
induced Env-specific neutralizing antibody responses, lymphoproliferative responses, and 
cellular cytotoxicity responses.   
 
 
4.2 MATERIALS AND METHODS 
 
4.2.a Experimental vaccinations and challenge  
 
 
All equine procedures were conducted at the Gluck Equine Research Center of the University of 
Kentucky according to protocols approved by the University of Kentucky IACUC.  Twenty-four 
ponies were vaccinated with the previously described attenuated EIAVD9 vaccine (32, 36, 79).  
Serological typing of the MHC I locus was performed as previously described (9, 10).  Direct 
sequencing of the DRA and DQA MHC II loci was performed using previously published 
protocols (Table 4.1) (4, 44).  
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Table 4.1 Summary of EIAVD9 vaccinated ponies. 
DRA DQA
A27 F 7 A9/W11 101/101 ND
C27 F 5 W11/W11 101/JBH11 301/1501/1301b
C28 F 5 A10/A10 101/101 301/1301 49 dpc
C34 F 5 A8/A10 101/201 201/201
E31 M 3 A1/A3 101/101 301/401
E33 M 3 A9/A9 101/101 701/701
E34 F 3 A1/A9 101/JBH11 301/1201/1301
E35 F 3 A1/A1 201/JBH11 301/701
558 M 12 A2/A9 101/301 301/1301 113dpc
A32 F 7 A9/A9 101/301 301/1301
A33 M 7 A9/A9 101/101 301/401/1301 4 dpc
C29 M 5 A3/A9 101/101 701/701
C33 F 5 A1/A1 201/JBH11 1001/1201
C36 M 5 A1/A1 101/JBH11 301/1201 47 dpc
D31 M 4 A2/A9 101/101 301/301
D44 M 4 A2/A9 101/301 301/1501
886 F 9 A5/A6 101/101 1301/1301 70 dpc
B22 M 6 NDa 101/101 301/401 14 dpc
B27 M 6 A5/A6 101/101 1101/1101 36 dpc
D34 M 4 A5/A9 201/201 701/1001/1301
D38 M 4 A2/A3 101/101 1501/1501 85 dpc
D39 M 4 A1/A2 101/201 201/201 17 dpc
D40 M 4 A2/A2 101/101 601/1501
E30 M 3 A9/W11 101/101 301/301
a Due to insuffient PBMC, MHC typing was not performed
b Three MHC II sequences including the 1303 allele for DQA are not uncommon.  See 
Fraiser and Bailey, 1998.
EV13 
Challenged
EV6 
Challenged
EV0 
Challenged 
MHCII Acute 
DiseasePony Sex Age MHC I
 
 
Serum and plasma were obtained from the vaccinated ponies at regular intervals throughout the 
trial.  At seven months post vaccination, blood was drawn from each pony, and PBMC were 
isolated and cryopreserved in autologous serum and 10% DMSO for future use in cellular 
immune assays.  On the following day, the vaccinated ponies (8 per group) were intravenously 
challenged with 103 median tissue culture infectious doses (TCID50) of EV0, EV6 or EV13 (8 
ponies/group) (36).  The challenge viruses were derived from the same reference proviral clone 
and differed only in the gp90 segment of the Env gene.  The EV0 Env is homologous to EIAVD9 
vaccine strain; the EV6 and EV13 gp90 proteins diverge from EV0 by 6% and 13% in their 
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respective amino acid sequences.  The EV0, EV6, and EV13 were shown to be neutralization 
distinct, each being inactivated by immune serum from ponies infected with the homologous, but 
not heterologous, virus strain.  Temperature and platelet counts were taken for 120 days post 
challenge as previously described to monitor disease progression (36). During the observation 
period, one EV0 challenged pony, three EV6 challenged ponies, and five EV13 challenged 
ponies developed clinical signs of equine infectious anemia (EIA).  The remaining 15 ponies 
were protected from disease (Table 4.1).   
4.2.b Neutralizing antibody assay   
 
 
The development of neutralizing antibodies to EV0, EV6, and EV13 at DOC and 4 weeks post 
challenge (4wpc) was assessed in an ELISA-based infectious center assay as previously 
described (52).  Briefly, 105 fetal equine kidney (FEK) cells were plated in 24 well plates and 
incubated 18-24 hours at 37°C.  Two-fold dilutions of heat inactivated serum (56°C, 1 hour) 
from DOC and 4wpc were added to 100 infectious units of EV0, EV6, or EV13.  After one hour 
incubation, the serum-virus supernatant was added to the FEK cells in triplicate. The following 
day, an overlay of 0.8% carboxymethyl cellulose was added to the cells to prevent the virus from 
spreading throughout the culture.  The cultures were incubated an additional seven days at 37° 
before being fixed with 3.7% formaldehyde and permeabilized with 1% Triton X-100.  A 
reference α-EIAV primary serum antibody was used at 1:200, and secondary antibody, 
horseradish peroxidase-conjugated goat anti-horse IgG (United States Biochemical Corp.) was 
used at 1:5000.  The labeled cells were stained with 3-amino-9-ethyl-carbazole (Sigma) in a 
sodium acetate buffer (pH 5.5) supplemented with H2O2, and visualized with a dissecting 
microscope.  The 50% neutralization titers of each serum sample were determined by linear 
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regression analysis of the log10 reciprocal dilution versus the number of apparent foci.  A 
neutralization titer of 1:25 was used as the cutoff for a positive response.       
 
4.2.c Production of variant synthetic peptides   
 
 
EIAV Env specific peptides (sequential 20-mers overlapping by 10 residues) were synthesized in 
the Biomedical Research Support Facilities Peptide Synthesis Core of the University of 
Pittsburgh using an Advanced Chemtech Model 396 Omega Synthesizer.  Variant specific 
peptides were designed using EV6 clone #567IVC8 and EV13 clone #567p10 (35, 76).   
Previously described UK peptides served as the EV0 peptides, since EV0 and UK have identical 
Env amino acid sequences (132).  Seventeen EV6 specific peptides and 26 EV13 specific 
peptides were synthesized to account for the amino acid sequence differences with EV0 (Table 
4.2).  All peptides were dissolved at 2mg/ml in 100% DMSO and stored at -80°C.  To construct 
variant specific matrix pools, the variant peptides were substituted for their EV0 counterpart and 
added to the conserved EV0 peptides in a matrix format as previously described (132).  
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Table 4.2 Variant specific Env peptides. 
EV0 Peptide Sequence EV6 Peptide Sequence EV13 Peptide Sequence
1 MVSIAFYGGIPGGISTPITQ
2 PGGISTPITQQSEKSKCEEN
3 QSEKSKCEENTMFQPYCYNN QSEKSKCEENT YNN
4 TMFQPYCYNNDSKNSMAESK T QPYCYNNDSKNSMAESK
5 DSKNSMAESKEARDQEMNLK
6 EARDQEMNLKEESKEEKRRN
7 EESKEEKRRNDWWKIGMFLL
8 DWWKIGMFLLCLAGTTGGIL
9 CLAGTTGGILWWYEGLPQQH
10 WWYEGLPQQHYIGLVAIGGR
11 YIGLVAIGGRLNGSGQSNAI
12 LNGSGQSNAIECWGSFPGCR
13  ECWGSFPGCRPFQNYFSYET
14 PFQNYFSYETNRSMHMDNNT PFQNYFSYETNRSMH NT PFQNYFSYETNR T
15 NRSMHMDNNTATLLEAYHRE NRSMH NNTATLLEAYHRE NR NNTATLLEAYHRE
16 ATLLEAYHREITFIYKSSCT
17 ITFIYKSSCTDSDHCQEYQC
18 DSDHCQEYQCKKVNLNSSDS DSDHCQEYQC LN DSDHCQEYQCKKVN
19 KKVNLNSSDSSNPVRVEDVM NLN DV KKVN D
20 SNPVRVEDVMNTTEYWGFKW DV TEYWGFKW D WGFKW
21 NTTEYWGFKWLECNQTENFK TEYWGFKWLECNQTENFK WGFKWLECNQTEN
22 LECNQTENFKTILVPENEMV LECNQTEN TILVPENEMV
23 TILVPENEMVNINDTDTWIP TILVPENEMVNIND WI TILVPENEMV
24 NINDTDTWIPKGCNETWARV NIND WI GCNETWARV GCNETWARV
25 KGCNETWARVKRCPIDILYG
26 KRCPIDILYGIHPIRLCVQP
27 IHPIRLCVQPPFFLVQEKGI IHPIRLCVQPPFFLVQEK IHPIRLCVQPPFFLVQE
28 PFFLVQEKGIANTSRIGNCG PFFLVQEK TSRIGNCG PFFLVQE NCG
29 ANTSRIGNCGPTIFLGVLED DN GNCGPTIFLGVLED
30 PTIFLGVLEDNKGVVRGNYT PTIFLGVLEDNKGVVR T PTIFLGVLEDNKGVVRG
31 NKGVVRGNYTACNVSRLKIN NKGVVR TACNVS N NKGVVRG CNV IN
32 ACNVSRLKINRKDYTGIYQV ACNVS NRKDYTGIYQV ACNV INRKDYTGIYQ
33  RKDYTGIYQVPIFYTCNFTN  RKDYTGIYQ CNFT
34 PIFYTCNFTNITSCNNEPII PIFYTCNFTNITSCNNE P FYTCNFT SCN
35 ITSCNNEPIISVIMYETNQV ITSCNNE ISVIMYETNQV ITSCN VIMYETNQV
36 SVIMYETNQVQYLLCNNNNS SVIMYETNQVQYLLC
37 QYLLCNNNNSNNYNCVVQSF QYLLCNNNNSN CVVQSF QYLLC VVQSF
38  NNYNCVVQSFGVIGQAHLEL  N VVQSFGVIGQAHLEL VVQSFGVIGQAHLEL
39 GVIGQAHLELPRPNKRIRNQ GVIGQAHLELPRPNKRI
40 PRPNKRIRNQSFNQYNCSIN PRPNKRI NCSIN
41 SFNQYNCSINNKTELETWKL NCSIN NKTELETWKL
42 NKTELETWKLVKTSGITPLP
43  VKTSGITPLPISSEANTGLI
44 ISSEANTGLIRHKRDFGISA
IFQPYC
IF
IDN NIHIDNN
ID NIHID
NKVN LNSF FTVSKA
NKV LNSFDSSIHVE K FTVSKANGSSIPSIHVGGVE AE
DSSIHVE KDT NGSSIPSIHVGGVE AETTIEY
DT TTIEY LK
LK
NDT A KIKNGTWTP
NDT AK KIKNGTWTPK
EV NRG
EVAN NRGDNIARIG
IARI
ENY SPT
ENY HLRI SPTA RKLG
HLRI RKLG G
GPMFYT S
SII M SIT DESIT
SI DESITS
KYNTT
HYN KYNTTDSNYTC
HYNC  DSNYTC
MNP
MNPNFNQY
NFNQY
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4.2.d Lymphoproliferation assays   
 
 
DOC PBMC from the 24 vaccinated ponies were tested for recognition of EIAV envelope 
peptides in a standard seven-day thymidine incorporation assay, as previously described (132).  
Briefly, DOC PBMC from 22 of the 24 vaccinated ponies were >80% viable upon thawing and 
maintained viability throughout the assays, as measured by trypan blue exclusion.  DOC PBMC 
from ponies B22 and D34 were not viable and therefore not used in further cellular assays.  C36 
had abnormal DOC PBMC which yielded nonspecific hyper-reactivity in the cellular assays, and 
therefore was excluded from this study.  PBMC were plated at 2 X 105 cells/well in complete 
RPMI-1640 (10% fetal equine serum, 1% penicillin/streptomycin, 1% L-glutamine, 55uM β-
mercaptoethanol) with 5uM AZT (Sigma) and stimulated in triplicate wells with 2.5ug/ml 
Pokeweed Mitogen (PWM), 20ug/ml peptide matrix pools, or 10ug/ml individual peptides.  The 
initial scan for potentially reactive peptides utilized challenge strain specific matrix pools to 
account for possible differences in T-cell recognition and reactivity.  AZT was replenished every 
other day in 5ul of media.  Triplicate media control wells were set up with DMSO to match the 
DMSO concentration in the peptide pool and peptide wells.  The PBMC were incubated for 48 
hours with PWM, and for six days with the peptide pools or peptides prior to labeling with 
0.75uCi 3H-thymidine (Amersham Biosciences).  After 16-18 hour incubation, the cells were 
harvested and quantified for 3H-thymidine incorporation by liquid scintillation counting.  
Stimulation indices (SI) were calculated by dividing the mean counts per minute (c.p.m.) of 
stimulated cells by the mean c.p.m. of non-stimulated cells.  A positive response to the peptide 
matrix pools was SI>1 and SI>2.5 for individual peptides.  Broadly reactive peptides were 
identified as peptides that caused positive proliferation in >50% of the ponies and that were 
presented by the majority of the MHC II molecules.   
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4.2.e CTL assays   
 
 
DOC PBMC were used to assay CTL activity in a standard chromium release assay as previously 
described (132).  Briefly, DOC PBMC from the vaccinated ponies were expanded in vivo for 7-
10 days with either 2.5ug/ml PWM (target cells) or 10ug/ml gradient purified EIAV (effector 
cells) in complete RPMI supplemented with 200U rhIL2 (Hoffmann-La Roche INC.).   The 
target cells were labeled with 100uCi 51Cr (Na51CrO) (MP) for one hour at 37°C, 5% CO2, and 
washed four times with 1X PBS, 1% horse serum.  About 30,000 target cells/well were pulsed 
with either 20ug/ml of the peptide matrix pools or 10ug/ml of individual peptides for two hours 
at 37°C, 5% CO2.  EIAV-stimulated effector cells were added at a 20:1 E:T ratio and incubated 
12-16 hrs prior to being harvested.  A 25ul sample of cell supernatant was added to 175ul of 
OptiPhase SuperMix scintillation fluid (Perkin Elmer) and analyzed for 51Cr release with a 
MicroBeta reader (Perkin Elmer).  Maximum 51Cr release was determined by plating 51Cr-
labeled target cells with the non-ionic detergent Nonidet P-40 to lyse cells.  Background 
spontaneous lysis was determined by plating 51Cr-labeled target cells with 0.1ml of medium 
alone.  Percent specific lysis was calculated as follows: 
(51Cr release in peptide wells - spontaneous 51Cr release) x 100/ (51Cr release by NP-40- 
spontaneous 51Cr release) = % Specific lysis 
A positive response to the peptide matrix pools was SL>5% and SL>10% for individual 
peptides.  Broadly reactive peptides were identified as inducing a CTL response in >50% of the 
responder ponies, and being presented by the majority of MHC I alleles. 
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4.2.f Statistical analysis  
  
To determine the statistical relevance of peptide responses in the group of protected ponies 
compared to the non-protected ponies, a two tailed Students T-test with unequal variances was 
preformed.  P-values <0.05 were considered to be statistically significant.  To determine if there 
was a correlation between amino acid divergence and loss of CTL reactivity, Excel’s CORREL 
function was used where array one was divergence from EV0 and array two was CTL response 
of the individual ponies.  A correlation coefficient r-value of +/- 1 signifies perfect correlation. 
 
 
 
 
4.3 RESULTS 
 
4.3.a Neutralizing antibody response   
 
 
To determine if neutralizing antibodies raised against the EIAVD9 vaccine were associated with 
vaccine protection from disease, the level of neutralizing activity to the vaccine envelope was 
measured with DOC sera from each vaccinated pony.  The 24 vaccinated ponies were grouped 
according to those protected from disease and those that developed equine infection anemia 
(EIA) after virulent virus challenge.  The neutralizing antibody response elicited by the vaccine 
was quantified using DOC sera and the EV0 challenge strain, which had a homologous envelope 
to the EIAVD9 vaccine.  At DOC, only eight of the 24 vaccinated ponies had detectable 
neutralizing antibodies to EV0 (Fig 4.1A).   
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Figure 4.1A Neutralizing antibody response elicited by the EIAVD9 vaccine at day of 
challenge.  A positive neutralization response was set at 1:25 titer.  The p-value was obtained 
using the Student’s T-test. 
 
Only two ponies with detectable neutralizing antibodies were protected, while the other six 
ponies with EV0-specific neutralizing antibodies at DOC were not protected from disease after 
virulent challenge.  While the data initially appeared to indicate that the non-protected ponies 
developed better neutralizing antibody responses compared to protected ponies, there was in fact 
no statistical difference between the neutralizing activity of the protected ponies compared to the 
non-protected ponies (Student’s T-test p-value = 0.090).  Based on these assays, it appeared that 
EV0 specific neutralizing activity elicited by the EIAVD9 vaccine was not associated with 
protective vaccine immunity.     
 The contribution of challenge strain-specific neutralizing antibodies to protection from 
disease was analyzed by measuring the level of neutralization in four week post challenge sera 
against the specific challenge strain for each vaccinated pony (Fig 4.1B).   
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Figure 4.1B Challenge strain-specific neutralizing antibody response at four weeks post 
challenge.  The ponies were grouped according to challenge strain.  Underlined ponies were 
protected from disease. 
 
Only two ponies, E34 and C28, had detectable challenge strain-specific neutralizing antibodies at 
4wpc; no detectable challenge strain-specific neutralizing antibodies were measured in the 
remaining 22 ponies.  Based on the current in vitro neutralization assay, an association between 
vaccine protection from disease and neutralizing activity to the respective challenge virus at 
4wpc was not evident. 
 
4.3.b Proliferation response to an EIAVD9 Env-specific peptide pool   
 
 
Day of challenge (DOC) PBMC from each pony were used in proliferation and CTL assays to 
determine if Env-specific immune responses elicited by the EIAVD9 vaccine could be associated 
with protection from disease.  The overall Env-specific proliferative response elicited by EIAVD9 
was measured in PBMC from each vaccinated pony in a 3H-thymidine incorporation assay 
against a comprehensive Env peptide pool.  The comprehensive Env pool contained sequential 
EV0 Env peptides spanning the entire gp90 protein.  The 21 ponies with viable DOC PBMC had 
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variable proliferative responses to the comprehensive Env pool, as expected from an outbred 
population of ponies (Fig 4.2A).   
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Figure 4.2A Env-specific proliferation responses of vaccinated ponies.  Proliferation against 
a comprehensive Env peptide pool spanning the entire EV0 gp90 was tested against day of 
challenge PBMC from vaccinated ponies in a thymidine incorporation assay.  A SI = 2.5 was the 
cutoff for a positive response.  P-value was obtained with the Student’s T-test. 
 
There was no statistical difference between the proliferation responses of the protected ponies 
compared to the non-protected ponies (Student’s T-test p-value = 0.416), therefore a more 
detailed analysis of peptide-specific proliferation was performed to determine if a relationship 
existed between Env-specific proliferation and protection from virulent EIAV challenge.  
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4.3.c Env peptide specific proliferation   
 
 
Challenge strain specific peptide matrix pools were tested against the PBMC from the 21 
vaccinated ponies in a thymidine incorporation assay to execute an inclusive scan of all Env 
peptides.  Specific peptides were chosen from the matrix pools to be tested individually if they 
were reactive (SI>1.0) in 11 or more of the 21 ponies tested.  Following these criteria, 33 EV0 
specific peptides were indicated for individual analysis (data not shown).    
 To identify peptide specific proliferation that was potentially associated with protective 
immunity, the 33 EV0 specific peptides indicated by the peptide matrix were tested against DOC 
PBMC from the 21 vaccinated ponies in a thymidine incorporation assay.  Peptides 17 and 61 
caused a positive proliferation response (SI>2.5) in 11 or more of the 21 ponies (Fig 4.2B), and 
were presented by the majority of the represented MHC II alleles.  Therefore, these vaccine Env 
specific peptides were considered to be broadly reactive in this group of ponies. 
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Figure 4.2B Env peptide-specific proliferation in vaccinated ponies.  Thymidine 
incorporation was used to measure proliferation of DOC PBMC from the 21 EIAVD9 vaccinated 
ponies in response to peptides indicated by the matrix pools.  Variant peptides are italicized, 
conserved peptides are bold.  A shaded block identifies ponies positively proliferating (SI>2.5) 
to specific peptides. 
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 Peptide specific proliferation responses potentially associated with vaccine protection 
were identified by grouping the ponies according to protection or progression to disease after 
virulent EIAV challenge.  For each peptide, the SI of the 14 protected ponies were averaged and 
the SI of the seven non-protected ponies were averaged (Fig 4.3A).  A clear separation between 
the two groups of ponies was observed for peptides 5, 10, and 53.  A more thorough analysis of 
these peptides was achieved by plotting the SI values of the individual ponies within the two 
groups (Fig 4.3B).  The only statistically significant difference between the individual peptide 
responses of the protected and non-protected ponies was for peptide 5 (Student’s T-test p-value 
0.0156).  
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 Figure 4.3 Peptide specific proliferation responses in protected and non-protected ponies.  
(A)  The stimulation indices for each peptide from the thymidine incorporation assay were 
averaged for the 14 protected ponies and the seven non-protected ponies to highlight differences 
in the peptide responses.  Variant peptides are italicized, conserved peptides are bold.  (B)  
Specific reactivity for each pony to the peptides of interest in the thymidine incorporation assay.  
P-values from the Student’s T test are listed for each statistically significant peptide. 
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4.3.d Peptide specific CTL reactivity   
 
 
The Env-specific CTL response was examined to determine if the EIAVD9 vaccine elicited 
peptide-specific cytotoxic responses associated with vaccine protection from disease after 
virulent challenge.  In an initial evaluation, the CTL responses to a comprehensive Env pool of 
peptides was tested in DOC PBMC from the 21 vaccinated ponies (Fig 4.4A).  Cytolytic activity 
was detected in 12 of the 21 vaccinated ponies at DOC, presumably reflecting natural 
fluctuations in virus specific CTL activity during persistent EIAV infection (52).  Of these 12 
ponies, seven were protected from disease and five developed EIA after virulent EIAV 
challenge.  Differences in cytolytic activity between the protected and non protected ponies in 
response to the Env peptide pool was not statistically significant (Student’s T-test p-value = 
0.676).   
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Figure 4.4A Env-specific CTL responses of vaccinated ponies.  CTL lysis of day of challenge 
PBMC from vaccinated ponies pulsed with a comprehensive peptide pool spanning the entire 
EV0 gp90 was measured in a chromium release assay.  A %SL = 5 was the cutoff for a positive 
response.  P-value was obtained using the Student’s T-test. 
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 A more comprehensive study to identify individual peptide responses potentially 
associated with vaccine protection from disease was performed next.  The DOC PBMC from the 
12 vaccinated ponies with detectable CTL activity were tested in a chromium release assay 
against challenge strain-specific peptide matrix pools to identify potentially reactive CTL 
peptides (data not shown).  From this analysis, 20 EV0 were identified for individual analysis.  
Peptide specific CTL responses elicited by the vaccine were identified by testing the EV0 
peptides against the DOC PBMC of the 12 vaccinated ponies in a chromium release assay.  Of 
the 20 EV0 peptides, peptides 8, 9, 17, 18, 20, 21, 27, 32, 36, 38, 52 and 62 were reactive (>10% 
SL) in >50% of the ponies tested (Fig 4.4B).   
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Figure 4.4B Env peptide-specific CTL responses of vaccinated ponies.  Chromium release 
assays were used to measure CTL lysis of DOC PBMC from the 12 vaccinated ponies in 
response to peptides indicated by the matrix pools.  Variant peptides are italicized, conserved 
peptides are bold.  A shaded block represents a positive cytolytic peptide response (SL>10%) by 
the pony.  E:T ratio was 20:1. 
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These peptides, with the exception of peptides 18 and 21, were presented by the majority of 
MHC I alleles present in this cohort of ponies, and were therefore considered to be broadly 
reactive.  Peptides 18 and 21 appeared to be restricted to the A1, A9, and W11 alleles, and 
therefore not broadly reactive.  The remaining EV0 peptides failed to generate appropriate 
cytolytic responses in more than six of the vaccinated ponies; for this reason, they were not 
considered to be broadly reactive.   
 
4.3.e CTL responses associated with protective immunity   
 
 
Peptide-specific CTL responses potentially associated with protective vaccine immunity were 
identified by grouping the vaccinated ponies according to disease development.  For this 
comparison, the %SL of the seven protected ponies and five non-protected ponies were averaged 
for each reactive peptide (Fig 4.5A).  There was an apparent demarcation between the two 
groups of ponies for peptides 5, 8, 9, 17, 18, 20, 21, 24, 26, 32, 36, and 38.  Closer analysis 
revealed a statistically significant difference between the protected and non-protected ponies for 
peptides 5, 8, 9, 17, 20, 24, 26, and 38 (T-test p-values ranged from 0.0007 to 0.0344) (Fig 
4.5B).  There was no statistical significance between the %SL of the protected and non-protected 
ponies for peptide 36.  Because peptides 18 and 21 were MHC restricted, reactivity to these 
peptides segregate with the MHC alleles, not with protection.  Therefore, these peptides were not 
associated with vaccine protection from disease.  From this study, it appeared that peptides 5, 8, 
9, 17, 20, 24, 26, and 38 were associated with protective vaccine immunity. 
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Figure 4.5 Peptide specific CTL responses in protected and non-protected ponies.  (A)  The 
%SL for each peptide in the chromium release assay was averaged for the seven protected ponies 
and the five non-protected ponies to highlight the different peptide responses.  Variant peptides 
are italicized.  (B)  Specific reactivity for each pony to the peptides of interest in the chromium 
release assay.  P-values from the Student’s T test are listed for each statistically significant 
peptide.  E:T = 20:1. 
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4.4 DISCUSSION 
 
 
Using EIAV variants with divergent Env proteins to challenge EIAVD9 vaccinated ponies 
provided the unique opportunity to address the effects of defined Env variation on vaccine 
efficacy, and also to identify potential determinants of protective immunity.  The study by Craigo 
et al. (2007) (36) definitively revealed Env as a primary determinant of lentiviral vaccine 
efficacy, indicating a significant inverse relationship between the extent of challenge-strain Env 
divergence from the vaccine strain and the observed vaccine protection.  In the current study, we 
have taken advantage of this unique vaccine trial to characterize the humoral and cellular 
immune responses to Env that may be associated with vaccine protective immunity.  
Neutralizing antibody titers, Th proliferation, and CTL lysis of the EIAVD9 vaccinated ponies 
protected from disease were compared to those that were not protected to evaluate potential 
determinants of vaccine immunity.  For the first time, Th and CTL envelope peptides associated 
with protective EIAV vaccine immunity have been identified.   
 Like other lentiviral model systems (HIV, SIV and SHIV), there is considerable debate 
about the role of neutralizing antibodies in protective immunity.  Various studies with EIAV, like 
SIV, have failed to establish a correlation between neutralizing antibody development and 
vaccine protection (26, 32, 50, 54, 102, 103).  While a range of  studies have shown that passive 
immunization with neutralizing antibodies can protect against HIV or SHIV challenge (85, 86, 
115), there have been other studies demonstrating that passively administered immune serum 
cannot protect animals from SIV infection (6, 95, 102, 103, 127).  When the neutralizing 
antibody titers of the 24 vaccinated ponies were measured against the homologous Env strain, 
EV0, only eight ponies had detectable neutralization titers at DOC, but these responses could not 
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be correlated with vaccine protection from disease.  At four weeks post challenge, two of the 24 
vaccinated ponies had challenge strain-specific neutralizing antibodies.  Both ponies were 
challenged with EV0; one pony was protected from disease, while the other pony developed EIA 
after challenge.  Because an in vitro assay was used to measure neutralization titers, the 
possibility that EV6 and EV13 neutralizing antibodies were present in the vaccinated ponies but 
undetectable in our neutralization assay could not be discounted.  However, with the current 
assay, we were unable to correlate a neutralization response with vaccine protection from 
disease.    
 With no established relationship between antibody neutralization and vaccine protection, 
the cellular immune response elicited by EIAVD9 was analyzed.  Effective vaccines against 
viruses that cause chronic infection, such as Epstein-Barr virus and cytomegalovirus, elicit 
polyfunctional Th and CTL responses (55).  During HIV infection, there is a skewing of the Th 
response, such that CD4+ T-cells with proliferative capabilities are destroyed while CD4+ T-
cells secreting IFNγ are abundant (113).  Targeting an appropriate Th proliferation response is 
therefore a desirable quality for lentiviral vaccines.  The thymidine incorporation assay for 
PBMC proliferation identified one Env-specific peptide which was associated with vaccine 
protection from disease, and the amino acid sequence of this peptide was conserved across the 
three variant challenge strains. As equine-specific reagents become available to study the 
cytokine profile of the Th cells, it will be of interest to study the cytokine response evoked by the 
EIAVD9 vaccine to determine if there is an association with vaccine immunity. 
 The proliferation assay also distinguished broadly reactive regions of EIAV Env.  A 
group of peptides was recently described as broadly reactive in 12 EIAVD9 vaccinated horses 
demonstrating protective immunity from disease (132).  One of the peptides identified in the 
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current trial, peptide 61, overlaps with a previously described broadly reactive peptide, peptide 
60.  Additionally, when the two EIAVD9 trials are combined, peptides 9, 17, 27 and 70 can be 
described as broadly reactive peptides in the two groups of ponies.  It should be noted that ponies 
having the same DRA/DQA alleles in this study do not always have the same peptide specific 
proliferation responses.  This may be attributed to the third MHC II allele, DRB.  There is not 
complete sequence analysis for DRB, therefore it was not characterized in these ponies (43).  
 As with a Th response, a polyfunctional CTL response is regarded as necessary for a 
protective lentiviral vaccine (57).  In HIV, various studies have shown a correlation between 
CTL levels and long-term nonprogressors (56, 120), and control of acute (16, 72) and chronic 
viremia (105).  Additionally, in the SIV model of infection, depletion of CD8+ T-cells results in 
loss of immune control (67, 87, 124).  As of yet, CTL peptides correlating with HIV or SIV 
vaccine protection have not been identified.  The bulk of HIV and SIV CTL research has relied 
upon IFNγ and tetramer staining, but it is becoming increasing clear that determining the 
functional diversity of the CTL response is equally important to quantifying the CTL response 
using these techniques (107, 141).  In the current study, a functional chromium release assay was 
utilized to test PBMC from 12 vaccinated ponies with measurable DOC CTL activity to identify 
potentially protective CTL peptide specific responses elicited by the EIAVD9 vaccine.   Broadly 
reactive CTL peptides elicited by the EIAVD9 vaccine were previously described (132).  Again, 
without a more discriminating assay to type the ELA-A allele, firm MHC restrictions cannot be 
assigned to identified peptides (132, 143).  However, the peptides identified in the current 
vaccine trial do not seem to be MHC restricted and confirm four of the broadly reactive peptides 
from the previous trial, peptides 9, 17, 27, and 52 (132).  Additionally, when data from the two 
EIAVD9 trials are combined, peptides 5, 32 and 62 are also found to be broadly reactive.   
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 In defining CTL peptide responses associated with vaccine protection from disease, our 
analysis revealed a statistically significant association between protection from disease and CTL 
responses to peptides 5, 8, 9, 17, 20, 24, 26 and 38.  In an independent study, lipopeptides 
corresponding to the amino acid sequences of EIAV gp90 peptides 20 and 21 were used to 
vaccinate three horses.  While the vaccine did not prevent infection, it was capable of reducing 
the severity of disease, indicating that the CTL responses associated with these peptides can have 
some protective effect (119).  The cytolytic response to peptides 5, 8, 9, 17, 20, 24, 26 and 38 
can be targeted in future lentiviral vaccine trials to enhance protective immune responses.    
 Five (peptides 5, 8, 9, 17, and 26) of the eight CTL peptides associated with vaccine 
protection from disease were found in more conserved regions of gp90 (Fig 4.6), with each 
challenge strain having identical amino acid sequences for these five peptides. Additionally, 
there were no N-linked glycosylation sites found in these five peptides.  The three other CTL 
peptides were variable between the three challenge strains.  CTL peptide 20 spanned the V3 
region of gp90, peptide 24 included the V4 region, and peptide 38 contained part of the V7 
region.  The variant challenge strains each had unique amino acid sequences for these peptides 
and were also variable in the number and placement of N-linked glycosylation sites.  The strain 
specific peptides along with the variant peptides identified in the matrix analysis will be tested 
against these PBMC to determine if the amino acid changes altered the observed cytolytic 
activity.     
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Figure 4.6 Env specific peptide responses associated with vaccine protection.  Schematic 
model of gp90 adapted from Ball et al. (1992).  Variable domains are circled and labeled V1-V8.  
N-linked glycosylation sites are marked with a star.  PND is the principal neutralization domain.  
CTL peptides associated with protection are highlighted in yellow.  Proliferation and CTL 
peptide highlighted in red. 
 
 In conclusion, the current studies have used the EIAV vaccine system to evaluate 
potential Env-specific immune responses associated with the development of protective vaccine 
immunity.  The reactive Th and CTL Env peptides identified here as being associated with 
vaccine protection may serve as critical determinants of vaccine efficacy and should be targeted 
in the design of new immunization strategies for EIAV vaccine development.  
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5.1 INTRODUCTION 
 
 
Equine infectious anemia virus (EIAV) is a macrophage tropic lentivirus that infects equids 
through horsefly bites (97).  While genetically and structurally similar to other lentiviruses (HIV, 
SIV, FIV), EIAV infection induces a dramatically different disease course characterized by three 
distinct phases: acute, chronic and inapparent.  By two months post infection, horses develop an 
acute episode of disease characterized by fever, thrombocytopenia, and high viral loads.  CTL 
responses control virus replication after the acute episode, but envelope (Env) variation of EIAV 
allows the virus to escape immune control and produce a second febrile episode, which initiates 
the chronic phase of disease.  During the chronic phase, an infected horse cycles through 
recurrent disease episodes for approximately one year, after which, full immunological control is 
typically attained, and the infected horse becomes an inapparent carrier of EIAV.  The inapparent 
phase of disease is due to host immune control and cannot be attributed to viral attenuation, as 
immune suppressing or stressing an infected horse will cause a recrudescing disease episode with 
a viral quasispecies distinct from the previous febrile episode (64, 89, 97).  Although viral 
replication is strictly controlled in inapparent carriers of EIAV, whole blood transfers to naïve 
horses result in acute EIA in recipient horses.  Additionally, inapparent carriers of EIAV are 
resistant to further EIAV challenge, demonstrating natural prophylactic immunity (97).  
 The limited characterization of equine immune responses to EIAV has revealed that 
virus-specific CTLs are associated with control of the acute episode, but these responses 
fluctuate throughout the course of disease (52, 90).  Both T-helper and CTL immune epitopes 
have been described for the Gag and Pol proteins of EIAV (22, 46, 93, 94), but vaccines based 
on eliciting these immune responses have failed to protect ponies from virulent challenge (45, 
119).  Recently, broadly reactive Env peptides were identified in vaccinated ponies protected 
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from homologous challenge, but their role in vaccine protection has yet to be established (132).  
Using the same vaccine but challenging immunized ponies with EIAV strains containing 
divergent Env proteins proved Env to be a primary determinant of vaccine efficacy (36).  
Additionally, analysis of peptide specific cellular responses identified one Th and eight CTL Env 
specific peptides associated with vaccine protection from disease (131). 
 While neutralizing antibodies have been detected after the acute episode of EIAV (93), 
they typically do not develop until two months post infection (52, 60).  Initial peptide mapping 
studies revealed that neutralizing antibodies bind three specific areas of gp90, which were later 
mapped to the V3 and V5 regions of Env (12, 77).  The two peptides encompassed by V3 
compose the principal neutralization domain (PND) of EIAV.  Studies with a natural PND 
deletion mutant, EIAVΔPND, revealed that after immune suppression, neutralizing antibodies 
developed against EIAV without the PND, suggesting that other areas of gp90 could serve as 
targets for the neutralizing antibodies (33).  Further studies revealed that the V3 and V4 regions 
of Env confer neutralization specificity to EIAV in ponies chronically infected with EIAV (59, 
60).   
 Recent cellular and humoral epitope mapping studies of the Env proteins have focused on 
the reference strain EIAVPV or the EIAVD9, both of which share the same Env proteins.  To 
begin understanding the effects of Env variation on immune reactivity, variant strains of EIAV 
with divergent gp90 proteins were constructed from viral isolates of a pony chronically infected 
with EIAVPV (32).  Sequence analysis was performed on sequential fevers to determine the level 
of amino acid divergence in the Env proteins from the EIAVPV infecting strain (35, 76).  Viral 
clones from the IV febrile episode and pre-immune suppression serum yielded gp90 proteins 6% 
and 13% divergent from the infecting EIAVPV strain.  The gp90 of each variant strain was placed 
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into the backbone of the infectious molecular clone EIAVUK3, which shares a homologous Env 
with EIAVPV (36).  To determine the pathogenesis of each variant, groups of four ponies were 
infected with EV0 (homologous EIAVPV Env), EV6 (6% divergent), or EV13 (13% divergent).  
Each variant produced a febrile episode by 45 days post infection, with four ponies developing 
chronic disease.   
 We hypothesize that the immune responses to each variant Env EIAV challenge strain 
would alter the observed immune responses associated with the EIAVD9 vaccinate (131, 132).  
To test this hypothesis, PBMC and serum from the variant infected ponies were tested in the 
cellular and humoral assays to identify regions of the variant Env that evoked an immune 
response.  PBMC from the EV6 and EV13 infected ponies were also tested against EV0 peptides 
to determine if the amino acid differences in EV0 would alter the observed cellular immune 
responses to the strain specific peptides.  Sera from the infected ponies were tested against the 
three different challenge strains to determine the extent of cross-reactivity of the neutralizing 
antibodies.  Additionally, the serum was used against chimeric constructs to verify the target 
region of Env for neutralizing antibodies.  To understand the effects of Env variation on immune 
recognition in vaccinated ponies, PBMC from the EIAVD9 vaccinated ponies challenged with 
EV6 and EV13 were tested against EV6 or EV13 specific peptides, respectively.  Sera from 
EIAVD9 vaccinated ponies were also tested against all three variant challenge strains to 
determine the extent of cross-reactivity induced by the vaccine.  The results of these studies 
suggest that Env variation can have profound effects on the immune recognition in infected and 
vaccinated ponies.        
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5.2 MATERIALS AND METHODS 
 
 
5.2.a Experimental pony infections with variant isolates 
 
 
All equine procedures were conducted at the Gluck Equine Research Center of the University of 
Kentucky according to protocols approved by the University of Kentucky IACUC.  Twelve 
ponies were infected with 103 tissue culture infectious doses (TCID50) of either EV0, EV6, or 
EV13 (four ponies per variant EIAV) as previously described (36).  EV6 and EV13 diverged 
from the EV0 gp90 amino acid sequence by 6% and 13% respectively (c.f. Fig 1.8).  Serum and 
blood were obtained at regular intervals throughout the infections, with peripheral mononuclear 
cells (PBMC) being isolated from the blood and cryopreserved in autologous serum and 10% 
DMSO for future use in cellular immune assays.  Regular temperature and platelet counts were 
taken throughout the course of infection to monitor disease development.  EV0 infected pony 
9959 was euthanized at 178 days post infection (dpi) along with EV6 infected ponies #10 (65dpi) 
and #50 (130dpi) due to severe disease.  The remaining ponies were euthanized at nine months 
post infection (mpi) after developing mature immune responses to the infecting EIAV strain.  
Viral loads were sustained above 103 RNA copies/ml of plasma in each infected pony (36).  
PBMC and serum were utilized from the EIAVD9 variant challenge trial (36) to examine the 
effects of Env variation on immune recognition.     
5.2.b Lymphoproliferation assays 
 
 
PBMC from six months post infection were tested against variant-specific Env peptides in a 
standard seven-day thymidine incorporation assay, as previously described (132).  As the 
immune system requires 6-8 months to develop a mature immune response (52, 99), PBMC and 
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serum were taken six months after infection for immune analysis.  Two of the EV6 infected 
ponies were euthanized before six months post infection and were not included in the cellular 
assays.  PBMC from ten of the 12 infected ponies were >80% viable upon thawing and 
maintained viability throughout the assays, as measured by trypan blue exclusion.  PBMC were 
plated at 2 X 105 cells/well in complete RPMI-1640 (10% fetal equine serum, 1% 
penicillin/streptomycin, 1% L-glutamine, 55uM β-mercaptoethanol) with 5uM AZT (Sigma) and 
stimulated in triplicate wells with 2.5ug/ml Pokeweed Mitogen (PWM), 20ug/ml of a 
comprehensive Env peptide pool, 20ug/ml matrix pools, or 10ug/ml of individual peptides.  The 
comprehensive pool contained variant strain specific peptides spanning the entire gp90 protein.    
AZT was replenished every other day in 5ul of media.  Triplicate media control wells were set up 
with DMSO to match the DMSO concentration in wells containing Env peptides.  The PBMC 
were incubated for 48 hours with PWM, and for six days with the Env peptides prior to labeling 
with 0.75uCi [3H]thymidine (Amersham Biosciences).  After 16-18 hour incubation, the cells 
were harvested and quantified for 3H incorporation by liquid scintillation counting.  Stimulation 
indices (SI) were calculated by dividing the mean counts per minute (c.p.m.) of stimulated cells 
by the mean c.p.m. of non- stimulated cells.  A positive response to peptide pools was SI>1 and 
SI>2.5 for individual peptides.   
5.2.c CTL assays  
  
PBMC after six months post infection were used to assay CTL activity in a standard chromium 
release assay as previously described (132).  Briefly, PBMC from the 10 infected ponies were 
expanded in vivo for 7-10 days with either 2.5ug/ml PWM (target cells) or 10ug/ml gradient 
purified EIAV (effector cells) in complete RPMI supplemented with 200U rhIL2 (Hoffmann-La 
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Roche INC.).   The target cells were labeled with 100uCi 51Cr (Na51CrO) (MP) for one hour at 
37°C, 5% CO2, and washed four times with 1X PBS containing 1% horse serum.  Approximately 
30,000 target cells/well were pulsed for two hours at 37°C, 5% CO2 with 20ug/ml of a 
comprehensive variant-specific Env peptide pool, 20ug/ml of peptide matrix pools, or 10ug/ml of 
individual Env peptides (131).  EIAV-stimulated effector cells were added at a 20:1 E:T ratio 
and incubated 12-16 hrs prior to being harvested.  A 25ul sample of cell supernatant was added 
to 175ul of OptiPhase SuperMix scintillation fluid (Perkin Elmer) and analyzed for 51Cr release 
with a MicroBeta reader (Perkin Elmer).  Maximum 51Cr release was determined by plating 51Cr-
labeled target cells with the non-ionic detergent Nonidet P-40 to lyse cells.  Background 
spontaneous lysis was determined by plating 51Cr-labeled target cells with 0.1ml of medium 
alone.  Percent specific lysis was calculated as follows: 
(51Cr release in peptide wells - spontaneous 51Cr release) x 100/ (51Cr release by NP-40- 
spontaneous 51Cr release) = % Specific lysis 
A positive response to peptide pools was SL>5% and SL>10% for individual peptides.  
 
5.2.d Neutralizing antibody assay 
 
The development of neutralizing antibodies to EV0, EV6, and EV13 throughout the course of 
infection was measured using an ELISA-based infectious center assay as previously described 
(52).  Briefly, 105 fetal equine kidney (FEK) cells were plated in 24 well plates and incubated 18-
24 hours at 37°C.  Two-fold dilutions of heat inactivated serum (56°C, 1 hour) were added at 100 
infectious units of EV0, EV6, or EV13.  After one hour incubation, the serum-virus supernatant 
was added to the FEK cells in triplicate. The following day, an overlay of 0.8% carboxymethyl 
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cellulose was added to the cells to prevent the virus from spreading throughout the culture.  The 
cultures incubated an additional seven days at 37° before being fixed with 3.7% formaldehyde 
and permeabilized with 1% Triton X-100.  Primary α-EIAV serum was used at 1:200, and 
secondary antibody, horseradish peroxidase-conjugated goat anti-horse IgG (United States 
Biochemical Corp.) was used at 1:5000.  The labeled cells were stained with 3-amino-9-ethyl-
carbazole (Sigma) in a sodium acetate buffer (pH 5.5) supplemented with H2O2, and visualized 
with a dissecting microscope.  The 50% neutralization titers of each serum sample were 
determined by linear regression analysis of the reciprocal dilution versus the number of apparent 
foci.  A neutralization titer of 1:25 was used as the cutoff for a positive response. 
 
5.2.e Development of chimeric viruses   
 
 
Chimeric viruses were constructed between EV0 and EV6 by utilizing the two HindIII sites in 
gp90 to switch the V3 to V4 region between the two strains.  Attempts to make similar chimeric 
constructs between EV0 and EV13 did not yield viable virus.  PCR products containing the V3 
to V4 regions were synthesized using a three step overlapping PCR reaction with variant strain-
specific primers (Fig 5.1, Table 5.1).  PCR A: The first Hind III site to V4 region of the donor 
strain was amplified (~240bp) using primer 1 and strain specific primer 2 with donor strain 
DNA.  PCR B: The V4 to second Hind III site was amplified (~513bp) using primer 4 and 
variant specific primer 3 with backbone strain DNA.  Standard PCR conditions were used on the 
first round of PCR, followed by Qiagen PCR Clean-Up.  
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Table 5.1 Primers for chimeric clone construction. 
Primer Primer Sequence Specificity Chimeraa
EV-1 FWD GCTACATTATTAGAAGCTTATCATAGGGAG universal all
EV-4 RVS GGTTAAAGCTTTGGTTCCTTATTCT universal all
EV0-2 RVS CCAGGTATCAGTATCATTGATATTTACC EV0 V4 EV6v0 and EV13v0
EV6v0-3 FWD AATGATACTGATACCTGGATAGCTAAGG EV0 V4 with EV6 backbone sequence EV6v0
EV13v0-3 FWD AATGATACTGATACCTGGACACCTAAGG EV0 V4 with EV13 backbone sequence EV13v0
EV6-2 RVS CCAGGTATCATTATCATTGATATTTACC EV6 V4 EV0v6
EV0v6-3 FWD AATGATAATGATACCTGGATACCTAAGG EV6 V4 with EV0 backbone sequence EV0v6
EV13-2 RVS CCAGGTACCATTTTTGATTTTTACC EV13 V4 EV0v13
EV0v13-3 FWD CAAAAATGGTACCTGGATACCTAAGG EV13 V4 with EV0 backbone sequence EV0v13
a chimera naming = receptor strain with donor V3/V4  
  
 The second reaction was an asymmetric PCR adapted from a previously described 
protocol (137).  Primer 2 and 3 share overlapping sequences that allow for limited self priming 
when the PCR products from PCR A and B are combined.  Therefore 3ul each of PCR A and 
PCR B were combined in a 50ul standard PCR reaction without primers and double MgCl2 
(3mM).  The reaction cycled 16 times at 95°C for 60sec, 55°C for 60sec and 72°C for 60sec, 
after which the third PCR was conducted using 20ul of PCR 2 with the addition of 1ul each of 
primer 1 and primer 4.  New PCR buffer, MgCl2, dNTP and Taq were added to make up a 50ul 
reaction.  The third PCR cycled through 92°C for 60sec, 55°C for 60sec and 72°C for 3min 25 
times and finished with 72°C for 15min.  The final PCR product (~750bp) was run on a 1% 
agarose gel and purified with the Qiagen Clean-up kit.   
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Figure 5.1 PCR strategy and chimeric clones.  (A)  Three PCR reactions were conducted to 
obtain the V3-V4 region of each variant EIAV strain.  The first PCR reaction separately 
amplified the Hind III to V3 region and the V4 to Hind III region.  Self-priming of PCR product 
A and B occurred during the second PCR step.  The third PCR then amplified the entire region 
using primers 1 and 4.  Conserved PCR primers are in black, the variable PCR primers are 
colored to match the variant DNA.  The large block represents V3, the small block represents 
V4, and the triangles represent the HindIII sites.  (B)  Schematic representation of the parental 
DNA and chimeric clones.  EV0v13 was obtained from Chengqun Sun. 
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 The PCR products were digested with Hind III; EV0 and EV6 were digested with Hind 
III and shrimp alkaline phosphotase (SAP).  The digested backbone DNA was phenol chloroform 
extracted and ethanol precipitated prior to ligation with the PCR products.  Ligations were 
performed with T4 ligase at 23°C for 4 hours before transformation into dam-/dcm- competent E. 
coli (New England BioLabs).  Miniprep cultures were grown for DNA isolation and sequence 
analysis. 
  
5.2.f Transfection of chimeric clones   
 
 
After sequence analysis, suitable chimeric clones were transfected into equine dermal cells (ED) 
using LipofectamineTM 2000 (Invitrogen).  ED cells were plated in 6 well plates at 2x105 cells in 
2ml eMEM the day before transfection.  For the transfection, 2.5ug of chimeric DNA was 
incubated for 30min at room temperature with 500ul OptiMem and 6.25ul of LipofectamineTM 
2000, following the manufacturer’s protocol.  The DNA was added to ED cells and incubated for 
4 weeks at 36°C, 5% CO2.  To quantify the amount of virus production, supernatant samples 
were taken every 3-5 days for micro-RT analysis as previously described (77).   The TCID50 of 
the supernatant from the transfected cells was determined using the previously described 
infectious center assay (52).  The supernatants were aliquoted and stored at -80°C for future use.                 
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5.3 RESULTS 
 
5.3.a Clinical progression of EIAV Env variant infected ponies 
 
   
Each pony infected with the EIAV variant Env strains developed acute EIA episodes by 43 days 
post infection (Table 5.2).  Four ponies, 9955, #10, #50 and 9959, developed chronic EIA and 
cycled through multiple fevers.  EV0 infected pony 9955 cycled through five additional fevers 
before being euthanized at 178dpi due to severe disease.  EV6 infected ponies, #10 and #50 were 
also euthanized at day 65 and 130, respectively, due to the severity of their disease.  EV13 
infected pony 9959 cycled through four additional fevers before becoming an inapparent carrier 
of EIAV.  Ponies 009 and A26 each had one atypical fever more than 130 days after the acute 
episode; the remaining ponies were asymptomatic after the acute episode for the 9 month 
observation period.  It has been established that immune responses to EIAV evolve from an 
immature, ineffective response to a mature protective response by 6-8 months post infection (52, 
99), therefore, PBMC from >6mpi were isolated for Th and CTL analysis.  Because ponies #10 
and #50 were euthanized before developing a mature immune response, they were not used in the 
cellular assays.  
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Table 5.2 Disease and immune response of variant infected ponies. 
Pony Proliferationb CTLc
Neutralizing 
Antibodiesd
A23 - - +
9913 - - +
9955 + - +
9961 + - +
#10 NDe ND +
#50 ND ND +
B32 + + +
956 + + +
009 + + +
9959 + - +
A26 + - +
B023 + + +
† Pony euthanized
a dpi = days post infection
b Proliferation in response to comprehensive Env peptide pool in PBMC from 6-9 months post infection
c CTL in reponse to comprehensive Env peptide pool in PBMC from 6-9 months post infection
d Infecting strain neutralizing antibody development through 9 month observation period
e Ponies euthanized before 6 months post infection, assays were not performed
16dpi, 49dpi, 58dpi, 65dpi †
17dpi, 63dpi, 99-100dpi, 124dpi, 126dpi, 130dpi †
16dpi 
Febrile episodes
14dpia
28dpi, 106dpi, 111-112dpi, 173-174dpi, 177dpi, 178dpi †
43dpi
14dpi
EV
13
 
In
fe
ct
ed
EV
6 
In
fe
ct
ed
EV
0 
In
fe
ct
ed
19dpi
14dpi, 247dpi
14dpi, 49dpi, 74dpi, 105-106dpi, 132-133dpi
13-14dpi, 267dpi
12dpi
 
 
5.3.b Env-specific PBMC proliferation 6 months post infection  
 
 
To measure the proliferation response of the variant infected ponies, PBMC from >6mpi were 
used in a thymidine incorporation assay with a variant Env-specific comprehensive peptide pool.  
PBMC from the EV0 infected ponies underwent limited proliferation in response to the EV0-Env 
peptide pool (Fig 5.2).  Since EV0 shares a homologous Env with EIAVD9, for which cellular 
immune peptides were previously mapped (131, 132), cellular analysis outside of the 
comprehensive peptide pool was not conducted on these four EV0 infected ponies.  The PBMC 
from the two EV6 infected ponies demonstrated low proliferation responses to the EV6-Env 
peptide pool.  All four of the EV13 infected ponies developed an EV13-Env specific 
proliferation response by 6mpi, with ponies 9959 and A26 demonstrating the highest 
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proliferation responses out of the ten infected ponies.  The remaining two EV13 infected ponies 
had similar proliferation responses to the EV6 infected ponies. 
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Figure 5.2 Proliferation responses to variant Env-specific peptide pools.  PBMC from >6mpi 
were utilized in the thymidine incorporation assay against comprehensive variant Env-specific 
peptide pools.  A proliferation cutoff was set at SI>2.5. 
  
 For the EV6 and EV13 infected ponies, variant Env-specific peptide matrix pools were 
used in the lymphoproliferation assay to scan for potentially reactive proliferative peptides.  
Twelve EV6 peptides and ten EV13 peptides were indicated in the thymidine incorporation assay 
using Env-specific peptide matrix pools.  To determine the reactivity of each peptide, the 
indicated peptides were tested individually in the proliferation assay, and the responses were 
averaged for the two EV6 infected ponies (Fig 5.3A) and the four EV13 infected ponies (Fig 
5.3B).  PBMC from the EV6 infected ponies proliferated in response to EV6 peptides 7, 9, 25, 
27, 35, 43, 49 and 84.  For the EV13 infected ponies, there was a positive proliferative response 
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to EV13 peptides 19, 24, 25, 30, 35, 78 and 84.  Due to the limited number of ponies, we could 
not establish the broadly reactive nature of the identified peptides. 
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Figure 5.3 Variant peptide-specific proliferation responses in EV6 and EV13 infected 
ponies.  PBMC from EV6 and EV13 infected ponies were isolated >6mpi and utilized in the 
thymidine incorporation assay against matrix indicated, EV6 (A) or EV13 (B) specific peptides, 
respectively.  A positive proliferation cutoff response was set at SI>2.5. 
 
5.3.c Effects of Env variation on PBMC proliferation in variant infected ponies   
 
 
To determine if Env variation affected the proliferation responses elicited during infection with 
EV6 or EV13, the EV0 peptides corresponding to the variant matrix-indicated peptides were 
used in the lymphoproliferation assay with PBMC from EV6 and EV13 infected ponies.  Due to 
the limited number of ponies infected with each variant EIAV strain, statistically relevant 
conclusions could not be established; however, trends in proliferation were noted.  Five of the 
twelve EV6 peptides indicated in the matrix analysis were divergent from EV0, and four of the 
EV0 peptides (peptides 19, 23, 27 and 31) did not appear to alter PBMC proliferation compared 
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to the EV6 peptides (Fig 5.4A).  For peptide 35, the amino acid differences between EV0 and 
EV6 seemed to suppress the proliferation response the EV0-35, as SI=1.4 for this peptide while 
EV6-35 SI=3.   
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Figure 5.4 Effects of variation on PBMC proliferation in variant EV6 and EV13 infected 
ponies.  EV0 peptides that diverged from matrix indicated EV6 or EV13 peptides were tested 
against PBMC from EV6 (A) and EV13 (B) infected ponies in the thymidine incorporation 
assay.  A positive proliferation cutoff was set at SI>2.5. 
  
 Seven of the ten matrix indicated EV13 peptides had variable amino acids from EV0, and 
three of the EV0 specific peptides appeared to alter the proliferation response compared to the 
EV13 specific peptides (Fig 5.4B).  EV13 infected ponies responded to EV13-24 and EV13-35 
better than the EV0 complementary peptides.  Conversely, EV13 infected ponies appeared to 
respond better to EV0-34 compared to EV13-34.  The remaining EV0 specific peptides did not 
seem to alter PBMC proliferation of the EV13 infected ponies.  
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5.3.d Effects of Env variation on PBMC proliferation in EIAVD9 vaccinated ponies   
 
To understand the effects of Env variation on PBMC proliferation in vaccinated ponies, DOC 
PBMC from the EIAVD9 vaccinated ponies challenged with EV6 or EV13 were used in the 
thymidine incorporation assay against variant-specific peptides.  Challenge strain-specific 
peptide matrix pools indicated 11 EV6 and nine EV13 specific peptides for individual analysis in 
the lymphoproliferation assay.  Due to the low peptide specific proliferation responses from the 
vaccinated ponies, it was difficult to ascertain the effects of amino acid variation on Th 
recognition.  With the exception of peptides 6-34 (Fig 5.5A) and 13-27 (Fig 5.5B), it appeared 
that proliferation was not affected by the amino acid variations of the selected peptides.  The 
amino acid changes in peptides 6-34 and 13-27 appeared to block the proliferative responses 
compared to the EV0 complementary peptides, although not to a significant level (T-test p-
values 0.0600 and 0.2323, respectively).  These data suggest that the sequence variation of these 
specific peptides does not affect PBMC proliferation, at least within the limits of the thymidine 
incorporation assay.  
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Figure 5.5 Effects of variation on PBMC proliferation in EIAVD9 vaccinated ponies.  Day of 
challenge PBMC from EV6 and EV13 challenged ponies were tested against EV6 or EV13 
specific matrix pools to identify potentially reactive peptides.  The EV6 (A) and EV13 (B) 
peptides were tested against the PBMC in the thymidine incorporation assay to determine the 
effects of variation on proliferation.  Positive response SI>2.5. 
  
5.3.e Env-specific cytolytic activity 6 months post infection   
 
 
The CTL response of the EV0, EV6 and EV13 infected ponies was determined using variant-
specific comprehensive Env peptide pools in a chromium release assay with PBMC from >6mpi.   
The PBMC from the EV0 infected ponies did not have cytolytic activity at the time points tested 
(Fig 5.6) and were not included in further CTL assays.  PBMC from the two EV6 infected ponies 
demonstrated low cytolytic responses to the EV6-Env peptide pool.  Two of the four EV13 
infected ponies, 009 and B023, had high CTL responses, while the remaining two did not have 
cytolytic activity at the time point tested.  EV13 infected ponies 9959 and A26 were therefore 
dropped from further CTL analysis. 
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Figure 5.6 Cytolytic responses to variant Env-specific peptide pools.  PBMC from >6mpi 
were utilized in the chromium release assay against comprehensive variant Env-specific peptide 
pools.  A positive %SL cutoff was set at %SL>5. 
 
 PBMC from the EV6 and EV13 infected ponies were tested against variant Env-specific 
peptide matrix pools in a chromium release assay to perform an inclusive scan of possible CTL 
peptides.  The matrix analysis identified 16 EV6-specific peptides and ten EV13-specific 
peptides to be tested individually.  The %SL of each peptide for the two EV6 infected ponies 
were averaged and only peptides 37 and 84 had positive CTL responses (Fig 5.7A).  When the 
%SL of each peptide was averaged for the two EV13 infected ponies with detectable CTL 
activity, peptides 8, 14, 21, 27 and 63 were positive for cytolytic activity (Fig 5.7B).  
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Figure 5.7 Variant peptide-specific CTL responses in EV6 and EV13 infected ponies.  
PBMC from EV6 and EV13 infected ponies were isolated >6mpi and utilized in the chromium 
release assay against matrix indicated, EV6 (A) or EV13 (B) specific peptides, respectively.  A 
positive cytolytic cutoff response was set at %SL>10. 
 
5.3.f Effects of Env variation on CLT lysis in EV6 and EV13 infected ponies   
 
To determine if Env variation affected the CTL response in variant infected ponies, PBMC from 
EV6 and EV13 infected ponies were tested against EV0-specific peptides in a chromium release 
assay.  Only two of the 16 EV6 matrix-indicated peptides varied from EV0, and four of the ten 
EV13 matrix-indicated peptides were divergent from EV0.   The limited number of infected 
ponies with CTL reactivity prevented the data from achieving statistical relevance; however, 
there were noticeable trends in the data.  While EV0-14 did not alter cytolytic activity compared 
to EV6-14, EV0-37 appeared to reduce the level of CTL lysis compared to EV6-37 (Fig 5.8A).  
The %SL in response to EV0-37 was 5.6 while the response to EV6-37 was %SL=10.9.  For the 
EV13 infected ponies, only EV0-27 appeared to reduced the level of cytolytic activity compared 
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to the EV13 specific peptides, %SL=2 compared to 25.7% (Fig 5.8B).  The remaining divergent 
peptides did not seem to alter CTL activity. 
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Figure 5.8 Effects of variation on CTL lysis in variant EV6 and EV13 infected ponies.  EV0 
peptides that diverged from matrix indicated EV6 or EV13 peptides were tested against PBMC 
from EV6 (A) and EV13 (B) infected ponies in the chromium release assay.  A positive cytolytic 
response cutoff was set at %SL>10. 
 
5.3.g Effects of Env variation on CLT lysis in EIAVD9 vaccinated ponies   
 
 
To gain better insight into the effects of Env variation on immune recognition in vaccinated 
ponies, DOC PBMC from the EIAVD9 vaccinated ponies challenged with EV6 or EV13 were 
utilized in a chromium release assay against variant-specific Env peptides.  Challenge strain-
specific matrix pools identified nine EV6 and 11 EV13 specific peptides in the chromium release 
assay.  Three of the peptides identified with the variant matrices were CTL peptides associated 
with vaccine protection from disease.  To ascertain if these peptides were reactive against DOC 
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PBMC from the vaccinated ponies, the variant specific peptides were tested against the DOC 
PBMC (Fig 5.9).  
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Figure 5.9 Effects of variation on CTL lysis in EIAVD9 vaccinated ponies.  Day of challenge 
PBMC from EV6 and EV13 challenged ponies were tested against EV6 or EV13 specific matrix 
pools in the initial screening for reactive peptides.  Variant peptides corresponding to amino acid 
differences between EV0, EV6, and EV13 were used in the chromium release assay against DOC 
PBMC from EV6 and EV13 challenged ponies.  Statistically significant changes in reactivity 
compared to the EV0 complementary peptide are indicated by with *. 
  
 The amino acid variations for peptide 21 did not affect CTL activity.  For peptides 18 and 
20, the amino acid changes did influence specific lysis; as the sequence diverged from EV0, 
cytolytic activity was incrementally lost (correlation coefficient r-value -0.9999 and -0.9982, 
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respectively).  With some peptides, such as peptide 32, CTL activity can be completely negated 
with divergence from EV0-32.  While the reduction in CTL response to peptide EV6-32 is not 
statistically significant, the loss of response to EV13-32 is significant (T-test p-values 0.2134 and 
0.0371, respectively).  For EV0-27, CTL specificity is lost only against EV13-27 (T-test p-value 
0.01); while EV6-27 maintains the same level of CTL activity as EV0-27.  The sequence 
changes in peptide EV6-38 causes a loss of CTL reactivity, but CTL lysis is not hindered with 
the amino acid differences present in the EV13 variant, indicating sequence variation does not 
always equate with loss of CTL response.  In fact, amino acid changes can lead to gain of CTL 
recognition, as observed with the variants for peptides 23 and 24.  Additionally, the EV13 
variants of peptides 34 and 36 also caused a gain of CTL reactivity (T-test p-values 0.0321 and 
0.0122, respectively) (Fig 5.9).          
5.3.h Neutralizing antibody response is variant infected ponies   
 
 
An ELISA based infectious center assay was used to monitor the development of variant specific 
neutralizing antibodies in monthly serum samples from each infected pony.  Three of the four 
EV0 infected ponies developed EV0 specific neutralizing antibodies by 90dpi.  The titer for 9913 
was minimally positive, never exceeding 1:40, while ponies 9961 and 9955 sustained titers 
~1:102 (Fig 5.10A).  The fourth EV0 infected pony developed a neutralization titer more slowly 
compared to the other three EV0 infected ponies, but sustained a comparable titer to 9961 and 
9955.   EV6 specific neutralizing antibodies were detected in EV6 infected pony 956 by 30dpi 
(Fig 5.10B), while the remaining EV6 infected ponies did not develop significant titers until 
60dpi.  Ponies 956 and B32 maintained their titers around 1:102-103.  The titer for pony #50 
peaked around 1:103 on day 60, corresponding to the second febrile episode for this pony.  While 
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#50 maintained a neutralization titer at 1:102, the disease signs were severe, and the pony was 
euthanized at 130dpi.  Pony #10 achieved a similar neutralization titer compared to pony #50, 
shortly before euthanasia at 65dpi.  Three of the four EV13 infected ponies had detectable 
neutralization titers against EV13 by 90dpi which were maintained above cutoff for the 
remainder of the observation period (Fig 5.10C).  Pony B023 did not develop neutralizing 
antibodies until 150dpi, but eventually achieved the titers of the other EV13 infected ponies. 
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Figure 5.10 Neutralizing antibody responses in variant infected ponies.  A cell-based ELISA 
was utilized to measure the development of neutralizing antibodies throughout the course of 
infection with EV0, EV6, or EV13.  A positive neutralization cutoff was set at a titer of 1:25. 
 
5.3.i Specificity of neutralizing antibodies   
 
 
Since these variants were developed from a pony chronically infected with EIAVPV (35, 36, 77), 
post immune suppression serum from that pony was used in the neutralization assay to determine 
if cross-reactive antibodies were present.  The pony was infected with EIAVPV, which shares a 
homologous Env with EV0; EV6 was developed from an isolate from the fourth febrile episode, 
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and EV13 was developed from a pre-immune suppression isolate.  Post-immune suppression 
serum from the infected pony had a very high neutralization titer to EV0 and was also capable of 
neutralizing EV6 (Fig 5.11A).  Serum neutralization was detected against EV13, but it did not 
reach the positive cutoff of 1:25. 
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Figure 5.11 Cross-reactivity of neutralizing antibodies from infected ponies.  (A) Post 
immune suppression serum neutralization of the pony from which EV6 and EV13 were isolated.  
(B)  Sera from variant infected ponies were tested against the three EIAV Env variant strains and 
were only able to neutralize homologous virus.   
  
 To determine if ponies infected with EV0, EV6, or EV13 developed cross-reactive 
antibodies, sera from selected ponies were tested against the three challenge strains.  Serum 
samples were chosen from ponies demonstrating a mature immune response with high 
neutralization titers.  Therefore, EV0 infected ponies 9961 (276dpi) and 9955 (151dpi), EV6 
infected ponies 956 (233dpi) and B32 (198dpi), and EV13 infected ponies A26 (295dpi) and 
9959 (295dpi) were selected for the cross-reactivity studies.  With the ELISA based infectious 
center assay, no cross-reactive neutralizing antibodies were detected against the three variant 
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strains (Fig 5.11B).  The neutralizing antibodies developed during infection with these variant 
strains were highly strain specific, and incapable of neutralizing the other two variants.  
 Finally, to determine if EIAV vaccinated ponies developed cross-reactive neutralizing 
antibodies, DOC and 4wpc sera from EIAVD9 vaccinated ponies challenged were tested against 
the three challenge strains.  Sera from the vaccinated ponies were only able to neutralize the 
homologous Env, EV0.  Even in the ponies that became infected by 4wpc, variant challenge 
strain specific neutralizing antibodies did not develop (Fig 5.12).  
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Figure 5.12 Cross-reactivity of neutralizing antibodies from EIAVD9 vaccinated ponies.  
DOC and 4wpc sera from each EIAVD9 vaccinate pony was tested against each challenge strain 
to determine the level of cross-reactivity.  Only EV0 specific neutralizing antibodies were 
detected.  The graph shows a representative pony from each challenge group. 
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5.3.j Neutralizing antibodies directed against the V3 and V4 region of Env   
 
 
It was previously established that neutralizing antibodies evolve to recognize the V3 and V4 
regions of Env during persistent EIAVPV infection (60, 76, 77).  To determine if the V3 and V4 
regions of EV0, EV6 and EV13 confer neutralization specificity to each variant Env strain, 
chimeras were constructed by switching the V3 to V4 region of EV0 and EV6 (c.f. Fig 5.1B).  
The chimeric constructs between EV0 and EV13 did not produce viable virus, but a colleague in 
the lab, Dr. Chengqun Sun, developed a construct containing the EV13 N-terminus in the EV0 
backbone.  This construct contained the V3-V4 region of EV13 and an additional amino acid 
change at 146 of gp90, where EV13 contained an isoleucine (I) residue and EV0 contained a 
methionine (M) residue.  We felt this amino acid would substitution would not alter the 
neutralization phenotype and used this clone, termed EV0v13, in the neutralization analysis.  
 Mature immune serum demonstrating high level neutralization activity was chosen for 
the analysis of neutralization specificity.  Based on these criteria, EV0 infected pony 9961 at 
276dpi, and EV6 infected pony B32 at 198dpi, and EV13 infected pony A26 at 295dpi were 
chosen for the study.  The serum from EV0 infected Pony 9961 was capable of equally 
neutralizing EV0 and EV6v0, with titers just below 1:200 (Fig 13A).  In comparison, the 
neutralization titer against EV0v6 was significantly lower, at 1:40, and there was no 
neutralization of EV6 with serum from 9961.  Serum from EV6 infected Pony B32 had very high 
neutralization titers against EV6 and EV0v6 (~1:600 and ~1:700, respectively), but was unable 
to neutralize EV0 or EV6v0.  For the EV0v13 chimeric clone, serum from A26 was capable of 
neutralizing EV13 and EV0v13, albeit to a lesser extent (~1:300 and ~1:150, respectively) (Fig 
13B).  Serum from EV0 infected pony 9961 was only able to neutralize EV0; the titer to EV0v13 
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was considerably weaker (~1:170 compared to ~1:30).  Collectively, these data indicate the 
serum neutralizing antibodies detected in these assays are primarily directed against the V3-V4 
region of gp90.      
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Figure 5.13 Neutralizing antibodies directed against the V3-V4 region of gp90.  Chimeric 
viruses were constructed by switching the V3-V4 region of EV0 and EV6 and by placing the N-
terminus to V4 region of EV13 into the EV0 backbone.  (A) Serum samples from EV0 infected 
pony 9961 and EV6 infected pony B32 were tested against the EV0:EV6 chimeric constructs in 
the neutralization assay. (B)  Serum samples from EV0 infected pony 9961 and EV13 infected 
pony A26 were tested against the EV0v13 virus. 
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5.4 DISCUSSION 
 
 
Lentiviruses escape immune recognition through alterations in key immune epitopes of viral 
proteins, and the level of viral replication is high enough in untreated individuals that every 
possible point mutation in the entire viral genome arises on a daily basis (11).  These point 
mutations permit the virus to escape neutralizing antibody and T-cell mediated immune 
responses allowing the virus to persist in the infected host indefinitely.  Due to fitness constraints 
on many viral proteins, the majority of escape mutations occur in the viral Env.  The effects of 
Env variation in EIAV infected ponies is easily observed during the chronic phase of infection, 
where escape mutants induce new febrile episodes (76, 77).  Viral quasispecies isolated during 
sequential febrile episodes are distinct from the preceding episode, indicating the virus has 
escaped immune control to cause disease.  Horses eventually gain enduring control of viral 
replication and become inapparent carriers of EIAV.   
 With the cellular peptide mapping of the EIAVD9 Env proteins in horses and the 
identification of Env-specific peptide responses associated with vaccine protection from disease, 
we sought to examine the effects of natural Env variation on these defined immune responses.  
Since the variant challenge of EIAVD9 vaccinated ponies demonstrated Env to be a primary 
determinant of vaccine efficacy, we hypothesized that the divergent amino acids in the two 
variant strains would alter the immune responses compared to EV0.  Ponies infected with these 
variants all developed acute episodes, with some becoming chronically infected.  In the 
proliferation assays, strain specific matrix pools were utilized to identify potentially reactive 
peptides, and some of the peptides identified were divergent from the EV0 peptide sequence.  
When both EV0 and variant-specific peptides were tested in the thymidine incorporation assay, 
the effects of variation on PBMC proliferation were minimal, with many of the EV0 peptides not 
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altering proliferation compared to the homologous variant-peptides.  With the limited number of 
ponies infected with the variant strains of EIAV, we could not conclude if the proliferative 
responses in each infected pony were cross-reactive with EV0 specific peptides.  However, the 
proliferation to peptides EV0-24, EV0-34 and EV0-35 suggest that Env variation can affect 
PBMC proliferation in infected ponies.  Additionally, the proliferative responses in the EIAVD9 
vaccinated ponies indicated that the amino acid variations in peptides EV6-34 and EV13-27 were 
sufficient to alter proliferation.  The low level proliferation of the EIAVD9 vaccinated ponies 
prevented a more stringent analysis of the effects of amino acid variation on PBMC proliferation.  
With this limited data, we were unable to conclusively determine the effects of Env variation on 
PBMC proliferation; perhaps if a more discriminating assay were used, changes in reactivity 
could be observed.  Additionally, the thymidine incorporation assay only measures T cell 
proliferation; without assays for equine cytokine expression, we cannot ascertain the effects of 
Env variation on other Th cell responses. 
 CTL escape mutations of lentiviral epitopes have been widely reported (22, 40, 47, 78, 
96, 111).  To understand the effects of amino acid variation on CTL recognition in EIAV 
infected and vaccinated ponies, PBMC were tested against variant peptides to determine the 
reactivity.  In the EV6 and EV13 variant infected ponies, peptide specific cytolytic activity was 
only affected by two EV0-specific peptides.  However, when PBMC from the EIAVD9 
vaccinated ponies were used, profound effects on CTL reactivity were observed.  The amino acid 
variation required to alter cytolytic activity did not need to be extensive, as one or two amino 
acid changes was enough to lose CTL reactivity, as with peptides 32 and 38 (Table 5.3). 
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Table 5.3 Variant peptide sequences and the effects on CTL reactivity in vaccinated ponies. 
Peptide Peptide Sequence CTL Reactivity Peptide Peptide Sequence
CTL 
Reactivity
EV0-18 DSDHCQEYQCKKVNLNSSDS ++ EV0-27 IHPIRLCVQPPFFLVQEKGI ++
EV6-18 ****************LNSF + EV6-27 ******************EV +++
EV13-18 **************FTV*KA - EV13-27 *****************NRG -
EV0-20 SNP------VR-VEDVMNTTEYWGFKW ++ EV0-32 ACNVSRLKINRKDYTGIYQV +++
EV6-20 DSS------IH-****KD********* + EV6-32 *****H*R************ -
EV13-20 NGSSIPSIHVGG***AE**I******* + EV13-32 ****RK*G************ -
EV0-21 NTTEYWGFKWLECNQTENFK + EV0-34 PIFYTCNFTNITSCNNEPII -
EV6-21 D******************* + EV6-34 *****************S** -
EV13-21 **I***************L* + EV13-34 *M*******S*****D*S*T +
EV0-23 TILVPENEMVNINDTDTWIP - EV0-36 SVIMYETNQVQYLLCNNNNS -
EV6-23 **************N****A ++ EV13-36 ***************KY*TT ++
EV13-23 **********K*KN-G**T* ++
EV0-38 NNYNCVVQSFGVIGQAHLEL +
EV0-24 NINDTDTWIPKGCNETWARV - EV6-38 *H****************** -
EV6-24 ****N****A********** +++ EV13-38 DSN*T*************** ++
EV13-24 K*KN-G**T*********** ++  
 
Without knowing critical anchor residues needed for binding the peptides to the MHC I 
molecules, we cannot determine if the cytolytic response was altered due to decreased binding 
affinity of the peptide to the MHC I molecule, or the inability of the T-cell receptor to recognize 
the peptide-MHC complex (30, 112).   
 It is established that N-linked glycosylation can affect antibody recognition, but 
glycosylation may also interfere with peptide processing and presentation on MHC I molecules 
(17, 41, 62, 130).  While it was desirable to determine the role of N-linked glycosylation in CTL 
recognition, it was not possible to access the effects of glycosylation on cytolytic activity with 
this panel of peptides.  First, heavily glycosylated areas of Env were excluded from cellular 
recognition, potentially indicating that N-linked glycosylation may inhibit cytolytic activity.  
Second, instead of gaining/losing N-linked glycosylation sites in the variant peptides, many of 
the glycosylation sites were shifted up or down stream.  The peptides that did gain/lose a 
glycosylation site did not offer a clear role of glycosylation in CTL recognition.  Again, without 
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knowing critical anchor residues, it cannot be determined if cytolytic activity was affected by the 
glycosylation site or by the changing of a critical anchor residue. 
 The most profound effects of Env variation on immune recognition were observed in the 
neutralization response.  In ponies infected with the variant strains, only strain-specific 
neutralizing antibodies were detected that were unable to cross-neutralize the other variant EIAV 
strains.  Using chimeric constructs, neutralizing specificity of EV0 and EV6 mapped to the V3 to 
V4 region of gp90, as previously reported for EIAVPV (59, 60).  The chimeric construct 
containing the EV13 N-terminus half in the EV0 backbone was less clear, as serum 
neutralization sensitivity from an EV13 infected pony was not fully restored against EV0v13.  
While serum from the EV13 infected pony was capable of neutralizing EV0v13, the 
neutralization titer was approximately half of the titer of EV13.  This observation has previously 
been reported (60), and has been attributed to the dominance of the neutralization resistant 
phenotype, indicating areas outside of V3-V4 may also contribute to Env neutralization 
resistance.   
 The lack of cross-neutralization between the variant infected ponies was a surprising 
result, as there was minimal variation between the three strains.  It is assumed that inapparent 
carrier ponies of EIAV are protected from further EIAV challenge due to broadly cross-
neutralizing antibodies.  Even EIAVD9 vaccinated ponies protected from virulent challenge 
against EV6 or EV13 did not have detectable cross-reactive neutralizing antibodies at day of 
challenge or four weeks post challenge.  These results may suggest either neutralizing antibodies 
do not play an important role in protection, or our in vitro neutralization assay cannot detect the 
cross-reactive neutralizing antibodies.  The later explanation is most likely correct as in vitro 
assays do not always correlate 100% with in vivo responses. 
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 These studies demonstrate that very little Env variation is sufficient to alter cellular and 
humoral immune responses in EIAV infected and vaccinated ponies.  Additional studies need to 
be performed with more animals to gain better insight into the true effects of Env variation on 
immune recognition.  These studies do suggest that more conserved regions of Env should be 
targeted in future vaccine trials, as variations in CTL and neutralizing antibody epitopes may 
ablate the protective vaccine response.   
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6.0 SUMMARY AND FUTURE DIRECTIONS 
 
 
 
 
The extensive research and public health programs aimed at combating HIV have been unable to 
weaken the deathly grip of the AIDS epidemic.  HIV continues to infect millions of individuals 
worldwide, with five million new HIV infections in 2005.  While sub-Saharan Africa continues 
to be to most affected area, Eastern Europe and Central Asia have witnessed the steepest rate 
increase in HIV infections (2).  Although antiretroviral drugs have improved the length and 
quality of life for HIV infected individuals in developed countries, the best hope for stopping the 
global spread of new HIV infections lies in the development of a protective vaccine.  Empiric 
approaches have largely failed in developing HIV vaccines, proving that a better understanding 
of protective immunity is essential to developing an effective lentiviral vaccine.  Due to the 
complexities in conducting human trials for HIV vaccine studies, lentiviral vaccine research 
must rely on animal models systems to unravel the immune responses necessary for protective 
immunity.   
 While the SIV/monkey system has been the “gold standard” for evaluating protective 
vaccine immunity, non-human primate models have also proven to be beneficial at elucidating 
appropriate anti-lentiviral immune responses.  FIV and EIAV have added tremendous insight in 
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the development of lentiviral vaccines by demonstrating major pitfalls of potential vaccines, 
including vaccine induced antibody enhancement of disease (128, 136) and the inability to 
achieve sterilizing immunity (32).  While sterilizing immunity is the ultimate goal of lentiviral 
vaccine research, it is becoming increasingly clear that that level of protection may not be a 
possibility.  Even when apparent sterilizing immunity was achieved against homologous 
challenge, we demonstrated through immune suppression that the EIAV vaccinated horses were 
indeed infected with the challenge strain (32).  If sterilizing immunity is not possible, a vaccine 
capable of limiting virus replication and preventing disease would be beneficial in halting the 
spread of new infections.  Unfortunately, we were unable to protect ponies from disease against 
challenge strains which were just 6% or 13% divergent in gp90 (36).  This does not bode well for 
HIV vaccine research as lentiviruses may diverge in the surface glycoprotein by more than 30-
40% (3).   
 The EIAVD9 vaccine trial also illustrated that Gag and Pol specific immune responses 
alone may not be sufficient in protecting vaccinated ponies from disease after virulent challenge.  
This is problematic as many of the current trial HIV vaccines only contain the more conserved 
Gag and Pol proteins.  We cannot conclude that Gag and Pol specific immune responses are not 
necessary for protective vaccine efficacy, just that these specific responses are not sufficient to 
protect EIAV vaccinated ponies from disease after challenge.  Up to recently, Env antigens have 
been neglected as viable vaccine candidates due to the extensive variability of the proteins.  
However, we have identified Env specific immune responses that were significantly associated 
with vaccine protection from disease.  These peptide based responses should be evaluated in 
more vaccine trials to determine their true correlation with vaccine protection.  These peptide 
 121
specific responses may serve as valuable vaccine targets that could potentially protect vaccinated 
ponies from disease or infection.         
  
 
 
6.1 SUMMARY OF RESULTS AND POTENTIAL IMPLICATIONS 
 
 
Understanding key immune responses necessary for vaccine protection has proven to be an 
elusive goal for many lentiviral researchers.  Some argue that neutralizing antibodies (85, 86, 
115) and CTL responses (67, 87, 124) are correlated with vaccine protection in SIV and SHIV, 
but both claims have been refuted in other studies (95, 102, 103, 127).  Now there is a consorted 
effort by the Live Attenuated Consortium of the International AIDS Vaccine Initiative to identify 
the mechanisms of protection conferred by attenuated SIV vaccines in monkeys (70).  The work 
presented in this dissertation may be a valuable complement to ongoing SIV and SHIV research 
as we have utilized the EIAV system to map protective Env immune responses associated with 
vaccine protection from disease.     
  
6.1.a No detectable association between neutralizing antibodies and vaccine protection 
from disease   
 
 
The EIAVD9 vaccine is capable of eliciting strain specific neutralizing antibodies, however, the 
antibodies were unable to recognize EV6 or EV13 (131).  Additionally, in ponies infected with 
each challenge strain, the neutralization response was highly strain specific and incapable of 
cross-neutralizing the other variants. A caveat of our neutralization study is the use of an in vitro 
neutralization assay to measure antibody responses.  It is well established that in vitro responses 
do not always correlate with in vivo responses.  In this regard, we cannot be absolutely certain of 
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the lack of correlation between neutralizing antibodies and protection, or that cross-reactive 
antibodies were not produced in the vaccinated and infected ponies.   
 Additionally, our neutralization assay only detects the ability of antibodies to bind 
infectious virus and prevent entry into target cells.  Outside of neutralization, there maybe other 
antiviral antibody mechanisms, such as activation of the complement cascade (101), antibody-
dependent cell-mediated cytotoxicity (68) and opsonophagocytosis by macrophage (133), that 
may contribute to viral clearance and reduce infection of new cells.  In fact, the broadly 
neutralizing HIV antibody b12 functions better when the antibody has an intact Fc (58).  The Fc 
portion of antibody allows for complement activation and opsonophagocytosis.  The observation 
that b12 function is enhanced with intact Fc indicates that other antibody mechanisms of action 
may be contributing to the documented neutralization.  Current neutralization assays only 
measure the ability of an antibody to block entry into target cells.  Therefore, new methods to 
detect different antibody mechanisms of protection need to be developed in addition to a more 
reliable neutralization assay.   
 
6.1.b Env-peptide specific cellular immune responses associated with protective immunity   
 
While we were unable to link neutralizing antibody development with vaccine efficacy, our 
studies with EIAV have identified one Th and eight CTL peptides apparently associated with 
vaccine protection from disease after virulent challenge (131).  An initial mapping of broadly 
reactive cellular peptides identified 17 Th and six CTL peptides in EIAVD9 vaccinated horses 
protected from homologous challenge (132).  The fact that more of these peptides were not 
associated with vaccine protection from disease after heterologous challenge suggests that 
broadly reactive responses do not always correlate with protective immune responses.  This may 
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be a potential pitfall for HIV vaccine development, as many of the broadly reactive immune 
responses reported on at the AIDS Vaccine 2007 Conference (Seattle, WA) from ongoing HIV 
vaccine trials may not protect the vaccinated individuals from infection or disease. While we 
have identified specific peptide responses statistically correlated with vaccine protection, only 21 
ponies were involved in the trial.  Therefore, it would be beneficial to test the identified peptides 
in more EIAV vaccinated ponies with different disease outcomes to strengthen the statistical 
relevance of the study.     
 The Th peptide and five of the CTL peptides associated with vaccine protection from 
disease identified in the study were located in more conserved regions of the Env that had 
identical peptide sequences for the three variant challenge strains.  This offers hope in the 
development of a lentiviral vaccine, as it was previously believed immune responses to Env 
would be ineffective due to the ability of the virus to develop escape mutants to evade the host 
immune response (18).  Since many of the escape mutations that develop during lentiviral 
infection revert back to wild type in the absence of selective pressure (40, 47, 78, 111) indicates 
there is a certain amount of fitness cost to the virus with each mutation.  Due to fitness 
constraints, there are portions of Env that must remain conserved for the protein to function 
properly (110).  Vaccines need to drive immune responses to these regions of virus in order to be 
efficacious.  Since the three variant challenge strains in our studies were developed from an 
ancestral species, we cannot say that the peptides identified would be conserved across other 
strains of EIAV.  Performing a gp90 alignment between EV0 and a natural isolate of EIAV that 
is >40% divergent, EIAVPA, demonstrates that there is little variation in the amino acid 
sequences of peptides associated with protective vaccine immunity (Fig 6.1).  The majority of 
the peptides have >70% conservation of the amino acid sequences.  The only exception is 
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peptide 5, where only 45% of the peptide sequence was conserved.  From the level of 
conservation in the peptides associated with vaccine protection, it may be suggested that these 
peptides are in regions integral to Env structure and function, and should be targeted in future 
vaccine trials.  
 
                                                       Pep 5
EV0    MVSIAFYGGIPGGISTPITQQSEKS--KCEENTMFQPYCYNNDSKNSMAESKEARDQE-M  
Pa     MVSIAFYGGIPGGISTPIAQQHQEVNTRDEDNAVFQPYCYIDGNKGKMAEGRDPRYSEDK        
       ******************:** ::   : *:*::****** :..*..***.::.* .*   
                                Pep 8/9 
EV0    NLKEESKE----EKRRNDWWKIGMFLLCLAGTTGGILWWYEGLPQQHYIGLVAIGGRLNG  
Pa     NLKEESKEDYDEEKGKKDWWKIGMLLLCLVGTTGSILWWYERVTHTSFIGLVAMGGRLNG  
       ********    ** ::*******:****.****.****** :.:  :*****:****** 
                                                          Pep 17 
EV0    SGQSNAIECWGSFPGCRPFQNYFSYETNRSMHMDNNTATLLEAYHREITFIYKSSCTDSD  
Pa     SDLTNVIECWGSFPGCRPFTNYFRYGTNRTIYYDNDTATLLHAYQRXVTYIYKTSCDDSD  
       *. :*.************* *** * ***::: **:*****.**:* :*:***:** *** 
                                   Pep 20 
EV0    HCQEYQCKKVNLNSSDSSNPVRVEDVMNTTEYWGFKWLECNQTENFKTILVPENEMVNIN  
Pa     HCQDYQCKQVNITQNNSG----LALESNNSIFWGFEWLECNQTEYAKTILIPKDEMVEWG  
       ***:****:**:...:*.    :    *.: :***:********  ****:*::***: . 
                  Pep 24/26 
EV0    DTDTWIPKGCNETWARVKRCPIDILYGIHPIRLCVQPPFFLVQEK--GIANTSRIGNCGP  
Pa     N-DTWRPKGCNETWARVKHCPADLLYGIHPIRLCVQPPFFLTNFNNNSDSNNTVISNCGP  
       : *** ************:** *:*****************.: :  . :*.: *.**** 
 
EV0    TIFLGVLEDNKGVVRGNYTACNVSRLKINRKDYTGIYQVPIFYTCNFTNITSCNNEPIIS  
Pa     LIRLRILEDNKGVISGNNNNCSVVKKFFQRPNYSGTYQVPIFYECNLT-LSSCEENSTVS  
       * * :*******: ** . *.* :  ::* :*:* ******* **:* ::**:::. :* 
                                Pep 38 
EV0    VIMYETNQVQYLLCN-NNNSNNYNCVVQSFGVIGQAHLELPRPNKRIRNQSFNQYNCSIN  
Pa     IIRYEQNNVQYLLCRRNDTKTNYSCVVQTFGVIGQAHLELPRKNKRIENPRFTYYNCSIN  
       :* ** *:******. *:...**.****:************* ****.*  *. ****** 
 
EV0    NKTELETWKLVKTSGITPLPISSEANTGLIRHKR 
Pa     NKTELKSWKLVKTSDITPVPVSSEAKTGLIRHKR 
       *****::*******.***:*:****:********  
Figure 6.1 Alignment of gp90 proteins from EV0 and EIAVPa.  EIAVPa is a natural isolate of 
EIAV.  The CTL peptides associated with vaccine protection from disease are labeled and 
highlighted in yellow.  The amino acid sequence of EIAVPa in these specific regions is >70% 
conserved compared to EV0, with the exception of peptide 5. 
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6.1.c Env variation has profound effects on immune recognition   
 
Three of the eight CTL peptides associated with vaccine protection from disease were in 
predefined variable domains of gp90, specifically the V3, V4, and V7 domains.  The cytolytic 
responses to these three peptides were altered when the complementary variant peptides were 
utilized in the CTL assay.  Peptide 20, which spanned the V3 region, was the most divergent of 
the CTL peptides, yet each variant was still recognized in the CTL assay, albeit at progressively 
lower levels (131).  The amino acid differences for peptide 20 spanned the entire 20 amino acid 
sequence.  CTL epitopes are typically nine to ten amino acids long; therefore, each potential 
CTL epitope in peptide 20 contained at least one variable amino acid, suggesting that the 
EIAVD9 vaccine is capable of eliciting CTL responses to epitopes not present in the original 
inoculum.  In addition, most of the CTL and Th responses identified in ponies infected with the 
three different variant strains were not altered by amino acid variations within specific peptides.  
Taken together, these data indicate that while Env variation may have profound effects on some 
immune recognition, the cellular immune response to EIAV is capable of recognizing different 
versions of the same peptide, as previously reported in an HIV model with Nef epitopes (84).   
 
 
 
6.2 PEPTIDE STRATEGIES TO ELUCIDATE MINIMAL CELLULAR EPITOPES 
 
 
It is established that a single amino acid change is enough to abrogate the CTL response to a 
specific peptide (140) by either decreasing T-cell receptor affinity or by changing critical anchor 
residues in the peptide (30, 112).  Without knowing the residues required for the equine MHC I 
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molecule to bind peptides, we cannot determine why cellular reactivity to a specific peptide is 
altered in response to variant peptides.  To better understand the effects of amino acid variation 
on cellular reactivity, the minimal cellular epitope should be defined for each reactive peptide.  
Then, more in depth studies may be conducted to determine the MHC anchor residues and how 
amino acid variation affects immune recognition.   
 Some of the minimal peptide epitopes may be inferred by closer examination of the 
reactive peptides.  If two overlapping peptides are both reactive in a CTL assay, such as peptides 
8 and 9, it may be inferred that the epitope is contained in the ten amino acid overlap of the two 
peptides.  Since CTL epitopes are 9-10 amino acids in length, a new ten amino acid peptide 
containing the region of overlap could be constructed for use in the CTL assay (Table 6.1).  In 
cases where an individual peptide is reactive and the surrounding peptides are not, such as 
peptide 26, it may be inferred that the central ten amino acids of the reactive peptide contain the 
minimal epitope.  To confirm, consecutively smaller peptides of the 20-mer could be constructed 
and tested in the cellar assays to identify optimal epitopes.  By defining the optimal epitopes, we 
would be in a better position to describe the effects of Env variation on immune recognition, and 
how the variation affected peptide presentation and recognition.  
Table 6.1 Peptide strategies to elucidate minimal cellular epitopes. 
Peptide Original Peptide Sequence New Peptide Sequences Implications†
8 DWWKIGMFLLCLAGTTGGIL (+) peptide contains epitope
9 CLAGTTGGILWWYEGLPQQH (-) two separate epitopes for pep 8 and 9
RCPIDILYGIHPIRLCVQ
CPIDILYGIHPIRLCV
PIDILYGIHPIRLC
IDILYGIHPIRL
DILYGIHPIR
†  Potential results if peptides were used in the cellular assays.  (+) indicates a positive response in the assay, (-) 
indicates a negative response in the assay.  These results do not include all potential outcomes, just most likely.
CLAGTTGGIL
26 KRCPIDILYGIHPIRLCVQP
(+) peptide contains epitope
(-) deletion knocked out important amino 
acid for peptide recognition, previous 
peptide contained entire epitope
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6.3 PEPTIDE STRATEGIES TO EXAMINE THE EFFECTS OF N-LINKED 
GLYCOSLYATION ON CELLULAR RECOGNITION 
 
Lentiviruses employ N-linked glycosylation on surface Env proteins to shield the virion from 
host immune responses.  Because areas of heavy N-link glycosylation are often excluded from 
cellular immune recognition (123, 131, 132), we were unable to fully examine the effects of 
glycosylation on lymphoproliferation or CTL lysis.  While there were glycosylation sites present 
in some of our identified Env peptides, the effects of glycosylation on cellular immune 
recognition could not be determined because the complementary variant Env peptides also had 
glycosylation sites that were shifted either up- or down-stream in the peptide sequence.  
Additionally, in the peptides that lost glycosylation sites, it was impossible to determine if the 
different immune responses observed in the cellular assays were due to glycosylation or due to 
changes in anchor residues attaching the peptide to the MHC molecule.    
 To clearly examination the affects of glycosylation on cellular recognition the minimal 
epitope of a peptide containing an N-linked glycosylation site must first be identified.  After 
identifying the minimal epitope, three forms of the peptide with different modifications to the 
glycosylation signal could be constructed for use in the cellular assays.  The first peptide would 
be the actual sequence encoded by the EIAV env gene (nonglycosylated peptide).  The second 
peptide would be a glycosylated analogue synthesized using a commercially available derivative 
of asparagine (N) bearing a N-acetyl-D-glucosamin moiety (62) (glycosylated peptide).  While 
the addition of a glycosyl group has decreased CTL recognition for some peptides, reactivity to 
other glycosylated peptides has been unaffected (61).  The third peptide would change the 
asparagine (N) to an aspartic acid (D) residue to represent the naturally processed form of the 
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peptide (deglycosylated peptide).  During peptide processing, a mammalian deglycosylation 
enzyme converts asparagine to aspartic acid to remove the glycosyl group (42, 130).  
Researchers have found better CTL reactivity to some deglycosylated peptides from HIV (42), 
Hepatitis C virus (126), and lymphocytic choriomeningitis virus (LCMV) glycoproteins (61, 62).   
 The three synthetic peptides could then be used in cellular immune assays to determine 
the affects of N-linked glycosylation on immune reactivity.  Recognition of the nonglycosylated 
peptide, without reactivity to the glycosylated or deglycosylated peptides, could indicate gp90 is 
not glycosylated or post-translationally modified at this specific site (41).  Recognition of the 
glycosylated peptide indicates N-linked glycosylation does affect cellular immune reactivity of 
the specific peptide.  Recognition of the deglycosylated peptide could indicate glycosylation 
does not affect cellular reactivity, but the glycosyl group must first be removed before proper 
recognition of the peptide can occur.  Conversely, failure to recognize the deglycosylated peptide 
may indicate that asparagine is a critical anchor residue for MHC binding.  Recognition of all 
three peptides may imply that the specific glycosylation signal present in the peptide is not 
always glycosylated and numerous forms of the peptide may exist in the context of gp90.  
Experimenting with these types of peptides could provide a better understanding of the affects of 
N-linked glycosylation on cellular immune recognition.               
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6.4 NEW ASSAYS TO CHARACTERIZE THE CYTOKINE PROFILE OF TH AND CTL 
CELLS 
 
Aside from determining the minimal epitopes of the peptides and the effects of variation on the 
immune responses, additional studies to understand the cytokine profile of the reactive Th and 
CTL cells would be beneficial towards understanding the immune responses required for vaccine 
efficacy.  While the cellular assays employed in this dissertation measured the proliferation of Th 
and the cytolytic activity of CTL,  it is now known that polyfunctional Th and CTL responses are 
required for successful vaccines against chronic infection (57).  While other lentiviral systems 
are capable of routinely measuring cytokine responses, such as IFNγ, TNFα and IL2, these 
techniques are not possible with EIAV due to the lack of equine specific antibodies for the 
appropriate cytokines.  In respect to measuring the Th response, these techniques are far superior 
and offer more reliable results compared to the proliferation assay.  Having these and other 
related antibodies could make flow cytometry and ELISpot possible.   
 While I attempted to develop a flow cytometry assay for Th proliferation, the procedure 
was hampered by the lack of specific antibodies, and the results from non-specific stains such as 
CSFE did not correlate with the thymidine incorporation assay.  Flow cytometry and ELISpot 
assays would improve the cellular assays in many ways, including utilizing less cells, more 
reproducible results, decreasing the amount of time, and allow us to better compare our results 
with other lentiviral systems, such as HIV and SIV.  Equine specific antibodies and reagents are 
currently in development and, when available, can be used to develop improved assays for 
lymphoproliferation.   
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6.5 ARE THE ENV PEPTIDE-SPECIFIC IMMUNE RESPONSES SUFFICIENT FOR 
PROTECTIVE IMMUNITY? 
 
As stated above, only 21 ponies were available to characterize the Th and CTL responses 
associated with vaccine protection from disease.  While this is an excellent starting point, with so 
few ponies, we cannot definitively conclude that the identified peptide specific responses are 
sufficient for vaccine protective efficacy.  As new vaccine trials are developed, PBMC from the 
vaccinated ponies should be tested against the Th and eight CTL peptides to determine if there is 
a definite correlation with vaccine efficacy.  Additionally, vaccines could be developed to target 
these specific responses to determine if they are sufficient for protection from virulent challenge.   
  
6.5.a Peptide based vaccines to induce specific cellular responses associated with protective 
immunity   
 
 
To determine if the peptide specific immune responses identified in these studies are sufficient 
for vaccine protection, peptide based vaccines could be utilized that target the specific cellular 
immune responses.  There are several advantages to using peptide based vaccines which include, 
targeting specific cellular immune response, incorporating multiple cellular epitopes, and using 
numerous variants of a peptide epitope to account for variability and MHC restriction (13, 88).  
Despite the numerous advantages, peptide based vaccines to date have been ineffective at 
mounting lasting cellular or humoral immune responses capable of protecting animals from 
lentiviral challenge (14).  In EIAV, a gp90 peptide was able to transiently induce CTL responses; 
however, the immunized ponies were not protected from disease or infection after virulent 
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challenge (119).  A SHIV peptide vaccine was capable of eliciting cellular immune responses 
that protected monkeys from disease but not infection (100).   
 In spite of these and other similar results, researchers have continued to investigate the 
potential benefits of peptide based vaccines for HIV.  Recently, a multivalent HIV peptide 
vaccine elicited CD4 and CD8 effector memory cells in mice.  This study demonstrated that 
adding a lipid group to the peptide enhanced the immunogenicity of the vaccine compared to 
non-lipidated peptides, and negated the need for an adjuvant.  The immune responses elicited in 
this trial were broadly reactive against numerous HIV-1 subtypes, demonstrating that peptide 
vaccines may provide protection from challenge (7).   
 There is a potential pitfall for peptide based vaccines: “original antigenic sin”.  While 
most commonly associated with antibody responses, “original antigenic sin” has been found to 
affect CTL responses as well (69, 74, 92).  Early escape mutants of poorly conserved CTL 
epitopes would not allow for the recognition of variant epitopes in different challenge strains 
(140).  One way to limit the effects of original antigenic sin is to develop peptide vaccines that 
encompass all variants of potential T-cell epitopes (PTE).  PTE peptides have recently been used 
to demonstrate that T-cells are capable of recognizing Nef variants early in infection, even before 
the peptide sequence is present in the circulating virus in the infected host (84).  This suggests 
that vaccine induced T cells may be able to recognize epitopes both in and outside of the 
subtypes represented in the vaccine.  
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6.5.b Chimeric challenge of EIAVD9 vaccinated ponies to determine which immune 
responses are necessary for vaccine protection   
 
Aside from peptide based vaccines, a new EIAVD9 vaccine trial could be conducted with a 
chimeric Env EIAV challenge strains to determine specific immune responses required for 
vaccine efficacy.  Nearly 100% of the EIAVD9 vaccinated ponies challenged with EV0 were 
protected from disease, whereas the majority of EV13 challenged ponies developed equine 
infectious anemia (32, 36).  Due to the prominent phenotypical differences between the two 
strains, EV0 and EV13 would be optimal for constructing chimeric challenge strains.  Only three 
of the eight CTL peptides associated with vaccine protection from disease had different amino 
acid sequences between EV0 and EV13; the Th peptide and remaining CTL peptides were in 
more conserved region on Env.  One variant CTL peptide was in V3, one was in V4, and the 
final one was in V7.  It was previously found that there was better success at making replication 
competent chimeric viruses when the V3 and V4 regions were switched together.  Therefore, 
chimeric challenge strains could be constructed by placing the N-terminus to the V4 region of 
EV13 into the EV0 backbone, and also by switching the V4 to C-terminus half of EV13 into the 
EV0 backbone (EV0N13 or EV0C13, respectively) (Table 6.2). 
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Table 6.2 Chimeric viruses for challenging EIAVD9 vaccinated ponies. 
EV0
EV13 
EV0C13 
EV0N13 
Protected from disease
Not protected from disease
Protected from disease
Protected from disease
Not protected from disease
Not protected from disease
N-term EV0 epitopes necessary
C-term EV0 epitopes or 
combination of N and C-term EV0 
epitopes necessary
C-term EV0 epitopes necessary
N-term EV0 epitopes or 
combination of N and C-term EV0 
epitopes necessary
Contains protective epitopes
Does not contain protective 
epitopes
CHALLENGE STRAIN OUTCOME IMPLICATIONS
 
 
EIAVD9 vaccinated ponies challenged with EV0N13 not protected from disease would indicate 
that the cellular epitopes present in the N-terminus of EV0 are important for vaccine protection.  
Conversely, if the ponies are protected, it would indicate that the cellular epitopes in the C-
terminus of EV0 are important for vaccine efficacy.  Depending on the results, new chimeric 
challenge strains could be made with smaller substituted regions to clearly define the minimal 
epitopes of Env that are necessary for vaccine efficacy.   
 
 
 
 
6.6 DETERIMINING THE ROLE OF NEUTRALIZING ANTIBODIES IN VACCINE 
PROTECTION 
 
In lentiviral vaccine research, the role of neutralizing antibodies in protective immunity is an 
ongoing debate.  While several researchers have found a protective role for neutralizing 
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antibodies in SIV protection (85, 86, 115), others have been unable to correlate neutralization 
with protection (95, 102, 103, 127).  In our studies, we were unable to correlate vaccine 
protection from disease with the development of neutralizing antibodies.  The above proposed 
chimeric challenge viruses would help to analyze the contribution of neutralizing antibodies to 
vaccine protection. Since the strain specific neutralizing antibodies to EV0 and EV13 are not 
cross-reactive, the EV0N13 chimeric challenge strain, which contains the EV13 PND, would 
help determine if neutralizing antibodies are important for vaccine protection.  If EV0N13 
vaccinated ponies are protected from disease, it could potentially indicate that neutralizing 
antibodies are not necessary for vaccine protection.  Alternatively, if the ponies are not protected, 
it maybe inferred that the neutralization response is essential for protective efficacy.  The data 
would need to be analyzed in the context of the CTL response to determine the contribution of 
each of arm of the immune system.  New challenge strains could then be developed to further 
dissect the appropriate immune responses required for protective vaccine efficacy.    
 
 
 
6.7 CONTRIBUTION OF GAG AND POL IN VACCINE PROTECTION 
 
 
While our EIAVD9 variant challenge trial identified Env as a primary determinant of vaccine 
efficacy, immune responses to other viral proteins may be necessary for complete vaccine 
protection.  Gp90 was the only divergent protein in the challenge strains compared to the 
EIAVD9 vaccine, making the challenge strains homologous to EIAVD9 in terms of the Gag and 
Pol proteins.  Even against this homologous challenge, the Gag and Pol specific immune 
responses were unable to protect the vaccinated ponies from disease.  It cannot be conclude that 
the Gag and Pol specific responses were not necessary for immune protection, as determined for 
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the Env-specific immune responses, only that Gag and Pol specific immunity was insufficient to 
protect the ponies from disease.  To determine the contribution of the Gag and Pol specific 
immune responses in vaccine protection from disease, similar studies that parallel the EIAVD9 
variant challenge trial could be performed where divergent Gag and Pol proteins can be placed in 
the homologous backbone to develop new challenge strains.   
 The Montelaro lab has several EIAV isolates with divergent Gag proteins, and is in the 
process of placing these Gag variants into the EV0 backbone to use as challenge strains for 
EIAVD9.  If all of the ponies are protected from disease after virulent challenge, this would 
indicate that Gag-specific immune responses do no contribute to vaccine protection.  However, if 
protective efficacy is lost, as observed in the Env variant challenge, Gag-specific immune 
responses could be associated with vaccine protection.  Depending on the outcome of the variant 
Gag challenge, mapping experiments with Gag-specific peptides could be performed to identify 
peptide specific immune responses associated with vaccine protection from disease.  Similar 
studies could also be performed using Pol variants of EIAV.  These types of studies would aid in 
the development of more effective EIAV vaccines and provide a better understanding of the 
immune responses needed for a protective lentiviral vaccine.     
  
 
 
6.8 INVESTIGATING THE EFFICACY OF POLYVALENT AND CONSENSUS ENV 
VACCINES 
 
While sterilizing immunity is desirable for a lentivirus vaccine, our current understanding of 
protective lentiviral immunity is not sufficient to develop such an effective vaccine.   A vaccine 
capable of decreasing viral load and protecting from disease maybe a beneficial alternative to 
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sterilizing immunity and may aid in halting the spread of HIV to uninfected individuals.  While 
the EIAVD9 vaccine was incapable of producing sterilizing immunity, improvements could be 
made to the vaccine provide better protective efficacy of the vaccine.  One potential way to 
induce better protection from disease would be to use a polyvalent attenuated EIAVD9 vaccine or 
a consensus Env EIAVD9 vaccine.  Polyvalent vaccines incorporate divergent repeats of the same 
antigen and/or a number of different antigens to elicit a protective immune response against 
different primary isolates.  Consensus vaccines are synthetic protein sequences based on the viral 
population (88).  While such techniques have been successful in preventing pneumococcus, polio 
and influenza (129); HIV researchers have found limited success in protecting polyvalent 
vaccinated animals from heterologous challenge (8, 19, 49, 74, 82, 106, 125).  While these types 
of vaccines are unable to elicit sterilizing immunity, they are capable of increasing the breadth of 
the immune response while increasing the time till the onset of disease. 
 To construct a polyvalent vaccine, attenuated EV6 and EV13 viruses could be 
constructed by deleting the S2 protein as performed in EIAVD9.  Then EIAVD9 with the new 
EV6D9 and EV13D9 strains could be used to inoculate ponies in our standard vaccination 
protocol.  Additionally, a consensus sequence could be constructed from the three variant Env 
sequences and placed into the EIAVD9 backbone for immunization.  An inoculum composed of 
equal parts EV0, EV6 and EV13 could then be used to challenge the polyvalent or consensus 
vaccinated ponies to evaluate the protective efficacy of the immunization.  This challenge 
strategy more closely mimics natural exposure to lentiviruses, which are not single isolates, but a 
quasispecies.  As the polyvalent inoculum has not been tested against the EIAVD9 vaccine, it 
would be of interest to determine the protective efficacy of the EIAVD9 vaccine against this 
challenge.  In the variant challenge trial of EIAVD9 vaccinated ponies, the ponies were 
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challenged with a very high dose of each variant strain.  Protective efficacy may be increased by 
more closely mimicking the natural exposure inoculum of EIAV.   
 Much of the research performed with HIV polyvalent vaccines has been performed in 
mice or other rodent model systems, where challenge with HIV is not possible.  EIAV has 
several advantages over the HIV rodent model system when discerning the effects of polyvalent 
or consensus vaccines.  First, the EIAV system has a reliable vaccination strategy with challenge 
strains that are 100% infectious in ponies.  Second, since the vaccination procedure is performed 
in the natural host of the virus, we are able to challenge the vaccinated ponies with virulent 
EIAV to determine the protective efficacy against infection and diseases.  Third, a reference for 
the protective efficacy of the polyvalent or consensus vaccines has already been established by 
challenging the EIAVD9 vaccinated ponies with the three individual variants used to develop the 
polyvalent and consensus vaccines (36).  Therefore, the EIAV system is in a unique position to 
help demonstrate the value of polyvalent or consensus vaccination strategies. 
 
 
 
6.9 CONCLUSION 
   
 
While SIV maybe the “gold standard” for testing HIV vaccine strategies, the work described 
here proves that EIAV can be extremely beneficial in elucidating appropriate lentiviral immune 
responses necessary for vaccine protection from disease.  Using the attenuated EIAVD9 vaccine, 
we were able to show for the first time that Env is a primary determinant of vaccine efficacy, and 
demonstrated that specific immune responses elicited by the EIAVD9 vaccine are associated with 
protection from disease.  With our assays, it appears that the cellular responses to Env-specific 
peptides are more crucial to protective immunity than the humoral immune responses.  We also 
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demonstrate that Env variation has profound effects on CTL recognition and neutralizing 
antibody responses.  The majority of the cellular peptides identified are located in more 
conserved regions, making them optimal targets for future EIAV vaccine trials. 
 SIV researchers have spent years attempting to meaningfully correlate neutralizing 
antibodies or CTL responses with vaccine protection from disease.  Only now is there a 
concerted effort at elucidating immune responses associated with vaccine protection (70).  With 
EIAV, we have shown Env-specific immune responses significantly associated with vaccine 
protection from disease.  We have also demonstrated Env to be an important determinant of 
vaccine efficacy, and are in a position to evaluate the role of Gag immune responses in vaccine 
protection.  These findings further establish EIAV as a powerful lentivirus model system that can 
identify key vaccine induced immune responses that have so far evaded SIV and HIV 
researchers.  Further research with EIAV will yield important information on lentiviral vaccine 
immunity that will undoubtedly aid in the development of an effective HIV vaccine.   
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